




Enzymatic DNA modifications for 
genetic diagnostics 
by 





A thesis submitted to the University of Birmingham for the degree of  










School of Chemistry  
College of Engineering and Physical Sciences 
University of Birmingham  















This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 








Techniques for genetic diagnostics are advancing at a rapid pace, with new technologies 
constantly emerging as we understand an increasing amount about the human genome. 
Methods of visualising DNA – such as fluorescence in situ hybridisation (FISH) – have been 
used for decades, but novel approaches are now opening up new applications for the 
technique, such as rapid hybridisation times for faster results, or investigation of areas of the 
genome that have previously been inaccessible due limitations in the current technology. This 
thesis shows how methyltransferase (MTase) enzymes can be used as a means to explore 
different regions of the human genome for various clinical applications. 
 
Chapter three sees the optimisation of the expression of the MTase, M.TaqI. This protein is 
used throughout this thesis, alongside natural cofactor AdoMet and cofactor analogue 
AdoHcy-6-N3, to label DNA site specifically. This technology is used for various 
experiments in the following chapters. Chapter three also attempts to produce mutated 
versions of other MTases for similar labelling experiments. 
 
Chapter four uses the M.TaqI labelling technology to label oligoprobes, short sequences of 
DNA, for potential use in FISH diagnostics; specifically looking at aneuploidy, which can be 
indicative of certain cancers. Different conditions are tested to obtain the highest signal to 
noise ratio, to ensure confident detection of centromeres of the chromosome 17 in patients. 
These results are used to design a probe set that can simultaneously detect the loss of 
chromosomes 1, 7 or 17 – which is associated with poor prognosis in acute lymphocytic 
leukaemia – by labelling each probe with a different colour dye. As oligoprobes can detect 
 
 
highly homologous sequences, this chapter also explores the use of this technique in 
potentially detecting single nucleotide polymorphisms in the human genome, which are 
associated with many diseases such as spinal muscular atrophy. 
 
In Chapter five, this MTase labelling technology is used to produce probes for single genes as 
opposed to centromeric regions. Focus is on the BCR gene, as it is associated with the 
BCR/ABL translocation, prevalent in most cases of chronic myeloid leukaemia.  
 
Finally, Chapter six explores DNA mapping as an approach to detect small DNA mutations, 
by investigating the pattern in fluorescence intensity of two highly similar sequences labelled 
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 DNA structure and function 
Deoxyribonucleic acid (DNA) is the hereditary material contained within the nucleus of cells. 
These molecules contain critical genetic instructions for development, function, reproduction 
and growth, and are of great importance in the understanding of inheritance, as well as the 
genetic basis behind disease. 
 
 The structure of DNA 
DNA is made up of nucleotides that contain a phosphate group, a sugar group and a nitrogen 
base. There are four nitrogen bases; adenine (A), thymine (T), cytosine (C) and guanine (G), 
and it is the order of these bases within a DNA sequence that determines the DNA’s 
instructions, or genetic code. A and G bases are referred to as purines, while C and T are 
pyrimidines, their structures are shown in Figure 1.1.  
 
Figure 1.1: Chemical structure of purines adenine and guanine, and pyrimidines 
cytosine and thymine. 
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The DNA sequence forms genes, which contain the genetic information that gets transcribed 
from DNA into ribonucleic acid (RNA), and then translated into proteins, discussed in more 
detail in 1.1.2. 
 
DNA was first observed in 1869 by biochemist Frederich Miescher, but the importance of 
this molecule was not fully appreciated until many years later1. Rosalind Franklin and 
Maurice Wilkins were the first to suggest that DNA formed a helical molecule based on their 
work using X-ray diffraction2. Erwin Chargaff was also investigating the structure of DNA, 
with notable observations that A, T, C and G were not found in equal quantities (and that this 
varied among different species) and that the amount of A was always equal to T, and C equal 
to G3. Thanks to this research – and data from a number of other researchers – James Watson 
and Francis Crick determined that these nucleotide building blocks were arranged in the 
famous DNA double helix. They published this data in 19534, and were awarded the Nobel 
Prize alongside Maurice Wilkins in 1962. 
 
Each helix within the double helix structure is formed by a chain of nucleotides linked by 
phosphodiester bonds. The helices are held together by hydrogen bonds between the base 
pairs; each pair consists of a purine and a pyrimidine as mentioned above, where adenine 
pairs with thymine and cytosine with guanine. Watson and Crick’s original model suggested 
that there were two hydrogen bonds between bases and, while this is true for A and T, we 
have since discovered that there are three bonds between C and G. 
 
There are three known conformations of DNA – A-DNA, B-DNA and Z-DNA. Watson and 
Crick’s model describes B-DNA, where the double helix contains one complete turn every 10 
4 
 
base pairs and is 34 Å (3.4 nm) long, Figure 1.2. Adjacent base pairs are appropriately 3.4 Å 
apart, and are stacked via Van der Waals forces. The energy associated with these forces is 
relatively weak, but as the helical structure contains many bases, there is a large amount of 
force to stabilise the overall structure of the helix. 
 
 
The stacking of bases within the double helix structure of DNA results in the molecule 
having two asymmetric grooves; the minor and major groove. This is a result of the 
configuration between the bonds and forces of the base groups. The grooves expose the base 
edges and are important sites for binding, allowing various proteins to interact with and 
maintain the DNA to regulate gene activity. 
Figure 1.2: The double stranded DNA helix as described by 
Watson and Crick (1953). Adjacent base pairs are 0.34 nm (3.4 Å) 
apart, and each complete turn is 3.4 nm in length. 
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 Transcription and translation  
Double stranded DNA runs in an antiparallel manner, with the two strands running alongside 
each other but in opposite directions (each strand is said to run from 5’ to 3’).  5’ is the 
phosphate-bearing end, whereas 3’ has a hydroxyl group, both strands align with each other 
in complement, i.e. the DNA sequences pair to their partner as mentioned above (A to T, C to 
G)5. 
 
These DNA sequences form genes, which encode for proteins, key molecules responsible for 
all functions necessary for life, such as cell division. When mutations occur and interrupt the 
functions of these proteins, this can lead to pathogenesis, which will be discussed later in this 
thesis. Genes manufacture – or express – proteins in a two-step process; transcription, 
followed by translation6, Figure 1.3. 
 
Transcription sees the DNA sequence as a template for complementary base-pairing. RNA 
polymerase II catalyses the formation of pre-mRNA (pre-messenger RNA), which is 
processed into mature mRNA; a single-stranded copy of the transcribed gene. 
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During translation, the mRNA is read in triplicate, i.e. three bases as a time; each three bases 
of mRNA is determined a codon. The order of codons denotes the specific amino acid 
sequence that is being translated, and the mRNA serves as a template to assemble the chain 
of amino acids to form the protein. 
 
 The cell cycle 
Cell division is an important process for eukaryotic cells, functioning in tissue growth, repair, 
and maintenance, and is a critical component of the cell cycle7. The cell cycle is an ordered 
sequence of crucial events that occurs prior to cell division. This process is divided into four 
stages; first the cell increases in size (gap 1, G1), before copying its DNA (synthesis, S) 
preparing to divide (gap 2, G2) and then undergoing cell division (mitosis, M), Figure 1.4. 
Eukaryotic cells spend the majority of their life (around 90 %) in interphase, the period of 
preparation before mitosis. There are a number of proteins – growth factors, growth factor 
receptors, signal transducers and transcription factors – involved in each of these critical 
 
Figure 1.3: Schematic showing the process of transcription and translation. DNA is 
copied into mRNA by RNA polymerase, before the sequence is read and translated into 
protein. Each codon codes for an amino acid and builds parts of the protein molecule. 
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stages8. Many of these act as checkpoint signalling systems to make sure that the cell cycle 
progresses correctly, with the end of G1 and G2 being vital in detecting DNA damage before 
continuing into S phase, preventing these errors from being replicated. 
  
Proteins, such as p539, play a crucial role in the DNA damage response pathway, and 
mutations within these proteins can cause cells to grow irregularly – instead of being 
instructed to undergo apoptosis, programmed cell death – resulting in diseases such as 
cancer7,10. These proteins are therefore often key targets for therapeutics, as well as 
diagnostic markers, which will be explored later in this thesis. 
 
Mitosis is the phase of cell division where two daughter cells are produced, containing the 
same genetic information as their parent cell11. The chromosomes that were replicated during 
Figure 1.4: The cell cycle is a controlled process of the replication of 
chromosomal material and, ultimately, division of parent cell to 
daughter cells. Different cell cycle stages check for error before 





S phase are divided in a highly controlled process to make sure that each daughter cell 
receives a copy of each chromosome. Mitosis is divided into five distinct stages: prophase, 
prometaphase, metaphase, anaphase and telophase, before finally, undergoing cytokinesis, 
Figure 1.5. During these stages, the nuclear envelope surrounding the chromosomes breaks 
down, and the duplicated chromosomes condense and attach themselves to spindle fibres 
(composed of microtubules). These spindle fibres help to align the chromosomes before 
pulling one copy of each to the opposite side of the cell. Once this has completed, the nuclear 
envelope begins to reform and the chromosomes decondense, before the spindle fibres 




Figure 1.5: Mitosis is the process of cell division whereby 
daughter cells are produced as exact genetic copies of their 
parent cells. This process is split into various stages each with 





The aim of mitosis is to produce daughter cells with exact copies of the genetic information 
as their parent cell – a full set of chromosomes. However, errors can occur during mitosis that 
result either in the cell being directed to apoptosis or, if the errors go undetected, cause 
mutations that can give rise to diseases such as cancer10. Nondisjunction, for example, is the 
failure of sister chromatids to separate during cell division – and can also occur during 
meiosis12,13, when haploid sex cells are formed from diploid parent cells – and results in a 
daughter cell with abnormal chromosome numbers (aneuploidy). Aneuploidy is associated 
with many cancers and genetic diseases such as Down's syndrome (trisomy 21)14,15. 
 
 DNA mutations 
DNA mutations are permanent changes to a DNA sequence that have implications that range 
in severity, potentially affecting the cell's physiology and ability to undergo normal cellular 
processes, resulting in disease. Mutations also range in how much of the DNA is affected; in 
some cases it can be a single nucleotide, and in others large segments of a chromosome are 
altered16. These mutations can occur by different mechanisms, for example they could be 
inherited from a parent, or from DNA failing to replicate correctly during cell division, which 
could be as a result of external influences – such as radiation or specific chemicals that cause 
strand breaks or DNA adducts – preventing efficient replication and repair17–19.  
 
There are a few different types of mutations that can occur, with some having significant 
clinical implications, and others having little to no effect. Mutations can be either structural 
or numerical (aneuploidy)20. Severity is determined by the location of the mutation within a 
gene (or genes), and the function of the gene(s) that is affected. As discussed briefly above, 
aneuploidy – of which monosomy and trisomy are both examples – is a common cause 
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of many genetic disorders, as well as cancers. Different examples of structural mutations are 
displayed in Figure 1.6. 
Insertions or deletions see the addition or loss of genetic material – from a single base to a 
large section (potentially hundreds of thousands of kilobases) of DNA. The size of the 
mutation will determine which diagnostic technique is used for detection, as will be discussed 
in greater detail in 1.2. These mutations can cause a shift in the codon that is translated, 
termed a frameshift mutation. Duplication also sees the addition of genetic material where a 
specific sequence is erroneously repeated. Substitution, or point mutation, sees the change of 
one nucleotide to another, e.g. an A becomes a G. Changing a single base could also 
potentially change the codon for translation, resulting in errors in the protein being produced. 
This is explored later in this thesis, where a single nucleotide change causes a truncated 
protein to be produced in spinal muscular atrophy (SMA). Translocation is a larger mutation, 
that sees part of a chromosome swap with part of another, which occurs in many cases of 
Figure 1.6: Various genetic mutations can occur, some of which give rise to 
disease. Structural mutations can involve insertion, deletion, duplication, 
inversion and translocation, where genetic information is lost, gained or 
transferred to a different part of a single, or multiple, chromosomes. 
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cancer, and is discussed in greater detail later in this thesis. Inversion is another large 
mutation, where a DNA segment is flipped 180 ° so that it runs in reverse to the original 
structure. 
 
 Genetic diagnostic techniques 
Cytogenetic techniques such as karyotyping G-banded chromosomes and FISH (fluorescent 
in situ hybridisation) allow us to obtain information on a whole chromosomal level, and 
hence to detect large genomic rearrangements21. These approaches, while effective for 
detection of certain mutations – such as the formation of the Philadelphia Chromosome22 
through chromosomal translocation in CML (chronic myeloid leukaemia) – are not suitable 
for diseases that involve smaller mutations e.g. SNPs (single nucleotide polymorphisms) that 
are present in CF (cystic fibrosis)23. Recently, research has increasingly moved from 
cytogenetics onto molecular genetics, with NGS at the forefront of diagnostic techniques.24 
While NGS is a high throughput technique that can provide results at single base resolution, it 
typically does so using short reads of ~40-400 bp (Illumina), therefore making it ineffective 
in analysing large chromosomal rearrangements25. Due to the mechanism of NGS and the 
necessary amplification of target sequences, this also makes the technique difficult to use in 
diseases where copy number variation (CNV) – a type of structural variation where sections 
of the DNA sequence are repeated or deleted – may play a role. Ensemble averaging of 
amplified sections may also cause problems for diagnosing residual diseases characterised by 
a small subset of abnormal cells, such as in leukaemia. By analysing samples on a single 
molecule level, this could allow for quantitative information on (ab)normal sequences to be 
gathered, rather than lost through ensemble averaging. There is a clear gap in potential to 
diagnose certain diseases effectively and in a less time-consuming manner, which could 
possibly be filled by the integration of both cytogenetic and molecular techniques26. Figure 
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 Methylation and disease 
Another disadvantage of most current genetic diagnostic techniques, is that they do not take 
into account epigenetic information that could be the cause of many different diseases. 
Epigenetics is starting to gain more attention from researchers who have acknowledged the 
link between DNA methylation and disease27. In mammals, methylation occurs mainly at 
CpG dinucleotides, converting the DNA base cytosine to 5-methylcytosine (m5C). As DNA 
methylation is involved in basic gene expression and regulation, as well as cellular 
differentiation and development, aberrations in methylation can lead to the progression of 
many genetic diseases such as Prader-Wili, Angelman28 and Beckwith-Wiedemann 
syndrome29. Hypermethylation of promoter regions on CpG islands of tumour suppressor 
genes results in silencing of those genes, and has been associated with almost all tumour 
types30. Hypomethylation has also been linked to cancer, as this can lead to chromosomal 
instability resulting in tumour growth31,32. 
 
Figure 1.7: Cytogenetic techniques (e.g. karyotyping and FISH) can be used to visualise 
large genetic mutations, while molecular techniques such as sequencing are better suited 




Karyotyping is a cytogenetic technique that involves the pairing and ordering of a patient’s 
chromosomes to check for large mutations that involve megabases or more of DNA. It is 
often used in cases of aneuploidy, where it is suspected that there are extra chromosomes, 
such as in the case of Down’s syndrome where the patient has trisomy 2133, or loss of entire 
chromosomes such as in Turner syndrome (associated with loss of chromosome X)34. 
Karyotyping can also show structural changes including translocations, deletions and 
duplications, and can be used to diagnose conditions such as genetic birth defects or cancers. 
An example of a "normal" 46 XX karyotype is shown in Figure 1.8. 
 
 Fluorescence in situ hybridisation (FISH) 
Fluorescence in situ hybridisation (FISH) is a molecular cytogenetic technique used to detect 
and localise specific DNA sequences both in metaphase and interphase cells35. It is 
considered the gold standard cytogenetic method for detecting large chromosomal mutations 
such as translocations and aneuploidy; FISH is particularly suited to chromosome 
enumeration as it can be performed on both cells both in interphase and metaphase, saving 






time in harvest as synchronisation is not required as it is in karyotyping. In metaphase, 
resolution is typically between 1 and 3 Mb, and in interphase, mutations of around 50 kb to 1-
2 Mb can be detected; the increase of resolution in metaphase is due to chromosome being 
more condensed and is another advantage of FISH. Due to the high specificity, sensitivity and 
speed in which this technique can be used, FISH is routinely used both for diagnostics and 
research for a range of disorders from haematological malignancies to solid tumour samples. 
The process works by using fluorescently-labelled probes that are designed to be 
complementary to the target of interest along chromosomes35. Once the probe has been 
deposited onto a slide containing fixed patient cells, it is heated to a temperature capable of 
denaturing the DNA of both probe – which is typically double-stranded in traditional FISH 
probes – and sample so that they are single stranded. The temperature is then reduced back 
down to around 37 ⁰C to allow the hybridisation of single-stranded probe to the target DNA 
sequence, though this process can take up to 16 hours. The slides can then be washed and the 




FISH was originally developed in the 1960s36, but as new methods have progressed in terms 
of probe labelling and design – increasing the technique's sensitivity – it is being used for a 
wider range of applications35,37–40. From the 1990s, there was a sharp increase in the amount 
of publications using this technique41, which has since steadied since the development of 
sequencing, but there are still new applications and technologies emerging that show promise 
for future diagnostics. FISH is still widely used for the diagnosis of cancers and other genetic 
disorders due to its precise and rapid nature, and these new technologies are likely to further 
improve the way we can treat patients, this is discussed further in Chapters 4 and 5.  
 
Various genetic abnormalities can be highlighted using FISH, such as aneuploidy as seen in 
Down's syndrome where an extra chromosome 21 is present, gene fusions as seen in certain 
cancers such as the formation of the Philadelphia Chromosome (BCR/ABL) in CML42, or 
Figure 1.9: Schematic showing the workflow of FISH. Fluorescently-labelled probes are 
used that are complementary to the target sequence. DNA is denatured by heating to 
around 72 °C before cooling to hybridise at 37 °C. The sample can be visualised using 
fluorescence microscopy.  
16 
 
loss/gain of chromosomal material such as a deletion of chromosome 5q43, commonly 
associated with myelodysplastic syndrome (MDS). FISH is commonly used to confirm 
abnormalities that have been identified via other diagnostic techniques such as karyotyping or 
microarray analysis, or to identify balanced rearrangements or microdeletions that alternative 
methods were unable to detect.  
 
Despite advances and ongoing research into various aspects of FISH technology, it is clear 
that there is a call for further improvement in availability of different probes to enhance its 
potential in both diagnostic and research applications. Currently there are a range of probes 
(~200) from commercial sources, that are derived from the human genome and used in 
diagnostics for common genetic diseases44. This number however, is relatively small and 
restrictive, and does not provide an option for diagnosis of less common genetic 
abnormalities, especially microdeletions and balanced re-arrangements which may not be 
detectable using other techniques. These probes are generally developed from DNA 
fragments, collected during the Human Genome Project, that are cloned in bacterial artificial 
chromosomes (BACs).45 This BAC library can then be called upon to retrieve probes that are 
designed for specific loci of interest.  
 
 OligoFISH 
Oligoprobes are short sequences of DNA (around 50 bp) designed to be complementary to 
the region of interest (ROI)46. Unlike most commonly used FISH probes, they are not derived 
from BACs, but are designed synthetically44. Due to the short length and low complexity of 
the probe, this leads to faster hybridisation kinetics compared to traditional probes (which can 
be hundreds of kilobases in length), as well as greater specificity to the target37. If these were 
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to be used clinically, this could result in faster results for patients, making them highly 
favourable over standard probes. Another benefit of these synthetic probes is the ability to 
design and tailor them with high specificity to target uncommon abnormalities and 
variations38. This flexibility sets them apart from other FISH probe manufacturers who are 
only able to create probes for common abnormalities, or those that are easily available within 
a BAC library. Research has also found that oligoprobes are able to discriminate between 
cytogenetically indistinguishable homologous samples44. Structural variations that differ only 
at a few bases are able to be detected by these oligoprobes when designed to target these 
areas47.  
 
OligoFISH is increasing in popularity due to its extensive capabilities; there is an emerging 
application of using oligos for FISH in single-molecule and super resolution imaging, with 
Beliveau et al. using Oligopaint probes – single-stranded libraries of fluorescently-labelled 
oligos – to visualise genomic regions ranging in size from tens of kilobases to many 






FISH can also be performed on DNA that has been stretched and immobilised across a 
microscope slide, to allow visualisation of smaller mutations down to around 1,000 bp; this 
technique is called fibre-FISH48,49. In this way, the physical order of DNA fragments can also 
be determined and could be used to investigate translocations or duplications/deletions of 
certain genes. Fibre-FISH can be used in conjunction with restriction mapping to assist in 




DNA microarrays are microscope slides capable of detecting thousands of genes at a time51. 
Each slide, or chip, has probes attached that are complementary to their target of interest, and 
can detect gene expression (mRNA). The process of running a microarray involves using 
mRNA samples from both the patient and a reference, which are then converted to cDNA and 
labelled with fluorescent probes of different colours. These samples are combined and then 
Figure 1.10: Fibre-FISH creates a physical map of DNA fragments (A) 




hybridised to the probes on the chip. The chip is then scanned to measure the level of gene 
expression and flags up positions where the patient differs from the reference sample, 
uncovering potential changes to gene expression which could be indicative of disease. This 
technique is highly effective in highlighting losses and gains of genetic information that a 
patient may have, from copy number variation down to SNPs detection, and at a higher 
resolution than cytogenetic techniques such as FISH. 
 
SNP arrays are a type of array/chip that can be used to investigate slight variations between 
whole genomes, and are frequently used for large genome-wide association studies to 
determine disease susceptibility52. Everyone has multiple SNPs within their genome53, and 
genetic linkage analysis can be performed using SNP arrays to map a person's SNP variants 
against difference disease loci, providing insight into markers for diseases such as rheumatoid 
arthritis54 and prostate cancer55. SNP arrays can also be used to detect loss or mutation of a 
specific allele (loss of heterozygosity (LOH)), which can be associated with oncogenesis. 
This technique has advantages over similar technologies as it can detect gene conversion 
events, highlighting the inheritance patterns of alleles from the parents, but they are not able 
to detect balanced translocations. 
 
 qPCR 
Quantitative PCR (qPCR) is another technique that uses hybridisation to detect DNA 
mutations. PCR amplifies a specific region of interest by performing a series of heating and 
cooling stages to denature the DNA56. Primers are designed to be specific to the end of the 
target DNA and, using DNA polymerase and added deoxynucleotides (dNTPs), the primers 
extend to synthesise new strands in the cooling stage. As the cycles repeat this amplifies the 
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amount of DNA in the sample. qPCR uses either dyes that intercalate into double-stranded 
DNA or fluorescently-labelled primers, so that after amplification the DNA can be detected. 
This allows direct quantification of a specific DNA target such as in cases of gene 
amplification or translocations57,58.  
 
 Sanger sequencing  
DNA sequencing provides genetic information down to single base resolution, determining 
the exact position that each base is in. It still remains a challenge to sequence entire genomes 
due to their complexity, which is why these methods require the DNA to be broken into 
smaller fragments and reassembled into a consensus sequence. This has become a quicker 
and less expensive process since the completion of the Human Genome Project in 200359. 
 
Sequencing was first investigated in the 1960s, where Robert Holley and colleagues 
sequenced the first whole nucleic acid sequence – alanine tRNA from Saccharomyces 
cerevisiae60. It wasn’t until 1977 that a major breakthrough progressed this technology 
further, with Fred Sanger developing dideoxy chain-termination sequencing61, Figure 1.11, 
now referred to as Sanger sequencing. This method uses dideoxynucleotides (ddNTPs), 
molecules similar to dNTPs but lacking a hydroxl group on the 3’ carbon. During PCR, 
dNTPs are amplified by joining at the 3’ hydroxyl group; by incorporating ddNTPs into the 
mix, this prevents the chain from growing further. Each base (A, T, C or G) of ddNTPs is 
fluorescently labelled, so that when the chain is terminated, the colour of the dye acts as a 
marker for that base. For Sanger sequencing, fractions of dNTPs and fluorescently-labelled 
ddNTPs are mixed and amplified by PCR, with each strand randomly terminated during 
replication by the presence of the ddNTP. These molecules can be applied to capillary 
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electrophoresis which separates fragments by length and, as they run through the capillary, 
the fluorescent signal is recorded by a detector. This reports which ddNTP was incorporated 
into the strand at each point based on peaks in the fluorescence intensity, and the 
chromatogram acquired can be used to determine the sequence.  
 
Sanger sequencing can be used for fragments of up to around 900 bases in length, beyond this 
it becomes inefficient and expensive. Shotgun sequencing can improve this technique further 
Figure 1.11: Sanger sequencing uses a chain termination technique to detect base 
position within a DNA sequence. Fluorescently-labelled ddNTPs incorporate into single 
stranded DNA during extension, terminating the chain, and these fragments can be 





by incorporating several rounds of fragmentation of DNA into smaller segments than chain-
termination sequencing, which can then be assembled in silico to produce a longer, 
overlapping contiguous sequence62. 
 
 Next generation sequencing 
Since the development of Sanger sequencing, new large-scale sequencing techniques that are 
faster and less expensive have emerged24,25. The first human genome took ten years to 
sequence, at a cost of around $3 billion, but now, the same can be achieved with next 
generation sequencing (NGS) in a single day, for around $1,000. This progression has 
allowed NGS to become feasible for clinical applications, and is now a widely used 
technology. 
 
There are a variety of different NGS techniques that vary slightly, but they all have the same 
features that distinguish them from Sanger sequencing. NGS processes samples at large scale 
in parallel, i.e. many sequencing reactions happening at the same time, which means that 
multiple results can be processed at once. This high-throughput process translates into 
sequencing potentially thousands of genes at one time, as well as providing deep sequencing 
and therefore accuracy to detect novel or rare variants. This not only decreases time to result, 
but always dramatically lowers the cost of sequencing. One of the limitations of NGS, 
however, is that there can be a significantly higher error rate than traditional Sanger 
sequencing, and that the reads are much shorter (between 35 and 700 base pairs). Shorter 
reads can make it more challenging bioinformatically to piece together the genome. Large 
rearrangements – such as duplications, deletions, insertions and translocations – can be 
troublesome or impossible to detect, and complex regions in the genome containing repeats 
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and gaps may be difficult to map. As discussed in 1.1.4, these large-scale mutations can be 
associated with a number of diseases, and it is critical that these can be detected accurately. 
 
 
 Single molecule real time sequencing 
New long-read technologies have been developed in an attempt to overcome some of the 
limitations of NGS, one of which is single-molecule real-time (SMRT) sequencing, 
commercialised by Pacific Biosciences63. This technique again uses DNA replication to 
sequence long fragments of DNA. Thousands of individual wells – named the zero-mode 
waveguides (ZMWs) – each contain a single DNA polymerase fixed to the wells' transparent 
bottom, alongside a single DNA template. As a labelled nucleotide is incorporated into the 
DNA sample in each well, a camera records the emitted light that allows the sequence to be 
read. As the pore is too small for light to easily pass through, the emitted light is that only of 
a single nucleotide. On average, SMRT sequencing can typically reach reads of around 20 kb, 
a huge improvement to other sequencing platforms, making it seem a good choice for 
deciphering difficult regions of the genome. However, there are some drawbacks to this 
system, as the flow cells used do not have as high throughput as Illumina NGS platforms. The 
ZMWs do not always carry out successful sequencing reactions either due to failure of the 
polymerase to anchor to the ZMW, or inaccurate loading of more than one DNA molecule 
into the ZMW64. Error rate is also high for this technique, with the single-pass error (the rate 
of error per read) approaching 15 %, which naturally impacts both time and cost, making it 
not ideal in a clinical context. In 2019, Illumina acquired Pacific Biosciences, with discussion 
to merge the two techniques to produce a high-throughput long-read hybrid technology with a 




 Nanopore sequencing 
Another type of long-read sequencing is Oxford Nanopore Technologies’ nanopore 
system65,66. This is one of the only platforms that does not use the incorporation of 
nucleotides to detect the sequence, but instead directly reads the bases themselves of single-
stranded DNA (or RNA). This means that the technique does not rely on PCR amplification, 
avoiding the bias that this can produce. For this technique, an electric current is applied 
across a protein pore. As strands pass through these pores, the current is disturbed and this 
shift in voltage is noted. The characteristic shift of each nucleotide is recorded and, by 
training the data according to this, the sequence of an unknown fragment can be determined 
based on these shifts. This technology currently produces reads of similar size to Pacific 
Biosciences on average (between 10 and 20 kb67) but there are reports of maximum lengths 
reaching ~ 2 Mbp68. It's important to note that fragment length is limited by sample 
preparation, and not the technique itself, as shearing of the DNA can occur prior to analysis. 
 
One of the main disadvantages of this technique is that the pore only remains operable for a 
certain numbers of runs before it breaks down. This means that in terms of cost, it may not be 
feasible for clinical applications, although the company has recently released higher 
throughput systems such as the GridION to join their expanding range of products69. Another 
challenge is that further work needs to be done to improve the technology's accuracy. The 
speed that the strand moves through the pore (1 to 5 µs per base) can make deciphering the 
recording difficult as, if there is noise present, this affects the ability to accurately detect a 
single nucleotide, and increases error rate70. Various groups are working on new algorithms 





 Fluorescence  
As discussed previously, some genetic diagnostic approaches use fluorescence microscopy to 
visualise molecules such as DNA. These techniques use fluorescently-labelled probes to bind 
to the target of interest, which allows it to be detected for further analysis. 
 
 Fluorescence and emission of light 
Fluorescence was described by George Stokes in 185220, when he observed that the mineral 
fluorspa was capable of emitting red light when excited by UV light. Fluorescence occurs as 
a result of a molecule in the singlet ground state (S0) absorbing photons of energy, which 
promotes electrons into a higher-energy orbital, Figure 1.12. This excited state (S1’) only 
lasts a short period of time (nanoseconds) before the electrons begin to relax, releasing 
energy as photons. The emitted light typically has a longer wavelength and lower energy than 
that absorbed. This difference in absorption – the Stokes shift – allows sensitive (single 
molecule) detection of emitted photons in fluorescence-based experiments, Figure 1.13.  
Figure 1.12: Fluorescence occurs when a molecule in the singlet 
ground state (S0) absorbs photons of energy, which promotes 
electrons into a higher-energy orbital. This excited state lasts 
nanoseconds before the electrons relax and release energy as 





 Fluorescence microscopy 
Fluorescent probes are invaluable tools, as they provide sensitivity and specificity in complex 
samples such as cells. In this way, they can be used to detect genetic abnormalities that may 
play a role in the pathogenesis of certain diseases.  
 
Fluorescence microscopy is a popular technique used to visualise biological samples that 
have been labelled with fluorophores (fluorescence probes)72. The most basic fluorescence 
microscopy technique is widefield, with the set up typically consisting of a light source, a 
dichroic mirror, excitation and emission filters, an objective lens and a detector/camera, 
Figure 1.14. Excitation is achieved by light – typically from lasers or mercury bulbs – 
Figure 1.13: Stokes shift is the difference in absorption (excitation) and emission, that 




passing through an excitation filter that only allows specific wavelengths through72. The light 
reflects off of the dichroic mirror, focuses through the objective lens and then hits the 
fluorophores within the sample. The fluorescent molecules are then excited and emit light as 
described in 1.3.1. As the emitted light is a different wavelength to the excitation, this allows 
the emission filter and dichroic mirror to distinguish between the two, preventing the 
excitation light from reaching the detector. Emitted light is collected by an eyepiece or a 
camera for image acquisition and analysis. 
Figure 1.14: Typical widefield microscope set up. Excitation 
light is passed through a filter, reflected off of the dichroic 
mirror and focused through the objective lens to excite the 
fluorophores within the sample. The subsequent emitted light (of 
a longer wavelength that the excitation light) passes through the 
dichroic mirror and emission filter, to acquire the image. 
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While widefield microscopy can produce high-resolution images, there are some limitations 
that affect it. The whole sample is flooded with illumination during excitation; this causes 
emitters that are above and below the focal plane to be excited, which can contribute to high 
background noise in images compared to techniques such as confocal microscopy73. 
Computational techniques such as deconvolution can be used however to improve the 
resolution of images acquired from widefield microscopy, by removing light that is out of 
focus and re-assigning blurred noise to source points. 
 
 Methyltransferase enzymes 
Methyltransferases (MTases) are enzymes that each recognise, with high specificity, 
sequences of DNA between 4 and 8 bps in length74. Bacteria have developed a unique 
defence mechanism against viral invasion which uses these DNA MTase enzymes. When 
viral DNA enters the host, it is unmethylated; to distinguish between self and non-self DNA, 
the bacteria methylates its own genetic information using MTases. As corresponding 
endonucleases (restriction enzymes) recognise and act on the same DNA sequences, this 
allows them to cleave and remove the unmethylated viral DNA, while protecting self-DNA 
from restriction (as it is blocked by a methyl group)75. The MTases’ high specificity for DNA 
sequences has since been used by many research groups to deliver methyl groups to target 
DNA sequences of interest76–79.  
 
 DNA alkylation using MTases 
Recent research has shown that it is possible to use the MTases’ specificity, and modify their 
natural co-factor, in order to transfer extended functional groups to specific targets or features 
of interest on DNA. This enzymatic method allows labelling of the DNA without 
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modification of the sequence itself. As there are thousands of known DNA MTases targeting 
more than 250 different recognition sites80, using these for DNA modification seems a 
promising approach for many applications, including gaining more knowledge and 
understanding of gene expression81, cellular differentiation and the link between methylation 
pattern and disease32,82,83, as well as aiding detection of genetic variation within a 
population27,81,84.  
 
MTases can be split into two major groups, and interact with either adenine or cytosine, 
shown in Figure 1.15A-C. The m5C class of enzymes mentioned previously (e.g. M.HhaI, 
M.BsaWI) methylate the ring carbon at position 5 of cytosine, converting it to 5-
methylcytosine (m5C)85. The other group consists of amino MTases which target the 
exocyclic nitrogen of either adenine (e.g. M.TaqI) or cytosine (e.g. M.BamHI) resulting in 
N6-methyladenine and N4-methylcytosine respectively80.  
 
Typically, the structure of a bacterial DNA MTase consists of a large and small domain, of 
which the large contains the cofactor binding site and catalytic domain, and the small 
accommodates the target recognition domain (TRD) responsible for sequence specific DNA 
recognition85,86. The structure of the catalytic domain remains similar for all DNA MTase 
enzymes and comparative sequence analysis has shown that within this domain there were 10 
conserved motifs in m5C MTases. The conserved motifs (of which I, IV and VI were most 
conserved)72,81 were examined using crystal structure analysis and their importance for 
function confirmed by performing mutagenesis of these conserved residues. Their mutation 
has a dramatic impact on catalysis, cofactor binding and DNA binding82. The ubiquitous co-
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factor S-adenosyl-L-methionine (AdoMet), acts as the donor for the transfer of a methyl 
group to the DNA target, leaving the product S-adenosyl-L-homocysteine (AdoHcy), Figure 
1.15. 
A novel concept for labelling DNA using synthetic cofactors was put forward in 200477, by 
replacing AdoMet’s amino acid side chain with a highly reactive aziridine group with 
fluorophore attached, it was found that the DNA MTase M.TaqI was able to catalyse DNA 
modification to the specific sequence of interest. This method, as well as the use of N-
Figure 1.15: MTases transfer methyl groups site-specifically to DNA. The target 
base differs depending on the type of MTase, resulting in A) C5-methylcytosine B) 
N4-methylcytosine or C) N6-methyladenine. AdoMet is the cofactor used for 
methylation, with the leaving product AdoHcy (D). 
31 
 
mustard chemistries as seen in 200587, involved the coupling of the entire cofactor itself to 
the target DNA sequence and was dubbed sequence-specific MTase-induced labelling 
(SMILing). This chemistry was again used by Schmidt et al. in 2008 and successfully used to 
study cell transfection88. In 2006, Dalhoff et al. reported the synthesis of the first AdoMet 
analogue with carbon chains replacing methyl groups79,89,90, allowing transfer of the extended 
linear groups alone to specific target DNA sequences, and evaluated the cofactors efficiency 
in enzymatic reactions with all three MTase classes. The Weinhold and Klimašauskas group 
continued research into synthetic cofactors with these extended propargylic side chains, with 
this transfer of activated functional groups being referred to as MTase-directed transfer of 
activated groups (mTAG)90. Using mTAG, many chemical entities can be transferred to a 
DNA target sequence, for example a fluorophore, that could then be used for optical mapping 
experiments.  
 
These synthetic cofactors have not provided efficient transalkylation with wild type m5C 
MTases, however, currently making them somewhat cumbersome to work with. Steric 
engineering of MTase enzymes has proven successful in more efficiently allowing the 
transfer of these unnatural groups from cofactor analogues to the target DNA, and will be 
discussed in greater depth in 1.4.2. Using two step mTAG labelling for single molecule 
mapping experiments has proven partly successful for Vranken et al. in 2014, while 
attempting to couple fluorophores to specific sequences of DNA78. However, while the 
MTases were able to functionalise the DNA, the step of coupling the fluorophore (azide–
alkyne cycloaddition) resulted in only 60 % labelling efficiency. Single-step labelling, using 
fluorescent arizidine-based cofactors as discussed above, allowing MTases to deliver a 
fluorophore directly from the analogue seemed to provide more successful results. Weinhold 
et al. have very recently published work demonstrating that single step labelling can be 
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efficient in labelling bacterial genomes29. This technique could be useful in the ability to 
rapidly screen organisms and pathogens and for bacterial strain typing. 
 
As described above, AdoMet analogues can be produced to contain extended chemical 
moieties, such as amine or azide groups, Figure 1.16C. When using amine cofactors, such as 
AdoHcy-6-NH2, Figure 1.16A, the primary amine is transferred, which can react with N-
hydroxysuccinimide (NHS) ester dyes. This coupling reaction occurs at slightly alkaline 
conditions of pH 7.2 – 9, creating a stable amide bond, Figure 1.16B.  
 
Labelling with DBCO-functionalised dyes enables coupling to azide chains via strain-
promoted azide-alkyne cycloaddition (SPAAC) chemistry, and can be used with azide 
Figure 1.16: A) Diagram of AdoMet analogues: AdoHcy-6-N3 (top) and AdoHcy-6-
NH2 (bottom) B) SPAAC coupling reaction (top) and amine-NHS coupling reaction 
(bottom) C) MTase-directed fluorophore coupling: labelling with AdoHcy-6-N3 or 
AdoHcy-6-NH2 using SPAAC and NHS coupling, respectively.  
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AdoMet analogues such as AdoHcy-6-N3, Figure 1.16A. The conformational strain on the 
eight-membered ring in the DBCO dye structure, allows it to react with the azide group of the 
cofactor without heat or added catalysts, via click chemistry, Figure 1.16B. Figure 1.16C 
shows how these AdoMet analogues can be used with the MTases to transfer azide or amine 
groups to the DNA site specifically, before undergoing SPAAC (azide) or NHS (amine) 
coupling reactions to label the site with a fluorophore. 
 
In order to test labelling efficiency, DNA protection assays are often used. This involves 
incubating DNA (usually pUC19 or lambda) with the MTase and cofactor of choice, followed 
by challenging the DNA with the MTase’s corresponding restriction enzyme (i.e. recognising 
the same DNA sequence). If alkylation is successful, this will protect the DNA against 
restriction. If alkylation is unsuccessful, the restriction enzyme can cut the DNA at all of its 
recognition sites. The DNA is then visualised on an agarose gel via electrophoresis. From 
analysing the presence of bands at certain points in the gel, it is possible to calculate how 
efficient the MTase has been at labelling the DNA and, quantify the level of protection. This 
technique will be used extensively in Chapter 3. 
 
 Steric engineering of MTases for improved labelling of DNA 
As discussed, DNA MTases are enzymes that target short sequences of DNA typically 
between 4-8 bases long76. The novel concept of using synthetic cofactors, with active 
functional side-chains in place of methyl groups, makes DNA labelling possible74,76,91. These 
side-chains can be transferred to DNA site-specifically using MTases and later attached to a 
range of biomolecules or dyes. This way of labelling has many advantages, one being that it 
does not cause damage to the DNA such as that seen with nicking and restriction enzymes92. 
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MTase-directed labelling has since been used for several applications such as optical 
mapping, DNA capture, and visualising DNA in situ. 
 
m5C-MTases (such as M.BsaWI), are present in both eukaryotes and prokaryotes, and share 
similar mechanisms and structure. Comparative sequence analysis has shown that these 
MTases share conserved sequences (I-X). From examining the crystal structure of these 
conserved motifs, it was suggested that by making mutations at specific residues this could 
have a dramatic impact on cofactor binding76. By systematically modifying these bases at 
non-essential positions, this opens-up the cofactor binding pocket, allowing for greater 
transalkylation with relatively bulky synthetic cofactors, compared to the natural cofactor 
AdoMet. Research performed by Lukinavičius et al76., showed that by making double and 
triple replacements in the amino acid sequence of the MTase M.HhaI (which recognises 
GCGC, methylating the underlined cytosine), efficiency of reactions with AdoMet analogues 
could be significantly increased. The modifications of M.HhaI in this research were 
performed in the cofactor binding pocket at two or three non-essential positions in the 





In particular, this study found that these mutations led to an increase in synthetic cofactor 
binding efficiency, and a higher rate of alkyl transfer (Figure 1.1876), as well as a reduction 
in the stability of the complex DNA-M.HhaI-AdoHcy, meaning reduced affinity towards 
natural cofactor AdoMet This is important, as it demonstrates that engineered MTases can 
react with the synthetic cofactors even in the presence of competing AdoMet. Research has 
also shown, however, that methylation efficiency can vary significantly depending on the 
cofactor and enzyme combination, so these changes in the MTase structure may not be 
functional with all AdoMet analogues. This research has shown significant applicability of 
expanding a range of engineered m5C-MTases to develop a toolbox for covalent sequence-
specific labelling of DNA both ex vivo and in vivo.  
 
Figure 1.17: Amino acid alignments at conserved 
motifs IV and X in C5-MTases, a target for 





 Optical mapping 
Used in conjunction with sequencing, optical mapping has been shown to be a highly useful 
for a number of applications, mainly as a tool to aid the assembly of genomes93. The aim of 
optical mapping is to provide short pieces of genomic information from a large single 
molecule of DNA every few thousand bases, thanks to enzymes which target and modify 
sequences of around 6-8 bps in length. Optical mapping techniques involve the linearisation 
and extension of single DNA molecules, which are then visualised through fluorescence 
microscopy26,78,93–95. Single molecule techniques such as this can allow a simple route to 
studying large DNA molecules (up to megabases in length), without the need for DNA 
amplification or building a complex library. This can lead to a more straightforward approach 
to assembling and studying whole genomes, even of complex samples. Novel techniques for 
optical mapping of DNA have been emerging over the past few years and are being 
Figure 1.18: Activity of wild type and mutated M.HhaI with 
AdoMet and a range of AdoMet analogues. DNA protection 
assays were used to acquire turnover estimates. Taken from 
Lukinavičius et al. (2012). 
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continuously improved96,97. These techniques look promising, as they address some of the 
challenges that current diagnostic techniques face (as discussed in 1.2) such as issues with 
CNV, ensemble averaging and reconstruction of the genome after amplification of sequences. 
Optical mapping is of great interest as it can provide a scaffold to aid genome assembly when 
used in conjunction with sequencing, as discussed below. Another highly effective 
application of optical mapping is for strain typing and sequence validation. Research 
published by Grunwald et al. in 201598, demonstrated how optical mapping was used to 
rapidly identify bacterial genomes for both T7 and lambda bacteriophages, which provides 
both an exciting and important practical application. This technique can therefore directly 
analyse DNA molecules without any a priori knowledge of the sample composition.  
 
 Restriction mapping 
Initial optical mapping studies in the mid-1990s were developed using restriction 
enzymes99,100, and remain the most established. These studies, carried out by the Schwartz 
lab, have formed the basis of all subsequent optical mapping techniques and have been used 
to sequence full genomes de novo, including the recent publication of the goat genome101. 
Other great achievements using the optical restriction map technique include the assembly of 
the highly repetitive maize genome102 in 2009 and the mapping of four human genomes103 in 
2010. More recently it was used to complete the genomic sequence of a new species of 
bacteria104. The technique works by depositing the sample onto a functionalised surface 
before cutting segments of DNA at specific sites. The DNA is stained, commonly with 
intercalating dye YOYO-1, imaged and analysed. This provides a scaffold for which 
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sequencing information can be assembled and sized, as well at the acknowledgement of 
where gaps lie within the sequence, illustrated in Figure 1.1993. 
Despite this being a highly recognised and published method for optical mapping of 
genomes, there are also some limitations. Restriction enzymes are usually chosen that cut on 
estimate every 7-10 kbs, this is to prevent small fragments of ~2 kbs or less from dissociating 
from the surface. This means that when the region of interest on the genome is fairly small, as 
may be the case seeing as the average human gene is only 3 kb, this method is impractical.  
 
 Nicking enzymes for optical mapping 
Optical mapping with nicking enzymes, uses these enzymes for labelling of the DNA, rather 
than cutting as in restriction mapping. This is a technique that has only been used for optical 
mapping fairly recently by Xiao et al.105, despite the labelling by DNA nicking technique 
being first described in 1970s by Rigby et al.106 Using “nickases” or nicking endonuclease 
enzymes, the backbone of the target sequence of the DNA is nicked to produce a single 
strand break. Subsequently, DNA polymerase is added to the reaction to begin DNA 
synthesis from the site of the nick. The polymerase can be designed to integrate a 
fluorescently-labelled nucleotide at the nicking site and therefore into the new (short) DNA 
Figure 1.19: Optical mapping can be used in conjunction with sequencing to provide 
information on location gaps, and the position of contiguous sequences. Taken from 
Neely et al (2011). 
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strand. An example of this was performed by Xiao et al. using the nicking enzyme 
Nb.BbvCI107 to introduce a break into the DNA strand of interest, followed by the DNA 
polymerase integrating Tamra-ddUTP at the nicking site for labelling. The sample was then 
combed onto a surface for visualisation and localisation of fluorophores via fluorescence 
microscopy. Using nicking enzymes for optical mapping does have many advantages, mainly 
the highly specific labelling of target DNA sequences with fluorescent dye. However, as 
nicks can occur in DNA naturally, this can lead to non-specific labelling by the polymerase, 
which is a limitation of the technique. This covalent modification approach allows the sample 
to be extended and analysed after labelling through nanofluidic devices108. 
 
 MTase-directed optical mapping  
In 2010, Neely et al. proposed a novel idea for mapping using DNA MTases109. This optical 
mapping concept involves direct observation of single molecules of DNA stretched via 
combing and using MTase enzymes to fluorescently label the DNA sequence specifically. 
This novel technology allows analysis of the DNA sequence without compromising the 
sequence’s integrity, providing an ordered optical map. The research performed by Neely et 
al. highlights the potential in using MTases as a way to label DNA with both a high level of 
specificity and at a high density, providing a “DNA fluorocode”. This fluorocode would be a 
simple representation of the DNA sequence, which after imaging can be read as a barcode, as 




Due to the range of MTases with different sequence specificities, this study suggests an 
established toolbox of MTase enzymes each with an appropriate synthetic cofactor would be 
highly beneficial for labelling and highlighting different mutations or methylation states in 
various disease states, as well as aiding genome assembly. By using sub-diffraction limit 
imaging techniques, combined with the highly specific MTase M.HhaI (which recognises 5’-
GCGC-3’) providing high labelling density, Neely et al. were successfully able to localise 
fluorophores with great precision at the single gene level. In order to localise tags, to a 
precision of ~76 bps, that were in close vicinity and therefore overlapping each other, 
photobleaching was used to “turn off” emitters in turn. One of the main strengths of this 
method over other optical mapping techniques is the ability to map genomes in a single 
experiment, without the need for initial sequencing studies. Neely et al. successfully showed 
that the fluorocode is able to achieve a barcode-like representation of a DNA sequence in the 
absence of a reference genome, which is therefore able to detect variations that other 
techniques cannot, such as CNV. Another advantage of MTase directed optical mapping over 
using restriction enzymes is the ability to provide a much higher density of DNA labelling, 
with approximately one site every 650 bp, as well as higher precision in localisation of 
labelled sites. Methylation in vitro can also be detected, as the transfer of functional group to 
Figure 1.20: Histogram displaying localised fluorophores along lambda DNA. Black 
lines represent sites of M.HhaI, and can be used to produce a DNA fluorocode. Taken 
from Neely et al. (2010). 
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the target sequence will be impossible if the region is already methylated. Comparing results 
from this sample with a generated reference map in silico, means missing fluorescent labels 
can be detected as methylated sites. This could be of great use when detecting biomarkers for 
disease. Multicolour labelling of DNA, using both high and low density MTases, could be the 
next step for MTase-directed optical mapping using two or more MTases to ensure even more 





 Concluding remarks 
Genetic techniques have evolved rapidly over the past few decades, but there are still 
limitations to these techniques that prevent detection and diagnosis of various mutations. 
Developing these technologies further could make it possible to discover new areas of the 
human genome that have previously been inaccessible, or could provide novel diagnostic and 
carrier detection tests for different mutations and diseases. 
 
Cytogenetic techniques are effective in the detection of large rearrangements such as 
translocations and chromosomal aneuploidy, but lack the resolution to determine SNPs and 
other small mutations. In contrast, molecular diagnostics (e.g. NGS) provides single base pair 
resolution, but loses the contextual information necessary to retain the sequence position 
within the genome. This makes larger rearrangements difficult to visualise, as well as 
diseases where CNV plays a role. Ensemble averaging of amplified sections (a step crucial 
for the NGS protocol) may also cause problems for diagnosing residual diseases characterised 
by a small subset of abnormal cells, such as in leukaemia. With the emergence of SMRT and 
nanopore sequencing, this also demonstrates that there is a trade-off between throughput (and 
cost), and the long-range information that is necessary for CNV detection. 
 
Optical mapping can provide a solution to the limitations of these traditional techniques by 
providing long-range contextual information. Combining this technology with highly specific 
MTase-labelling could allow the visualisation of single DNA molecules, while maintaining 
the sequence position within the genome. MTase-directed labelling has many benefits over 
other labelling techniques: 
• High specificity ensures that non-specific labelling does not occur;  
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• Multiple MTases with different recognition sequences can label at variable densities, 
providing unique intensity profiles for different DNA sequences of interest; 
• No damage to the DNA itself, as with nicking enzymes. 
 
The emergence of new probe designs for FISH have also allowed this technique to continue 
to evolve, and it is gaining increased recognition in its ability to provide a physical map of 
both small and large genetic mutations. Using oligoprobes for FISH is becoming a popular 
way to amplify signals, highlighting regions of the human genome that are normally only 
accessible via sequencing techniques, due to their high specificity. With further development, 
oligoprobes could be used to visualise SNPs while maintaining sequence context within the 
genome. There is also potential in these oligoprobes to highlight genetic abnormalities much 
quicker than current diagnostic techniques, making it a favourable approach for diagnosing 




 Research aims 
New diagnostic techniques emerge and evolve as we understand more about the human 
genome, and there has been substantial progress towards novel techniques to discover and 
detect links between genetic instability and disease – but it is apparent that there are 
limitations stopping these technologies from reaching their full potential. This thesis shows 
how MTases can be used to explore different regions of the human genome – at a high 
resolution without the need for sample amplification – for various clinical applications.  
 
 DNA labelling technology 
Using MTase enzymes to deliver functional groups to target DNA sequences with high 
specificity and at a high density can have numerous practical applications, such as detecting 
structural genomic rearrangements that can also be biological markers for certain diseases, or 
for reliably labelling DNA for use in diagnostic tests such as FISH. These techniques are also 
suited for rapid pathogen identification, which could aid hospitals in strain typing bacteria in 
samples.  
 
• Optimise the MTase-directed labelling of DNA, primarily with M.TaqI; currently 
synthetic cofactors do not lead to complete labelling with fluorophores. 
• Development of MTase toolbox to be used with modified cofactors for DNA 
mapping.  
o Directed sequence engineering of a range of MTases at specific conserved 
residues for improved transalkylation with synthetic cofactors. 
o Express and screen a range of mutated proteins with a variety of cofactors to 
see which demonstrate efficient transalkylation activity. 
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o Achieve both high- and low-density labelling by producing enzymes that 
recognise different length recognition sequences, to produce a dual colour 
map. 
 
 Oligoprobes for FISH 
By labelling probe sequences using MTase based labelling techniques, it is possible to design 
probes with any number of fluorophores attached simply by including the specific MTases’ 
recognition sequence within the probe sequence. This is an important feature of this probe 
design, as it is not limited in the amount of labels that can be added, therefore improving 
sensitivity when viewing images of samples.  
 
• Optimise the labelling of FISH oligoprobes using MTases technology. 
• Optimise the following parameters to ensure strong signals and no cross-
hybridisation: 
o Probe design; 
o hybridisation conditions (buffer and temperature); 
o washing conditions (stringency); 
o hybridisation time. 
• Investigate the sensitivity of MTase-labelled FISH probes. 
• Explore the effects that oligoprobes have on hybridisation times. 
• Design and produce centromeric probes for chromosome 1, 7 and 17 – associated with 
acute lymphoblastic leukaemia (ALL) – as suggested by collaborators at the West 
Midland Regional Genetics Laboratory (WMRGL). 
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o Create a probe cocktail with all three probes labelled in three spectrally-
distinguishable colours that will provide a quick diagnosis within one 
screening.  
• Design, produce and optimise probes to target single gene loci (p53 and BCR). 
 
 Detection of point mutations 
MTase labelling technology could also provide potential in diagnosing disorders and 
abnormalities that contain SNPs or other small structural changes that current genetic 
techniques struggle to detect. Spinal Muscular Atrophy (SMA), a neuromuscular disorder, is 
the most common genetic cause of death in infancy110. The disease is characterised by 
mutations and therefore loss of functionality in the gene SMN1111. Nearly identical gene 
SMN2, which only has one critical nucleotide difference, can be present in variable numbers 
in patients and therefore restore some of the functionality lost from the SMN1 mutation112. 
This can result in varying levels of severity of the disease. Due to the similarity in sequence, 
FISH cannot currently be used to distinguish between SMN1 and SMN2, which is critical for 
carrier detection. Due to variations in the arrangement of the SMN1 gene, with some carriers 
having two copies of the gene on a single chromosome, and none on the other – discussed in 
greater detail in 3.1.2 – this also causes problems in diagnosis using molecular techniques.  
 
• Explore the use of oligoprobes to distinguish between highly similar sequences, such 
as the SNP in SMA 
• Investigate the potential of DNA mapping with MTases to determine slightly different 
DNA sequences  
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o M.TaqI and M.HincII have overlapping recognition sites, TCGA and 
GTYRAC respectively, investigate whether methylating a DNA sequence with 
M.HincII can subsequently block the labelling of M.TaqI, thus allowing the 
detection of a slightly altered sequence.  
o M.Hpy188I – the recognition sequence of which is affected by a SNP in gene 
SMN1 – could be expressed, purified and screened for potential in 
SMN1/SMN2 detection after proof-of-concept mapping experiments using 











2 Methods and materials 
 
 Molecular biology  
 Alignment and sequence engineering 
Sequences for wild type M.HhaI, M.SfoI and M.BsaWI were obtained from REBASE113, and 
Jalview was used to align and identify the conserved regions (Figure 1.17). Double point 
mutations were made at the same non-essential site in each sequence based on the promising 
transalkylation activity of M.HhaI Q82A N304A76. The genes were synthesised by IDT 
DNA, and a Gibson Assembly (2.1.2) was performed to insert the gene for the mutated 
MTases into new vector pRSET-B. These MTases will be expressed and their efficiency with 




 PCR and Gibson assembly® 
Gibson assembly is a molecular cloning technique that joins multiple DNA fragments – such 
as genes into new plasmids – in a single isothermal reaction114. Primers (Table 2.1) were 
designed for PCR of the fragments needed for Gibson assembly to sub-clone mutated MTase 
sequences into pRSET-B, Figure 2.1, ahead of protein expression. 
 
Table 2.1: Primers ordered for Gibson Assembly to subclone mutated MTases into new 
expression vectors. 
 
A standard NEB Q5 High Fidelity protocol was used in order to amplify the desired 
fragments using PCR. After amplification, fragments were confirmed by gel electrophoresis, 
2.1.5. Manufacturer's instructions were then followed to perform Gibson assembly using 
NEB Gibson assembly kit. 












































 Restriction digests 
To ensure that the sub-cloning of mutated sequences was successful, samples were restricted 
and analysed using gel electrophoresis, before being sequenced. After purification of DNA, a 
restriction digest was carried out using enzymes BamHI (G^GATCC) and EcoRI 
(G^AATTC), both ordered from NEB. For each sample two tubes were set up with 
either BamHI or EcoRI. On ice, 1 µl restriction enzyme (BamHI or EcoRI), 4 
µl ThermoFisher 10X FastDigest Green Buffer, 800 ng DNA and water up to 50 µl total 
volume were mixed. Samples were incubated at 37 oC for 20 minutes before 40 µl from each 
tube per sample was mixed into a single fresh microcentrifuge tube to create a double digest. 
The samples were incubated at 37 oC for a further 40 minutes. After incubation, 10 µl per 
sample were analysed using gel electrophoresis, as described in 2.1.5. Samples were sent to 
sequencing for confirmation and then expressed.  
 
Figure 2.1: Gibson assembly process where “insert” is the gene to be subcloned, into 
the recipient plasmid. A and B are the forward and reverse primers used to amplify 
this fragment during PCR before annealing exonuclease chew-back and joining via a 




MTase DNA sequences were confirmed by sequencing using services provided by the School 
of Biosciences at the University of Birmingham. Typical reactions were made up as shown in 
Table 2.2, and submitted using universal primers designed for the T7 promotor and 
terminator region. 
 Amount 
DNA  ~500 ng 
Forward primer 
 5’ TAATACGACTCACTATAGGG 3’ 
10 µM 
Reverse primer 
5’ GCTAGTTATTGCTCAGCGG 3’ 
10 µM 
Water  up to 10 µl final volume 
Table 2.2: Sample prep requirements for sequencing DNA samples in a plasmid with a 
T7 promotor. 
 
 Gel electrophoresis 
DNA was analysed using gel electrophoresis for validation of the sequence. Gel 
electrophoresis is a technique used to separate DNA fragments according to size by running 
an electric current across the agarose gel, Figure 2.2. As DNA fragments are negatively 
charged, they are pulled towards the positive electrode, with smaller fragments travelling 
faster, and therefore further, down the gel. This means that the fragments can be identified 
according to how far down the gel they have travelled. Gel electrophoresis can also be used 




Unless otherwise stated, a 1 % agarose gel was prepared by mixing 80 ml TAE buffer and 
0.8 g agarose. This was heated until the agarose had dissolved, and then poured into the 
electrophoresis equipment to set. 2 µl 6x NEB loading buffer was added to 10 µl sample and 
loaded into the lanes, alongside 5 µl NEB 2-log ladder. The gel was run at 120 V for around 
45 minutes and then left to stain in Gel Red for 30 minutes. A UV visualiser was used to 
acquire an image using EtBr filter.  
 
 Preparation of LB broth and LB plates 
LB broth was prepared by mixing 20 g Sigma LB Broth (Lennox) with 1 L water and 
autoclaving. Once cooled, the appropriate antibiotic was added to the correct working 
concentration, Table 2.3. 
 
 
Figure 2.2: Gel electrophoresis separates DNA samples by applying an electric current 
across an agarose gel. Small, negatively charged DNA fragments run faster through the 
gel, leaving a distinct size-based pattern that can be used for DNA identification. 
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LB plates were prepared by autoclaving 500 ml water and 20 g Sigma LB Broth with 
agar (Miller). Once cooled, the appropriate antibiotic was added to the correct working 
concentration. Plates were poured in sterile conditions and left to set.  
 
 Bacterial transformation 
 Competent E. coli strains were selected for either DNA amplification (NEB Turbo 
Competent E. coli (High efficiency) – C2984) or protein expression (NEB T7 Express 
Competent E. coli (High efficiency) – C2566) and thawed on ice. In a microcentrifuge tube, 1 
µl of DNA stock (up to 1 ng DNA) and 25 µl competent cells were mixed and lightly 
triturated before being left to incubate on ice for 30 minutes. The sample was heat shocked at 
42 oC for 30 seconds, then returned to ice for 5 minutes. 495 µl room temperature SOC media 
was added and the sample was left in a shaking incubator, at ~250 rpm and 37 oC, for 30 
minutes to 1 hour. Bacteria was spread on 3 LB plates (containing the appropriate antibiotic), 
at different volumes; 25 µl, 50 µl and 300 µl before being left at 37 oC overnight.  
   
The following day, 3 colonies per plate were picked using a pipette tip, and each placed into 
5 ml LB media (with appropriate antibiotic) into 50 ml falcon tubes. Samples were again left 
to incubate overnight in a shaking incubator at ~250 rpm and 37 oC. For DNA amplification; 





pET-28c 5367  Kanamycin 100 µg/ml  
pRSET-B 2900 Ampicillin 50 µg/ml  
Table 2.3: Expression vectors and their appropriate antibiotic (and 
concentration) for growth. 
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samples were purified using a standard Qiagen QIAprep Spin Miniprep Kit the following 
day, and the DNA was analysed using gel electrophoresis to check that the DNA present was 
of the correct size, (2.1.5) before being sent for sequencing to confirm the sequence was also 
correct (2.1.4). For protein expression the protocol was continued as in 2.1.8. 
 
 Protein expression 
The following day, two colonies were picked in sterile conditions using a pipette and placed 
in 20 ml LB media plus antibiotics (see Table 2.3). These starter cultures were left shaking 
overnight at 37 ⁰C, 250 rpm. The next day, a 1/80th dilution of the starter culture was made 
i.e. 40 ml in a 2 L conical flask with 400 ml LB media (with appropriate antibiotic). This was 
left shaking at 37 ⁰C, 180 rpm, until reaching an OD A600 of 0.4-0.6. Once at OD 0.4-0.6, 
IPTG was added to final concentration of 0.5 mM and left shaking at 20 ⁰C, 180 rpm for 16 
hours (unless otherwise stated).  
 
 Cell lysis 
Cells were spun down at 4 ⁰C, 4,000 rpm for 20 minutes and the supernatant discarded. 
Pelleted bacteria cells were resuspended in 20 ml PBS with protease inhibitor and spun again 
at 4 ⁰C, 4,000 rpm for 12 minutes. Lysozyme was added to fresh PBS with inhibitor to final 
concentration 4 mg/ml, the supernatant was again discarded, and resuspended in 25 ml of this 
solution. The sample was sonicated four times in 30 second on/off pulses before being spun 
back down at 4 ⁰C, 4,000 rpm for 14 minutes. The supernatant was collected and pellet 
discarded. Attempts were made to remove residual AdoMet from the protein complex for 




 Protein purification 
1 ml Ni-NTA agarose beads were spun at 500 x g for 5 minutes, the storage buffer removed 
and replaced with 1 ml PBS. The beads were washed by inverting the tubes a few times and 
then being spun in the centrifuge at 500 x g for 5 minutes. This was repeated five times. 1 ml 
PBS was added to the beads to create a 50 % slurry, 50 µl of which was mixed per 1 ml 
lysate and left on an end-over-end spin for 1 hour at 4 ⁰C. PBS was poured through Biorad 
EconoColumns to wet, before the sample was dropped through the column with a pastette 
and collected. The sample was run through the column followed by 25 ml (100x the column 
volume) of wash buffer (PBS, 300 mM NaCl, 20 mM imidazole). 5 ml elution buffer (PBS, 
250 mM imidazole) was finally poured into the column, left for 10 minutes and then eluted 
and collected. An Amicon Ultra 0.5 ml 10 kDa kit was used to exchange the buffer following 
the manufacturer’s instructions. Storage buffer was made up of PBS, 5 mM EDTA and 5 mM 
β-mercaptoethanol. Protein presence was checked using SDS-PAGE as described in 2.1.12, 
and stored in 50-60 % glycerol at -20 ⁰C. 
 
 Removal of bound AdoMet from M.TaqI 
In an attempt to remove residual AdoMet from M.TaqI protein, a palindromic oligo 
containing the M.TaqI recognition sequence (5′CCGCCTCGAGGCGG3′) was annealed by 
incubation at 95 °C for two minutes, before cooling at room temperature overnight. Two 
equivalents of M.TaqI were added to oligos sample before purification, and the mixture was 
incubated at 50 °C for 30 minutes.  
 
 SDS-PAGE 
The presence of protein from each eluted fraction was checked using SDS-PAGE. 20 µl of 
sample was mixed with 5 µl 4x Laemmli Sample Buffer, heated at 100 ⁰C for 5 minutes, and 
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spun in a microcentrifuge for 30 seconds. 5 µl ladder (NEB Blue Prestained Protein Standard, 
Broad Range (11-190 kDa)) was loaded into a precast Protean 4-20 % gel, along with 20 µl 
of sample and run at 200V for around 45 minutes. The gel was stained in Instant Blue on a 
rocker for 2 hours, and then washed in water for 1 hour. Gels were visualised on a UV 
visualiser. Fractions that showed high concentrations of protein based on analysis after SDS-
PAGE were pooled together and concentrated using the Amicon Ultra 0.5 ml 10 kDa kit and 
stored in 50-60 % glycerol at –20 °C. 
 
 Western blot 
Western blots were performed using anti-His antibodies to check that the bands from the 
SDS-PAGE gel were the correct protein (purified using their His-tag). 40 µl of each sample 
was taken pre- and post-purification and boiled at 100 ⁰C for 5 minutes. Samples were then 
analysed using SDS-PAGE as in 2.1.12. A Biorad Trans-Blot turbo transfer cassette was used 
for the Western blot. A 50 ml solution was made up of 5 % milk in 0.1 % PBST (phosphate 
buffered saline with Tween-20) and 2.5 g of Marvel original dried skimmed milk, which 
blocks background proteins. After SDS-PAGE, the gel was placed between the transfer pack 
filters which were set up as described by the manufacturer. Transferred layer was covered in 
the 5 % milk 0.1 PBST solution and gently rocked at room temperature for 1 hour. The filter 
membrane was placed in a pouch with 10 ml of the milk solution and 3 µl anti-His (H1029) 
antibody from Sigma (a 1/3,000 dilution as per instruction). The pouch was sealed and left 
rocking overnight at 4 ⁰C. 
 
The following day, the sample was retrieved and washed in PBST, by gentle rocking for 5 
minutes at room temperature. This was repeated with fresh PBST 5 times. The sample was 
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then covered in 5 % milk 0.1 % PBST with 9 µl (a 1/3,000 dilution) of secondary antibody 
(CST antimouse IGG (70765, Cell Signaling Technology)). This antibody is conjugated to 
horseradish peroxidase (HRP) which can be used for chemiluminescent detection, this offers 
a means to identifying a His-tagged protein. The sample was left gently rocking for 1 hour at 
room temperature, before the solution (and antibody) was poured off and washed 5 times 
with PBST (for 5 minutes rocking each time). Excess liquid was gently shaken off the sample 
before it was placed on cling film. 1 ml of detection reagent (1 and 2) from the ECL kit was 
added, and left for 5 minutes to develop a signal. The sample was shaken gentle to remove 
excess liquid, wrapped in sling film and placed in hypercassette. High performance 
radiography film was placed over the sample and visualised in X-ray developer, with an 
exposure time of 2 minutes. If bands are present in the image, then His-tagged protein is 
present. 
 
 Protection assay 
Activity of protein was checked using a protection assay. Active MTases, in optimal 
conditions, should methylate DNA, blocking restriction by corresponding restriction enzymes 
that have the same recognition sequence (e.g. MTase M.TaqI and restriction enzyme R.TaqI 
both recognise the sequence, TCGA). This protocol was adapted depending on the MTase 
and cofactor tested. The following is a general protocol for testing M.TaqI methylation with 
AdoMet, but can also be used for other cofactor analogues such as to test the alkylation 
activity with AdoHcy-6-N3. 
 
On ice, a master mix was created by mixing 67 µl molecular grade water, 8 µl 10x NEB 
CutSmart buffer, 4 µl pUC19 (1,000 ng/µl), 1 µl AdoMet (32 mM) (or 2 µl AdoHcy-6-N3 
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(15mM) for final cofactor concentration of ~ 375 mM, and reduce volume of water to total 
reaction volume 80 µl). The master mix was split into 1x 20 µl and 5x 10 µl and labelled 1-6. 
A 2x serial dilution was made by adding 1 µl MTase (1 mg/ml) to tube 1 and mixing before 
adding 10 µl from tube 1 to 2 and continuing until tube 6 (discarding the final 10µl leaving 
10 µl in each tube).  
 
The following controls were prepared as shown in Table 2.4.  
  AdoMet 
control (Tubes 
7&8)  
No cofactor  
(9&10)  
No MTase  
(11&12)  
10x NEB CutSmart  2 µl  2 µl  2 µl  
pUC19 (1,000 ng/µl)  1 µl  1 µl  1 µl  
SAM (3.5 mM)  0.5 µl  -  -  
M.TaqI  0.5 µl  0.5 µl  -  
Water  16.5 µl  17 µl  17 µl  
Table 2.4: Controls set up in protection assay. 
 
All samples were incubated at 50 oC for 1 hour before adding 0.5µl restriction 
enzyme (R.TaqI) to all tubes except 8, 10 and 12. Samples were again incubated for 1 hour at 
65 oC. 0.5 µl proteinase K was added to all tubes and incubated at 50 oC for 1 hour before 




Other MTases and cofactor analogues were tested throughout this thesis, using the following 
buffers. Different MTases have different optimum active temperatures, so this should be 
determined beforehand, Table 2.5. Note that restriction enzymes also require different 
incubation temperatures as stated by the manufacturer, and this should be considered when 
performing the assay. 
MTase Recognition 
sequence 
Number of sites 
on pUC19 
Incubation 
temperature (⁰ C) 
M.TaqI TCGA 4 50 
M.HincII GTYRAC 1 37 
M.HhaI GCGC 17 50 
M.BsaWI WCCGGW 3 50 
M.SfoI GGCGCC 1 37 
Table 2.5: Table showing different MTases used in protection assays in this thesis, their 
recognition sequence, and their optimal incubation temperature. 
 
As some buffers contain the chelating agent EDTA, Table 2.6, MgCl2 was added (to final 
concentration 20 mM) in an additional step before restriction to counteract its effects. The 
presence of MgCl2 could prevent the activity of the restriction enzymes, leading to false 





Cutsmart (NEB) 20 mM tris-acetate, 10 mM 
magnesium acetate, 50 mM potassium 
acetate, 100 µl/ml BSA 
NEB2 (NEB) 50 mM Tris-HCl, 10 mM MgCl2, 100 
mM NaCl, 1 mM DTT 
NEB2.1 (NEB) 50 mM Tris-HCl, 10 mM MgCl2, 100 
mM NaCl, 100 µl/ml BSA 
Low salt buffer 50 mM Tris-HCl, 15 mM NaCl, 0.5 
mM EDTA 
HincII buffer 50 mM Tris-HCl, 5 mM β-
mercaptoethanol, 10 mM EDTA 
Table 2.6: Table showing different buffers that were used and their ingredients. 
 
 Fluorescence in situ hybridisation 
 Annealing centromeric hairpin probes 
For centromeric hairpin probes, oligos were ordered from IDT and resuspended at a 
concentration of 100 µM in Tris-EDTA (10 mM Tris and 1 mM EDTA at pH 8). 50 µl of 
oligo were placed in PCR tubes and heated to 85 ⁰C for 5 minutes. Hairpin oligos were 
immediately placed on ice for rapid cooling to form the hairpin structure. 
 
Sequences for oligos were ordered from IDT DNA (Table 2.7) following the standard hairpin 




Chromosome Sequence (5’–3’) 
1 TTTCAACCTGAACTCACAAG 
1 CTCATCAAAGCTACATGGAA  




Table 2.7: Table showing different recognition sites for centromeric probes 1, 7 and 17. 
These sequences were proceeded by the same hairpin sequence. 
17CEN sequences were taken from O'Keefe et al. (1996)44. 
1CEN sequences were taken from Pironon et al. (2010)115. 
7CEN sequences were taken from Waye et al. (1987)116. 
 
 Annealing docking and imaging strand probes 
For probe designs involving a docking and imaging probe, new sequences were ordered for 
17CEN. The docking strand was a single stranded piece of DNA which hybridised directly to 
the DNA. This sequence was: 
 
5’ 
ATCATTGCACTCTTTGAGGAGTACCG TTTTTT GGGT GGTT GTTT GTGT TTTG TG





ATAATTGCACTTCTTTGAGGCCTACCG TTTTTT GGGT GGTT GTTT GTGT TTTG T
GTG TTGG 3’ for 17CEN 2. 
 





All oligos were ordered from IDT and resuspended to 100 µM in 1x Tris-EDTA. 50 µl of 
oligo were placed in PCR tubes and heated to 85 ⁰C for 5 minutes. The single stranded 
docking oligos were left to cool slowly overnight, at room temperature, to prevent them 
forming secondary structures. The hairpin imaging strand was placed directly onto ice for 5 
minutes to form the hairpin structure. 
 
 Annealing single gene hairpin probes 
Oxford Gene Technology (OGT) kindly aided probe design for oligoprobes for the BCR 
gene, with a hairpin on the end for MTase labelling. 89 potential ROIs were sent from OGT, 
selecting target regions approximately 350 bp apart, which targeted the BCR gene 
specifically and fit the parameters needed for the oligoprobe conditions. From the 89 
sequences, 83 met the specification of being < 60 bases in length (once M.TaqI labelling sites 
(CCC TCG ACC CTT TTG GGT CGA GGG TT) had been added), ~55 % GC content, and 
Tm of ~70 °C. These specifications were required in order to keep cost of the oligos low, as 
well as ensuring that they had similar properties and would hybridise under the same 
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conditions. Probes were ordered in a 96 well plate from IDT in 1x TE to a concentration of 
100 µM, all of which can be seen in 8.2. 1 µl of each oligo was mixed into a PCR tube and 
heated to 85 ⁰C for 5 minutes. The oligos were immediately placed on ice for rapid cooling to 
form the hairpin structure. 
 
 Fluorescently labelling oligoprobes with DBCO dyes 
Oligoprobes were labelled site-specifically using M.TaqI (produced by myself in the Protein 
Expression Facility) and AdoHcy-6-NH2 (synthesised by Andrew Wilkinson), a scheme for 
this reaction is shown in Figure 1.16. 4 µl 10x cutsmart MES pH 5.7 was mixed with 2 
µl oligos (diluted 10x in Tris-EDTA), 1 µl AdoHcy-6-NH2 (15mM), 0.5 µl M.TaqI (1 mg/ml) 
and water (up to 40 µl total volume). The sample was incubated at 50 ⁰C for 1 – 1.5 hours. 
0.5 µl proteinase K was added and incubated for 1 hour at 50 ⁰C before sample was purified 
using mini Quick Spin Oligo (Sigma-Aldrich) sephadex columns (column buffer 10 mM 
Tris-HCl pH 7.5, 1 mM EDTA, 100 mM NaCl). 10 µl DMSO was added to samples, 
followed by the addition of 1 mM DBCO dye (in DMSO), Table 2.8, in 2x excess to M.TaqI 
sites. Sample was left at room temperature overnight for coupling. The following day 






 Fluorescently labelling oligoprobes with NHS-ester dyes 
For probes to be labelled with NHS-ester dyes and the azide cofactor AdoHcy-6-N3, an 
additional step is required. This reaction yields enough dye mix for labelling three probes 
(three lots of 10 µM oligo). 1.15 µl PBS, 0.8 µl DMSO, 0.175 µl DBCO-amine (20 mM) and 
0.21 µl Atto647N (or other NHS-ester dye) (50mM) were mixed and left at 4 °C for 1 to 3 
hours. Note, a final concentration of ~60 µM amine-linker is needed per 10 µM labelling 
sites. Samples were then prepared as in 2.2.4 up until after the first purification with 
Sephadex columns. 3.5 µl of DMSO was then added to the dye mix and left at room 
temperature for 15 minutes. 1.68 µl dye mix was taken per sample and added to 8.32 µl 
DMSO for a 20 % DMSO mixture (10 µl total). The full 10 µl dye/DMSO mix was added to 
each probe and left covered overnight at room temperature. Samples were purified using 
Qiagen QIAquick Nucleotide Removal Kit and eluted into 50 µl water. 















DBCO 501 526 
Alexa 647 Jena 
Biosciences 
DBCO 651 672 
Atto 647N Sigma 
Aldrich 
NHS-ester 647 661 




 Preparation of patient sample slides 
Anonymised 46 XX/XY white blood cell suspensions were kindly provided by West 
Midlands Regional Genetics Laboratory (WMRGL). 
 
Patient slides were prepared at WMRGL using their standard slide making SOP. Samples 
were spun at full speed for 5 minutes and the supernatant poured off (performed in one quick 
pour, note that some liquid will remain in the bottom of the tube). Meanwhile, slides were 
cleaned in a hood with methanol and tissue. Using a fine tip pipette, a drop of sample was 
added to the slide and left to dry, before viewing on an optical microscope to detect the 
presence of cells. If the sample was too thin i.e. not many cells present, another drop may be 
added. If the sample is overcrowded, a drop of fixative (3:1 methanol:acetic acid) is added to 
to the tube and resuspended, before being dropping onto a fresh slide as above.  
 
 Probe hybridisation for hairpin probes 
50 ml denaturation solution (0.07M NaOH, 70 % ethanol) was heated to 72 ⁰C. 46 XX/XY 
fixed patient slides containing interphases and metaphases were placed in denaturation 
solution for 2 minutes followed by a dehydration series (70 %, 85 %, 100 % methanol) for 2 
minutes each. Slides were left briefly to airdry. For the original hairpin probes, 5 
µl of each variant (or single gene) probe were mixed (~75 ng DNA each) with 5 
µl hybridisation buffer (6 mM NaOH, 40-70 % formamide, 20 % dextran sulphate) and 1µl 
COT-1. For the docking/imaging strand probes, 2.5 µl of each docking strand (17CEN1 and 
17CEN2) were mixed with 5 µl imaging strand and 5 µl of hybridisation buffer (40 % 
formamide). The whole volume was applied to slide. A coverslip was placed over sample 
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and bubbles removed with pipette tip. Samples were then hybridised at 37 ⁰C for 15 minutes 
(1 hour for single gene probes).  
 
 Washing slides 
The coverslip was removed from slides. Slides were then washed for 5 minutes at high 
stringency 0.4x SSC/0.3 % NP-40 at room temperature, followed by 5 minutes at low 
stringency RT 2x SSC/0.1 % NP-40. 10 µl DAPI (nuclear stain Ex/Em 358/461 nm) was 
applied to each slide to counterstain, and coverslip placed on top. Bubbles 
were removed using a clean pipette tip.  
 
 Imaging slides 
Samples were imaged using an inverted, epifluoresence microscope equipped with a 100× 
objective lens (Nikon, 1.49/oil TIRF) and cooled EMCCD camera (Photometrics, Evolve® 
512 Delta). Excitation at 405 nm, 488 nm, 561 nm and 640 nm was achieved using solid state 
lasers (Coherent, OBIS) to visualise DAPI (nuclear stain), Rhodamine Green and 
TAMRA/Atto 647N/Alexa 647 respectively. A quad-band filter set for 405 nm, 488 nm, 561 




 DNA mapping 
 Methylation of lambda DNA 
Lambda DNA was methylated with M.BseCI before being labelled with M.TaqI to see if 
blocked sites could be detected using mapping. The reagents in Table 2.9 were mixed and 
incubated at 37 °C for one hour. 
Reagent Source Concentration Volume 
Water - - 80 µl 
10x Cutsmart 
NEB2 buffer 
NEB - 10 µl 
M.BseCI Weinhold lab 4000 U/ml 3 µl 
AdoMet NEB 32 mM 1 µl 
Lambda DNA NEB 500 µg/ml 6 µl 
Table 2.9: Table showing concentrations and volumes of reagents for lambda 
methylation. 
 
 Ethanol precipitation  
10 µl (0.1x volume) 3M NaCl was added to DNA sample followed by addition of 200 µl 
EtOH. The tube was gently inverted and spun in a centrifuge at 14,000 x g for 15 minutes. 
The supernatant was removed and the pellet washed by addition of 200 µl 70 % EtOH. The 
sample was spun again at 14000 x g for 15 minutes. The supernatant was 
carefully discarded and pellet air-dried for 2 minutes. The DNA pellet was resuspended in 50 




 MTase-directed labelling of lambda DNA 
BseCI-methylated and unmethylated lambda were labelled with M.TaqI and AdoHcy-6-N3 
for DNA mapping. Solutions were made up for each sample, as shown in Table 2.10. 
Samples were incubated at 50 ⁰C for 1 to 2 hours. 
 
Meanwhile, the dye was prepared for labelling (a scheme for this is reaction is shown in 
Figure 1.16). For 2 x 100 µl reactions, the following were mixed: 8 µl 1x PBS, 2.72 µl 
DMSO, 2.4 µl DBCO-amine 20 mM, 2.88 µl Atto 647N NHS-ester. The dye was left at 4 ⁰C 
for between 1 to 3 hours.  
 
After the DNA had incubated for 1 hour, 2 µl proteinase K/10 % triton was added to each 
sample and left at 50 ⁰C for 1 hour. The DNA was then purified using ethanol precipitation as 
 Methylated lambda Unmethylated lambda 
Reagent Concentration Volume Concentration Volume 
M.BseCI methylated 
lambda  
127 ng/µl 42.5 µl - - 
Unmethylated 
lambda 
- - 500 µl/ml 4 µl 
10x NEB Cutsmart 
buffer 
- 10 µl - 10 µl 
M.TaqI 1 mg/ml 2 µl 1 mg/ml 2 µl 
AdoHcy-6-NH3 15 mM 2 µl 15 mM 2 µl 
Water - 43.5 µl - 82 µl 
Table 2.10: Table showing necessary reagents for labelling methylated and 
unmethylated lambda DNA with M.TaqI and AdoHcy-6-NH3. 
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in 2.3.2 (sample can be eluted into 55 µl water if wanting to carry out an additional protection 
assay (2.1.14) at this point. 
 
Before adding the dye to the DNA, 4 µl DMSO was added to the dye mix and it was left at 
room temperature for 15 minutes. 10 µl of this dye mix was then added to each sample as 
well as 5 µl 10x PBS. The solutions were left at room temperature overnight to efficiently 
label the DNA with dye. 
 
 Preparation of Zeonex-coated slides 
20 mm x 20 mm coverslips were placed in an oven overnight at 450 °C to sterilise. 1.5 % 
Zeonex solution (Zeon Chemicals) was made by dissolving Zeonex in chlorobenzene 
(typically 1 bead in 850 µl chlorobenzene). The mix was sonicated to ensure it had fully 
dissolved. The following day, 30 µl Zeonex mix was added to ovened coverslips and 
immediately spun at 3000 rpm on a spin coater for 90 seconds. Slips were left to dry in a 
dessicator overnight before use. 
 
 Deposition of DNA on Zeonex 
1.5 µl of sample was deposited on the surface of a Zeonex-coated coverslip. A pipette tip was 
used to contact the droplet and drag across the surface at a speed of 20 mm/min. The samples 




 Extraction and alignment of barcodes 
Custom code was written using MATLAB 2016b for automated extraction, in 
silico generation of barcodes and alignment procedures by Nathaniel Wand and Darren 
Smith. An annotated copy of the code is available on the University of Birmingham edata 





3 Optimisation of MTase-directed 




 Enzymatic modification of DNA and diagnostics 
 
Enzymes are powerful substrate-specific proteins which have been used widely over the past 
few decades. As discussed in the introduction, MTases are enzymes that catalyse the transfer 
of methyl groups to specific targets (DNA, RNA or protein); this thesis focuses on DNA 
MTases. By using the MTases’ natural specificity, DNA can be modified site-specifically and 
analysed, determining the underlying DNA sequence. Since the 1970s117, enzymes have aided 
DNA identification and genomic mapping. 
 
There are three enzymatic techniques used for site-specific DNA modification, involving 
restriction enzymes94, nicking enzymes108, or MTases109. The use of restriction enzymes in 
restriction mapping118 was the first of these techniques to be established. This provided a 
framework for the development and application of these enzymes in further mapping 
experiments.  
 
Advances in DNA hybridisation techniques (e.g. FISH) and sequencing technologies (e.g. 
next generation sequencing (NGS)) have surpassed the use of restriction mapping in rapid 
DNA identification. Though they are more commonly used, both hybridisation and 
sequencing techniques have their own set of problems. NGS is currently at the forefront of 
sequencing technologies – although long-read sequencing is rapidly developing – however it 
still faces issues with copy number variations (CNV), ensemble averaging, and reconstruction 
of the genome after amplification of sequences. As this technique focuses on small base 
differences, it loses any larger structural information. On the-other-hand, cytogenetic 
techniques such as FISH, focus on much larger regions of interest (ROI). FISH is currently 
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the gold standard in detecting large rearrangements, amplifications, or deletions of genetic 
material but it is not possible to detect changes at the single-base level using traditional 
probes. Optical mapping attempts to overcome some of these challenges.  
 
Since the emergence of optical mapping via restriction enzymes, nicking enzymes, and more 
recently MTases, have been explored26,93,94,96. MTases show great potential as a way to label 
DNA with both a high level of specificity and at a high density. This provides potential for 
MTases in a number of diagnostic applications which will be discussed later in this thesis. 
Labelling DNA sequence-specifically using MTases and stretching single DNA molecules 
onto a surface via combing, can provide an ordered optical map. This novel technology 
allows analysis of the DNA sequence without compromising the sequence’s integrity and can 
provide a scaffold to aid genome assembly in conjunction with sequencing.  
 
 MTases and SNP detection 
Some MTases display highly specific recognition of their target motifs. Therefore, it has been 
hypothesised that they could be used in detection of single nucleotide polymorphisms 
(SNPs). SNPs are variations of single nucleotides that occur at a specific position in a DNA 
sequence. This genetic variation can be the underlying cause for susceptibility to certain 
diseases e.g. cystic fibrosis, and also impact the severity of those illnesses23.  
 
Spinal muscular atrophy (SMA) is a recessive neurodegenerative disease characterised by the 
loss of the SMN1 gene119. A nearly identical gene, SMN2, has only one critical nucleotide 
difference. SMN2 can be present in variable numbers in patients and therefore restores some 
of the functionality lost from the SMN1 mutation, resulting in varying levels of severity of 
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the disease112. It is possible to be a carrier of SMA if you only have one copy of SMN1, or if 
you have two copies of SMN1 on one chromosome; a 2:0 “silent” carrier120, Figure 3.1.  
 
Currently it is not possible to determine with 100 % certainty whether someone is a silent 
carrier. Molecular techniques, such as multiplex ligation-dependent probe amplification 
(MLPA) – a variation of multiplex PCR that amplifies multiple targets using with a 
single primer pair – can detect two copies of SMN1, but cannot determine if they are in the 
2:0 formation or 1:1. Cytogenetic techniques, such as FISH, can also not be used for this 
arrangement, as they do not have the specificity to work at the single-base level.  
 
M.Hpy188I is an MTase which targets TCNGA113. This sequence is disrupted by a single 
base change difference in the sequence of SMN1, but not in SMN2. If a patient’s DNA could 
be labelled with M.Hpy188I and mapped, it could be possible to determine whether a 
SMN1 SMN2 
Wild type 
2 copies of 
SMN1 
Carrier 




2 copies SMN1 
Figure 3.1: Schematic showing copy number and position of SMN1 
and SMN2 in different patients. It can be difficult to determine 
carriers of SMA due to silent carriers with two copies of SMN1 on one 
chromosome (2:0 carriers). This makes it problematic to distinguish 
this from the wild type using molecular techniques. 
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patient’s SMN1 genes are in the 1:1 or 2:0 formation based on the pattern produced from the 
fluorophores. In this way it could be possible to detect silent carriers of SMA by locating the 





The preliminary aim of this chapter was to develop an optimised procedure for expressing 
and purifying MTases for various labelling and mapping experiments. M.TaqI will be tested 
to ensure it can provide efficient labelling with AdoMet as well as with synthetic cofactor 
analogues. Expression conditions will be optimised to ensure high protein yield that can reach 
complete labelling of DNA. 
 
As discussed above, SNPs can be the cause of genetic disorders, but they are troublesome to 
detect in certain diseases using current diagnostic techniques. As M.TaqI and M.HincII have 
overlapping recognition sites, TCGA and GTYRAC respectively, it would be interesting to 
see if methylating a DNA sequence using M.HincII can subsequently block the labelling 
of M.TaqI, thus allowing the detection of a slightly altered sequence. If M.HincII is not active 
after expression, and fails to methylate the DNA with AdoMet, attempts can also be made 
with M.BseCI, as the recognition site (ATCGAT) also overlaps with that of M.TaqI. 
M.Hpy188I is a specific target for this research as its recognition sequence (TCNGA) is 
affected by a SNP in the SMN1 gene, which is associated with SMA. This chapter will test 
the activity of both M.HincII and M.BseCI with AdoMet. If successful, these enzymes will be 
used to determine if it is possible to detect single-base differences using mapping later in this 
thesis. 
 
Finally, attempts will also be made to produce various MTases with different recognition 
sites to be part of a labelling toolbox for mapping. This will involve engineering the MTase 
sequence to open the cofactor binding pocket. Mutations will be made on the MTases, 
M.HhaI, M.SfoI, and M.BsaWI to produce enzyme for labelling at a range of recognition 
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sequences. This mutation will hopefully enhance activity with larger synthetic cofactors and 




 Results and discussion  
This chapter develops the production and application of MTase enzymes in DNA labelling 
reactions. MTases are highly specific enzymes that – when combined with synthetic AdoMet 
analogues – can label DNA sequences of interest with fluorophores, which can then be used 
for downstream diagnostic applications. This technology could be used for a range of 
applications, from densely labelling probes for FISH, to detecting long- and short-range 
genomic sequences in DNA mapping. 
  
 Optimisation of MTase preparation for directed-labelling of fluorophores 
As discussed in the aims and introduction of this chapter, MTases will be used in labelling 
reactions to attach functional groups site-specifically to DNA. In order to obtain the MTase 
protein it must be expressed in a bacterial system, E. coli in the case of this thesis. M.TaqI 
was chosen due to its versatile nature, and produced using the protocol in 2.1.8. Once 
purified, the sample was tested for activity using a protection assay; this determines whether 
M.TaqI could successfully methylate DNA, thus protecting it from restriction by 
corresponding restriction enzyme R.TaqI. M.TaqI methylates the underlined adenine within 
the DNA sequence 5’ TCGA 3’. This sequence is present four times within the pUC19 
plasmid (Figure 3.2A), resulting in a distinct pattern when analysed using gel electrophoresis 
if fully restricted or protected (Figure 3.2B). 
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It is important to note that when running plasmid DNA on a gel, the fully protected sample 
can often appear as multiple bands. This is due to the DNA existing in three conformations: 
supercoiled (SC) (where DNA is wound up tightly in a compact structure), open circular 
(OC) (where nicks have been introduced to one strand of the plasmid) and linear (nicked at 
both strands), shown in Figure 3.3. Supercoiled DNA runs the fastest through an agarose gel, 
whereas the larger open circle of OC runs the slowest, and will appear at the top of the gel. 
 
Figure 3.2: A) pUC19 plasmid showing the four TaqI (TCGA) sites present in 
its sequence B) Schematic of a protection assay workflow. pUC19 is labelled 
using M.TaqI at all TaqI sites before being restricted and analysed using gel 
electrophoresis to separate the DNA fragments by size. If the DNA has been 
successfully methylated by M.TaqI, restriction will be blocked and the DNA 




Varying concentrations of M.TaqI were incubated with AdoMet (0.4 nM) and pUC19 DNA 
(~20 nM) as described in 2.1.14, to check that the DNA could be successfully methylated, 
and how much of the MTase was needed for full protection. These samples were run on a 1 
% agarose gel, with each lane representing a 2 x dilution of M.TaqI (from 625 nM in lane 2 
down to ~ 80 nM in lane 5). As can be seen in Figure 3.4, M.TaqI has prevented restriction 
of pUC19 DNA in lanes 2-5, meaning the protein is functional even at the lowest 
concentration tested. As pUC19 has four TaqI sites, this means that there is a concentration of 
~ 200 nM sites to methylate in each well. As lane 5 still shows full protection (with only 80 
nM M.TaqI methylating 200 nM sites), this demonstrates that the protein has a turnover of at 
least two times. 
 
Figure 3.3: Schematic showing supercoiled, open 
circular (nicked on one strand) and linear DNA 
(nicked on both strands) conformations, all of 




In the absence of AdoMet (lanes 7-10), however, there is still partial protection seen, as the 
DNA is not fully restricted (the control in lane 11 shows full restriction). This suggests that 
residual AdoMet is being copurified with M.TaqI121 and is preventing full restriction by 
methylating DNA without added AdoMet.  
 
Having native AdoMet bound to M.TaqI protein has been shown to prevent efficient labelling 
of DNA when using cofactor analogues120. As MTase-directed labelling is intended to be 
used extensively in this thesis, the effects that this residual AdoMet could have on 
experiments were considered. For DNA mapping, residual AdoMet could cause problems as 
the sites will not be labelled with fluorophores if there is already a methyl group present, 
resulting in inaccurate recognition of barcodes. This could lead to false negative/positive 
results, especially when looking at small mutations, as loss of a fluorophore may suggest a 
SNP in the DNA sequence, when in fact this was as caused by residual AdoMet methylating 
3 kb  
Nicked  
OC  










Figure 3.4: Protection of pUC19 DNA using M.TaqI and AdoMet 
Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution of M.TaqI with AdoMet, lane 6 
= no M.TaqI control, lanes 7-10 = 2x dilution M.TaqI no AdoMet, lane 11 = 
restricted pUC19, lane 12 = unrestricted pUC19. 
 
M.TaqI has prevented restriction of pUC19 DNA in lanes 2-5, meaning the protein 
is functional even at the lowest concentration tested. In the absence of AdoMet 
(lanes 7-10), partial protection can be seen, as the DNA is not fully restricted. This 
suggests that residual AdoMet has coeluted with the M.TaqI protein during 
purification. 
SC  
10 kb  
1 kb  
0.5 kb  
1           2          3         4          5           6          7         8          9       10          11        12 
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the site and blocking labelling by the AdoMet analogue. Residual AdoMet could also cause 
problems with labelling of DNA for oligoprobes as again, if methylated, this would block 
labelling sites for the fluorophores, resulting in reduced sensitivity and brightness. If probes 
are not bright enough this may lead to inaccurate results as, even if the unlabelled probe 
binds, it will go undetected.  
 
Attempts were therefore made to remove bound AdoMet from the protein complex to enable 
efficient labelling of DNA. As cofactor degradation increases at temperatures above 50 ⁰C122, 
it was hypothesised that by heating protein samples to 72 ⁰C prior to purification, this may 
cause the AdoMet to dissociate from the M.TaqI complex. This was tested by heating half of 
a lysed cell preparation to 72 ⁰C for 2 minutes, while processing the other half as normal 
(described in 2.1.10). Both samples were purified under the same conditions and their results 
compared via denaturing SDS-PAGE. Both conditions produced intact M.TaqI protein as 
observed by a strong band at 48 kDa on the SDS-Page gel in Figure 3.5A and B. The heat-
treated (HT) M.TaqI sample, Figure 3.5B, also appears to be more pure, as there are a 
reduced number of non-specific bands in the gel. As the gels in Figure 3.5A and B display 
consistently strong bands at the 48 kDa mark, it suggests that the protein lost in the HT 
sample is non-specific proteins that have been copurified with the protein of interest 
(M.TaqI). It could be that heating the sample has caused these proteins to degrade, but as 
M.TaqI can withstand higher temperatures it remained intact. The heating process may have 
also caused the protein to refold differently, reducing the amount of aggregated M.TaqI 

















































Figure 3.5: SDS-PAGE gel of M.TaqI protein (48 kDa) eluted fractions 
after purification A) without and B) with heat treatment to 72 ⁰C. Non-
specific protein reduction can be seen in B, after heat treatment. 
M.TaqI protein has been produced in both conditions, as highlighted by 
the strong band at ~ 48 kDa. 
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Fractions 1 to 4 of the non-heat-treated sample were pooled, as they contained the highest 
yield of M.TaqI protein, as shown by the strong band at 48 kDa in Figure 3.5. Fractions 1 to 
5 of the heat-treated sample were pooled. Both samples were used to methylate pUC19 DNA 
to check that they were functional, and to detect residual AdoMet. Protection of pUC19 
appears to be equally effective in both as shown in Figure 3.6, which indicates that there is 
no decrease in M.TaqI activity with heat treatment. However, in lanes 14 and 15 where no 
AdoMet was added, there does not seem to be a reduced amount of residual protection. This 
means that bound AdoMet is still present within the protein complex, and that other attempts 
for removal could be explored. However, the amount of residual AdoMet, while present, is 
minimal, suggesting that using this concentration of M.TaqI (~300 nM) could still be suitable 




M.TaqI untreated M.TaqI heat-treated 











Figure 3.6: Protection assay comparing M.TaqI efficiency after heat-treatment 
Lane 1 = 2-log ladder, lanes 2-7 = 10x dilution untreated (UT) M.TaqI with 
AdoMet, lanes 8-13 = 10x dilution M.TaqI protein heat-treated (HT) at 72 
⁰C, lane 14 = UT M.TaqI no AdoMet, 15 = HT M.TaqI no AdoMet, 16 = 
unrestricted pUC19, 17 = restricted pUC19. 
 
Both untreated and heat-treated M.TaqI samples were active with AdoMet, as 
highlighted by full protection in lanes 2-7 and 8-13 respectively. They also both 
showed residual protection in the absence of AdoMet (lanes 14 and 15), suggesting 
that heating the sample does not remove residual AdoMet from the M.TaqI 
complex. 
1         2         3        4        5         6        7         8         9       10       11     12      13       14      15      16       17 
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In another attempt to remove bound AdoMet, drop dialysis was used. 20 µl of M.TaqI was 
placed on a drop dialysis filter disc (Merck, 0.025 µl pore size) over low salt buffer (10 mM 
phosphate buffer, 5 mM EDTA) overnight, in an attempt to remove excess salts and 
inhibitory substances (and bound AdoMet) from the protein. As can be seen in Figure 3.7, 
drop dialysis was ineffective in removing the residual AdoMet as protection can still be seen. 



















A - M.TaqI dialysed 
-AdoMet 
B - M.TaqI non-dialysed 
-AdoMet 
Figure 3.7: Protection assay comparing residual AdoMet protection of pUC19 
DNA using A) dialysed and B) non-dialysed M.TaqI 
Lane 1 = 2-log ladder, lanes 2-7 = 2x dilution of dialysed M.TaqI protein 
(A) no AdoMet, lanes 8-13 = 2x dilution of non-dialysed M.TaqI protein 
(B) no AdoMet, lane 14 = dialysed M.TaqI + AdoMet, lane 15 = non-
dialysed M.TaqI + AdoMet, lane 16 = restricted pUC19, lane 17 = 
unrestricted pUC19. 
 
Both dialysed and non-dialysed samples showed residual AdoMet protection 
(lanes 2-7 and 8-13 respectively), suggesting that dialysis does not remove 
AdoMet from the M.TaqI complex. 
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As M.TaqI recognises and methylates the palindromic DNA sequence 5’ TCGA 3’, 
incubating the protein sample with oligonucleotides (oligos) containing this sequence 
(5′CCGCCTCGAGGCGG3′) will result in removal of bound AdoMet121; bound AdoMet will 
be used up methylating sites within the oligos. 
 
This was tested in two different experiments, firstly the oligos were added directly after cell 
lysis during protein production (2.1.11). Samples were incubated at 50 ⁰C for 30 minutes 
before continuing with the purification as normal. The eluted protein was used in a protection 
assay as before to directly compare the amount of partial protection of pUC19 DNA. As seen 
in Figure 3.8, both untreated M.TaqI (Figure 3.8A) and that which had been incubated with 
oligos (Figure 3.8B) are functional, but also appear to have equal amounts of residual bound 
AdoMet. A longer incubation could have been carried out but this could have caused the 
protein itself to degrade, resulting in low yield. There is also a large amount of competiting 
(methylated) genomic DNA within the sample that could be used instead of the bound 
AdoMet. It could also be that the buffer conditions at this point were not suitable for MTase-
labelling, or that the M.TaqI protein was not active, and that purifiying the sample and then 
incubating with the oligos may prove more beneficial. In this way there would be more 
control over the conditions for the residual AdoMet to methylate the oligos which could be 




Attempts were then also made to remove bound AdoMet by adding the oligos after the 
protein has been purified and eluted. Oligos containing the recognition sequence (TCGA) 
were incubated with purified M.TaqI protein for 30 minutes at 50 °C. The samples were then 
directly added to a reaction mixture containing pUC19 to detect any residual protection of the 
DNA. At a glance, the results shown in Figure 3.9 do not appear to show a reduction of 
Figure 3.8: Protection assay comparing residual AdoMet protection using M.TaqI 
produced under A) normal conditions and B) lysate incubated with oligos containing 
M.TaqI recognition site for 30 minutes at 37 ⁰C.  
Lane 1 = 2-log ladder, lanes 2-6 = M.TaqI with AdoMet, lane 7 = no enzyme control, 
lanes 8-12 = M.TaqI no AdoMet, lane 13 = restricted pUC19, lane 14 = unrestricted 
pUC19. 
 
Both samples showed residual protection in lanes 8-12, as highlighted by the lack of full 
restriction. This suggests that incubating M.TaqI lysate with oligos containing the MTases 
recognition site prior to labelling does not remove residual AdoMet. 
A 
2-log 
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residual AdoMet. However, when looking at the control in lane 15, which has no enzyme and 
so should the DNA should not be protected, it shows that restriction has not gone to 
completion. This suggests that the presence of oligos prevented R.TaqI from fully restricting 
the DNA. The experiment was repeated with an added purification step using anion exchange 
columns to remove the oligos, to see if this could reduce the residual AdoMet. 
 
Oligos containing M.TaqI labelling sites were incubated with M.TaqI at 65 °C for 15 
minutes, before being purified using anion exchange columns. Samples were either A) Not 
purified B) Run through the column once C) Run through the same column twice or D) Run 
Figure 3.9: Protection assay of pUC19 after incubation of 
M.TaqI protein with and without oligos, to detect residual 
protection. 
Lane 1 = 2-log ladder, lanes 2-7 = M.TaqI + 2x dilution 
of oligo incubated at 65 ⁰C for 15 minutes beforehand, 
lanes 8-13 = M.TaqI – oligos, lane 14 = unrestricted 
pUC19 + oligos, lane 15 = pUC19 + oligos no M.TaqI, 
lane 16 = restricted pUC19, lane 17 = unrestricted 
pUC19. 
 
Lanes 1-4 suggest that the oligos are preventing full 
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through a column twice, with fresh columns each time. The samples were then used for a 
protection assay with a two times dilution of M.TaqI and compared for residual protection as 
seen in Figure 3.10.  
Each lane contained 10 µM of oligos, and started with ~ 117 nM of M.TaqI (before the 2x 
dilution). It does seem that the clean up using these columns had been successful; with no 











D - M.TaqI + 
Oligos 
- AdoMet 
B - M.TaqI + 
Oligos 
- AdoMet 
C - M.TaqI + 
Oligos 
- AdoMet 



















Figure 3.10: Protection assay showing residual protection after incubation of M.TaqI 
protein with oligos. Purification after incubation differed as follows A) No purification 
B) Flowed through column once C) Flowed through column twice D) Fresh column 
used 
 Lane 1 = 2-log ladder, lanes 2-4, 6-8, 10-12, 14-16 = M.TaqI + oligos (purified in 
conditions stated above) no AdoMet, lanes 5, 9, 13 and 17 = M.TaqI + oligos (purified in 
conditions stated above) + AdoMet, lane 18 = fully restricted pUC19, lane 19 = 
unrestricted pUC19. 
 
Results show that incubating M.TaqI with oligos containing its recognition site prior to 
labelling removes some of the residual AdoMet, as highlighted by the increase in 
restriction in lanes 6-8, 10-12 and 14-16. This also suggests that oligos need to be 
removed sufficiently from the preparation to enable restriction to go to completion, as 
residual protection did not decrease in this instance where the DNA was not purified 
(A). 
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experiment. However, all of the other samples that had been purified using the anion columns 
show some level of increased restriction, which is more apparent as the M.TaqI concentration 
decreases.  This suggests that incubation with the oligos is capable of removing residual 
AdoMet but care must be taken to ensure that the appropriate concentration of both M.TaqI 
and oligos is used. If too much M.TaqI is used, this could introduce high enough levels of 
AdoMet to cause the associated problems with residual protection. It is therefore compulsory 
that the lowest concentration of M.TaqI is used – while still being enough to provide 
adequate alkylation with the cofactor – in order to not unnecessarily add residual AdoMet 
into the reaction. The third sample in D (lane 16) appears to show no residual protection, 
using ~39 nM of M.TaqI, and samples B and C show limited protection, suggesting that this 
is the optimal concentration to use if using this approach for AdoMet removal. Each lane with 
oligos contained 10 µM oligos which corresponds to 80 µM of M.TaqI labelling sites (each 
one has 8 TCGA regions). This highlights the careful consideration needed when labelling 
using M.TaqI; there must be a high enough concentration of the enzyme to ensure that 
labelling is efficient, but not so unnecessarily high that residual AdoMet is added to the mix. 
A balance needs to be struck to prevent bound AdoMet potentially blocking fluorophore sites 
with methyl groups, leading to inefficient labelling and potentially false positives/negatives if 
the technology is being used for clinical applications.  
 
The results in this chapter suggest that the removal of bound AdoMet is not as 
straightforward as other research suggests. The presence of this residual AdoMet should be 
taken into consideration when planning labelling experiments, although it is not certain how 
much this affects the results. The majority of the DNA does get restricted, implying that there 
is only a small subset of M.TaqI which actually has the AdoMet bound; it is unclear how 
much this will affect labelling at this point. Further dialysis and extensive washing at various 
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points in the M.TaqI preparation could perhaps be considered in future to remove as much 
AdoMet as possible. For future experiments, it is worth noting that the minimum amount of 
M.TaqI needed for each reaction should be used. This is to ensure that excess AdoMet is not 
unnecessarily added to reactions and to reduce unwanted methylation during transalkylation. 
The proportion of M.TaqI carrying residual AdoMet appears to be small, as the majority of 
the DNA is unaffected at low M.TaqI concentrations, suggesting that this may not cause as 
many labelling problems as initially suspected. If problems are encountered, purification 
using the anion exchange columns appears to be successful in removing the oligos, and 
reduces residual protection. 
 
 Use of MTases in DNA alkylation 
 
As discussed in 1.4.2, AdoMet analogues can be used for various transalkylation reactions. 
These analogues contain functional groups such as an amine or azide which can be 
transferred to the MTase recognition site instead of a methyl group. These amine/azide 
cofactors enable the transfer of fluorophores to DNA site-specifically using NHS-ester or 
strain-promoted azide-alykne cycloaddition (SPAAC) chemistries respectively (Figure 1.16). 
Due to the NHS-ester dyes hydrolysing at low pH, dibenzocyclo-octyne (DBCO) dyes and 
SPAAC chemistry will be used for the majority of this thesis, as this allows the synthetic 
cofactors (which degrade at high pH) to be used more readily.  
 
AdoMet analogue AdoHcy-6-N3, shown in Figure 3.11, was produced by Andrew Wilkinson. 
This synthetic cofactor contains an extended, aliphatic linker terminating in an azide group in 
place of the methyl group. This means that when incubated with M.TaqI, the azide should be 
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transferred site-specifically to DNA. This was tested using a protection assay as described in 
2.1.14.  
 
A concentration of 375 nM AdoHcy-6-N3 was used in each lane, with varying concentrations 
of M.TaqI (from ~312 nM in lanes 2, 6 and 10 down to ~78 nM in lanes 4, 8 and 12) and 20 
nM pUC19 (200 nM M.TaqI sites). As can be seen in Figure 3.12, the azide group 
successfully transferred to pUC19 DNA as indicated by the lack of restriction by R.TaqI 
suggesting that there is a turnover of at least two times. This shows promise for using this 
combination of enzyme and cofactor for future labelling experiments. 
 
Figure 3.11: Structure of AdoHcy-6-N3. The functional azide 
group is transferred by MTases to specific DNA sequences. 
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To test the efficiency of MTase labelling, a short hairpin sequence of DNA was ordered that 
contained one M.TaqI recognition site (and therefore two labelling sites), Figure 3.13. A 
hairpin was used to provide a single piece of DNA which contained a double-stranded region 
with palindromic 5’ TCGA 3’ site. Previous research has shown that in order for M.TaqI to 
dock and label DNA it must be double stranded77, and a hairpin design allows for this.  
Figure 3.12: Protection assay showing protection of pUC19 DNA by different 
isomers of azide cofactor AdoHcy-6-N3 and M.TaqI. 
Lane 1 = 2-log ladder, lanes 2-4 = 2x dilution M.TaqI with AdoHcy-6-N3 
isomer I, lane 5 = control with AdoHcy-6-N3 isomer I no enzyme, lanes 6–8 
= 2x dilution M.TaqI with AdoHcy-6-N3 isomer II, lane 9 = control with 
AdoHcy-6-N3 isomer II no enzyme, lanes 10-12 = 2x dilution M.TaqI with 
AdoHcy-6-N3 isomer III, lane 13 = control with AdoHcy-6-N3 isomer III no 
enzyme, lane 14 = control with M.TaqI no cofactor, lane 15 = control with 
AdoMet and M.TaqI, lane 16 = restricted pUC19, lane 16 = unrestricted 
pUC19. 
 
M.TaqI protein is active with all isomers of AdoHcy-6-N3, as highlighted by 
the lack of restriction of the DNA in each case. 
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The hairpin was alkylated with an azide functional group as described in Chapter 2 using 
AdoHcy-6-N3 (Figure 3.11) and M.TaqI. Mass spectrometry was then used to detect the 
presence of the azide linker (mW 121) after alkylating the oligo (mW 18,378). In this way, it 
can be observed how efficient labelling is using this approach – as well as if the hairpin 
structure has formed correctly to enable alkylation – and the proportion of unlabelled DNA 
within a sample estimated. This is important as it gives some indication as to how residual 
AdoMet may affect future labelling reactions and therefore how reliable the results are. It 
may also show that the labelling protocol needs further optimisation to improve the labelling 
efficiency. 
 
The sample was purified by HPLC by Andrew Wilkinson. Figure 3.14A shows the HPLC 
trace of both unlabelled (black) and alkylated hairpin (blue). Three main peaks of varying 
sizes can be seen within the alkylated hairpin sample, with the smallest of those 
corresponding to the large peak of the unlabelled (black) sample. This suggests that the 
smallest peak is indicative of the labelling reaction not going to completion, as some was left 
unlabelled. After collecting the peaks and submitting to mass spectrometry, it confirmed that 
the peaks were unlabelled DNA (Figure 3.14Bi) , hemi-alkylated DNA (Figure 3.14Bii), and 
fully-alkylated DNA (Figure 3.14Biii). This means the second peak shows that some of the 
DNA had only the azide linker on one side of the hairpin (the oligo has a mW of 18,378 and 
Figure 3.13: Schematic of hairpin oligoprobe 
design containing one TaqI recognition site 
within the sequence for labelling with M.TaqI. 
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the aizde linker has a mW of 121) potentially due to slow turnover of enzyme leading to 
partial alkylation. The majority of the sample did end up with labels on both sides, as the 
spectra shows a peak at 18,620 (18,378 + 121*2). Only a small amount of the sample 
remained unlabelled (peak at ~18,379) after the reaction. Minimal amounts of M.Taq were 
used in this sample (78 nM) – in order to reduce the amount of residual AdoMet added into 
the reaction – compared to 2 µM of labelling sites. 100 % labelling of 2,000 nM sites after 1 
hour with 78 nM M.TaqI would be ~25 turnovers, so it is understandable that complete 
labelling would not be reached with this concentration. The spectra indicate that 
approximately 75 % labelling has been achieved (around 1500 nM of labelled sites), which 
corresponds to ~ 19 turnovers. This supports similar results published by Weinhold et al. in 
200589. M.TaqI is a thermophile, with an optimum working temperature of ~65 ⁰C113, 
however, temperatures of this heat would cause the cofactor to rapidly degrade. A 
compromise in temperature was used (50 ⁰C) meaning that a slight sacrifice in enzyme 
performance was made, this could also affect labelling going to completion, but is not 















Figure 3.14: Hairpin oligos were alkylated with azide cofactor AdoHcy-6-N3 
and M.TaqI A) HPLC trace of unlabelled (blue) and labelled (black) oligo B) 
Spectra of the three labelled peaks showing i) unlabelled ii) hemi-alkylated and 
iii) fully-alkylated oligos. This shows that ~ 75 % labelling was achieved with 
this concetration of M.TaqI, undergoing ~19 turnovers. 
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 Potential for use of MTases in small-scale mutation detection 
The MTase M.Hpy188i has a recognition site that is interrupted by the absence of SMN1 
(Figure 3.15A), the loss of which is associated with SMA. As discussed in the introduction 
of this chapter, carriers of a 2:0 mutation of SMA are impossible to detect using current 
methods as SMN1 cannot be distinguished between highly homologous SMN2, which differs 
at one critical nucleotide. Mapping this region could allow detection of this nucleotide 
difference (determined by a loss of fluorophore in SMN2) while maintaining sequence 
context (Figure 3.15B). This means that DNA mapping could highlight whether someone has 
the SMN1 gene in a 1:1 ratio, or is a 2:0 silent carrier.  
Figure 3.15: Schematic displaying A) The critical nucleotide 
difference between SMN1 and SMN2 that disrupts 
M.Hpy188i labelling sites B) A representation of loss of 
fluorophore in DNA mapping of SMN1/SMN2 with 




We sought to simulate this point mutation using a model system; the use of MTase M.HincII 
was considered as its recognition site, 5’ GTYRAC 3’, overlaps with that of M.TaqI. This 
will prevent a subset of M.TaqI sites from being modified (and labelled) if first methylated 
with M.HincII. By using DNA mapping, the lack of fluorophore could potentially be 
observed, therefore allowing detection of small deletions down to base pair level. M.HincII 
was expressed, as described in 2.1.8, from clones produced by Dr Robert Neely. The enzyme 
was tested for activity with AdoMet using a protection assay. As there is only one HincII site 
on pUC19, cutting with just R.HincII would result in linear DNA and be difficult to 
distinguish from uncut plasmid. Two restriction enzymes that cut at different sites were 
therefore used to ensure that DNA fragments of dissimilar sizes were produced, so that there 
was a noticeable difference (i.e. multiple bands) when analysed using gel electrophoresis.  
 
As can be seen in lanes 2-4 of Figure 3.16, the enzyme is achieving partial protection of the 
DNA, as it is not being fully restricted. It could be that the enzyme needs to be more 
concentrated or that turnover is too slow to achieve full protection. Full protection will need 




Previously, the commercially available NEB Cutsmart Buffer (50 mM potassium acetate, 20 
mM tris-acetate, 10 mM magnesium acetate, 100 μg/ml BSA) had been used for protection 
assays. Buffers are usually composed of a weak acid, salts, and potentially additives. These 
components provide a stable environment for the reaction by keeping the pH constant. This 
occurs by taking up protons released during the reaction or releasing them as they are 
consumed. The slightest change in pH or salt concentration can impair many biochemical 
processes including enzymatic reactions. As the buffer can play a role in the efficiency of the 
enzymes, alternates were considered for use with M.HincII.  
 
Two alternative buffers were tested based on their successful use in similar enzymatic 
reactions: buffer A76 (50 mM tris-hydrochloride, 15 mM sodium chloride 0.5 mM EDTA, 2 
-c 
-e 















Figure 3.16: Protection assay showing protection of pUC19 DNA by 
AdoMet and M.HincII. 
Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.HincII with AdoMet, 
lane 6 = control with enzyme, no AdoMet, lane 7 = restricted with 
r.ScaI, lane 8 = restricted with r.HincII, lane 9 = fully restricted. 
 
M.HincII is partially active with AdoMet as the DNA is not fully restricted 
(as in control lane 9) in lanes 2-5. It is not fully protecting the DNA, however, 
and will need to be optimised before further use. 
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mM β-mercaptoethanol, 0.2 mg/ml BSA), and buffer B124 (50 mM tris-hydrochloride, 5 mM 
β-mercaptoethanol, 10 mM EDTA). EDTA is commonly added into buffers to chelate 
multivalent cations and stop DNA degradation. The restriction assay protocol for buffers 
containing EDTA therefore had an additional step before restriction whereby cations were 
added back into the mixture. β-mercaptoethanol reduces disulphide bonds between cysteine 
residues, preventing protein aggregation to hopefully achieve higher MTase activity. 
Additives such as BSA can also be added in an attempt to stabilise the enzyme.  
 
Both buffer A and B appear to make no significant difference to the activity of M.HincII, 
Figure 3.18 and Figure 3.17 respectively, as both just show partial protection in lanes 2-5. It 
does appear that there is slightly more protected DNA with buffer B at lower enzyme 
concentrations – for instance when comparing lane 5 of both gels – suggesting that M.HincII 
is more active with buffer B. This suggests that the kinetics of M.HincII are too slow to reach 
complete protection; a higher concentration of M.HincII will improve this, as can be seen 
from the steady decrease in protection in gels. However, in order to achieve this, the construct 



















Figure 3.18: Protection assay showing protection of pUC19 DNA by AdoMet and M.HincII using 
“Buffer A” 
Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.HincII with AdoMet, lane 6 = control with 
AdoMet, no enzyme, lane 7 = control with enzyme, no AdoMet, lane 8 = restricted with R.HincII, 
lane 9 = restricted with R.ScaI, lane 10 = fully restricted. 
 
M.HincII is partially active with AdoMet as the DNA is not fully restricted (as in control lane 10) in lanes 
2-5. It is not fully protecting the DNA, however, and will need to be optimised before further use. 
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Figure 3.17: Protection assay showing protection of pUC19 DNA by AdoMet and M.HincII using 
“Buffer B” 
 Lane 1 = 2-log ladder, lanes 2-6 = 2x dilution M.HincII with AdoMet, lane 7 = 
control with enzyme, no AdoMet, lane 8 = restricted with R.HincII, lane 9 = restricted 
with R.ScaI, lane 10 = fully restricted, lane 11 = fully protected. 
 
M.HincII is partially active with AdoMet as the DNA is not fully restricted (as in control lane 10) 
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Fortunately, an alternative enzyme to M.HincII is available; M.BseCI. M.BseCI was 
considered as its recognition site (ATCGAT) also overlaps and blocks a subset of M.TaqI 
sites. The literature has also shown that this enzyme works well with synthetic cofactors in 
alkylation reactions125. M.BseCI expression was attempted using clones from Dr Robert 
Neely, however purification of active protein was unsuccessful. Upon troubleshooting it was 
noted that the His-tag of the M.BseCI construct was on N-terminus, as opposed to the C-
terminus as it is in the literature126. This may cause problems with the protein correctly 
folding and therefore affect its stability and functionality. 
 
Active M.BseCI protein was kindly provided by the Weinhold lab127 and tested in a 
protection assay to determine its activity. A comparison was made between three different 
buffers, BseCI buffer (100 mM Tris-HCl, 500 mM NaCl, 200 mM MgCl, 500 µM EDTA, 20 
mM β-mercaptoethanol)128, NEB Cutsmart and NEB2 (buffer A, B, and C respectively), and 
enzyme activity, as described in 2.1.14. As can be seen from Figure 3.19, the enzyme was 
active with all three buffers, with slightly decreased activity in BseCI buffer A, suggesting 
that these are not the optimum conditions for methylation with this enzyme. NEB2 buffer was 
selected as the most efficient buffer for methylation. After successfully methylating lambda 





 Producing mutated enzymes for human genome mapping 
 
As discussed in 1.1.4, enzymes containing mutations at certain points in their DNA sequence 
affect which amino acid is produced. This change in protein structure results in the opening-
up of the cofactor binding pocket. By changing the structure of this pocket, bulkier cofactor 
analogues can interact with the protein. It has therefore been suggested that these mutated 
MTase enzymes have a greater affinity to AdoMet analogues and are more efficient when 
performing transalkylation reactions. The promising results from Lukinavičius et al.76, 
discussed in 1.4.2, compared how enzyme M.HhaI Q82A N304A worked with a range of 
AdoMet analogues. They then extended this to other m5c MTases, which suggests that we 
could replicate this. By testing different mutated enzymes with AdoMet analogues, it was 


















A - BseCI buffer B - Cutsmart C - NEB2 
Figure 3.19: Protection assay showing protection of lambda DNA by AdoMet and M.BseCI using A) 
BseCI buffer, B) Cutsmart buffer, and C) NEB2 buffer. 
 Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.BseCI with AdoMet in Buffer A, lane 6 = 
fully restricted, lane 7 = fully protected, lane 8-11 = 2x dilution M.BseCI with AdoMet in Buffer B, 
lane 12 = full restricted, lane 13 = fully protected, lane 14-17 = 2x dilution M.BseCI with AdoMet 
in Buffer C, lane 18 = fully restricted, lane 19 = fully protected.  
 
M.BseCI is active with AdoMet in all buffers as the DNA is protected in all test lanes.  
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hypothesised that a toolbox of MTases could be developed for various mapping experiments. 
M.HhaI was chosen after the success shown in the literature, and M.BsaWI and M.SfoI were 
selected due to them also being m5C MTases (i.e. those that produce C5-methylcytosine). 
This means that all three enzymes share a similar amino acid sequence, and that the 
conserved motifs within them can be used to help select amino acids – corresponding to those 
identified as "activating" in the work by Lukinavičius et al.76 – for mutation. 
 
DNA sequences for M.BsaWI, M.SfoI, and M.HhaI were aligned using Jalview to locate 
these mutations. The mutated sequences, M.BsaWI E83A D384A, M.SfoI T77A D360A, and 
M.HhaI Q82A N304A (which will be referred to as M.BsaWI*, M.SfoI*, and M.HhaI* 
henceforth) were ordered from IDT DNA. The genes for each of the MTase enzymes were 
sub-cloned into the vector pRSET-B using Gibson assembly (described in 2.1.2). Successful 
cloning was confirmed via sequencing. The enzymes were expressed in E. coli using the 
protocol in Chapter 2 and analysed using SDS-PAGE (2.1.12) to verify the protein expression 
levels. As can be seen from Figure 3.20, expression-levels of all three proteins were low. The 
gel shows no obvious bands where the proteins should be, indicated by red arrows. This 
could be due to the various expression conditions not being optimised beforehand, and a 







Focus was shifted to M.BsaWI* and M.SfoI*, as they had not been tested before and could 
prove useful as enzymes for dual-colour DNA mapping. Protein expression conditions were 
altered for M.BsaWI* and M.SfoI* in an attempt to increase yield. The proteins were grown 
up at a larger volume and lysed more carefully using an Emulsiflex (a homogeniser as 
opposed to a sonicator). The Emulsiflex would hopefully offer less shearing whilst keeping 
the protein at a constant temperature, resulting in higher yield. Protease inhibitors were also 
used in all buffers to prevent protein degradation. The yield for M.SfoI* significantly 
improved, with a strong band appearing at the 42kDa mark, Figure 3.21. Conditions for 
M.BsaWI* still needed further optimisation for improved yield. 
 
Figure 3.20: SDS-PAGE gel showing low expression levels of 
mutated M.HhaI*, M.BsaWI* and M.SfoI*. Red arrows indicate 










As M.BsaWI is derived from a thermophile, Bacillus stearothermophilus113, expression was 
attempted again without lowering the overnight incubation temperature after induction. This 
meant that the culture was left to grow for 16 hours at 37 ⁰C as opposed to 20 ⁰C. This change 
in temperature had a significant effect on yield, as can be seen by a much stronger band at 
47kDa in Figure 3.22B, compared to Figure 3.22A. A Western blot was also used to confirm 
that the protein was present throughout the purification, as shown by a strong band in Figure 
3.22C.  





Figure 3.21: SDS-PAGE gel showing M.BsaWI* 
and M.SfoI* protein after optimised expression. 






These proteins were tested for their ability to alkylate DNA using both AdoMet and AdoHcy-
6-N3 via a protection assay. A low salt buffer was initially used (50 mM tris-hydrochloride, 
15 mM sodium chloride 0.5 mM EDTA, 2 mM β-mercaptoethanol, 0.2 mg/ml BSA). M.SfoI* 
appeared to show slight protection with AdoMet as seen in lanes 2-4, Figure 3.23A. As the 
enzyme was intended to be used for dual-colour mapping, it would ideally have increased 
activity with AdoHcy-6-N3. This was not that case, and no alkylation was seen, as indicated 
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Figure 3.22: SDS-PAGE gel showing M.BsaWI* grown at A) 20 ⁰C and B) 37 ⁰C after 
induction. Increase in yield is visible at the higher temperature. C) Western Blot 
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Low Salt Buffer 
Figure 3.23: Protection assay showing protection of pUC19 DNA with M.SfoI* in low salt 
buffer using A) AdoMet 
 
Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.SfoI* with cofactor, lane 6 = no enzyme + 
cofactor, lane 7 = fully restricted, lane 8 = restricted with R.ScaI, lane 9 = restricted with 




Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.SfoI* with cofactor, lane 6 = no enzyme + 
cofactor, lane 7 = fully restricted, lane 8 = restricted with R.ScaI, lane 9 = restricted with 
R.SfoI, lane 10 =  enzyme no cofactor plus restriction enzymes, lane 11= fully protected. 
 
M.SfoI was slightly active with AdoMet, as highlighted by the slight protection in A lanes 2-5, 
but will need to be optimised if intended for further use. M.SfoI was not active with AdoHcy-6-
N3 as highlighted by complete restriction in the test lanes of B.  
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M.BsaWI* was tested with AdoHcy-6-N3 in low salt buffer and appeared to show promise. 
As Figure 3.24 shows, there is slight protection of DNA with the cofactor analogue.  
As there are three BsaWI sites on pUC19 DNA, this means there is a site concentration of 
around 120 nM. Tube 1 contains approximately 875 nM of M.BsaWI, which should be plenty 
to alkylate the DNA. It may be the case that turnover is slow for this enzyme and so full 
alkylation cannot be achieved under these conditions. By altering the buffer conditions, it was  
thought that the rate of alkylation may be able to be improved. As M.BsaWI* had shown  
some signs of activity, it was then tested with both NEB2 and Cutsmart buffer and both 
AdoMet and AdoHcy-6-N3, Figure 3.25. 

















Low Salt Buffer 
Figure 3.24: Protection assay showing protection of pUC19 DNA with 
M.BsaWI* in low salt buffer using AdoMet and B) AdoHcy-6-N3 
Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.BsaWI* with 
cofactor, lane 6 = no enzyme + cofactor, lane 7 = no cofactor + 
enzyme, lane 8 = fully restricted, lane 9 = fully protected. 
 
There is slight protection of DNA with M.BsaWI and AdoHcy-6-N3 as 
highlighted by the lack of full restriction in lanes 2-4. Increasing the 
concentration of the enzyme may improve protection. 
 






































Figure 3.25: Protection assay showing protection of pUC19 DNA by i) AdoMet ii) AdoHcy-6-N3 and a 2x 
dilution of M.BsaWI in A) BsaWI buffer, B) Cutsmart buffer and C) NEB2 buffer: 
 Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.BsaWI with AdoMet, lane 6 = no enzyme + 
AdoMet, lane 7-10 = 2x dilution M.BsaWI with AdoHcy-6-NH3, lane 11 = no enzyme + AdoHcy-6-N3, 
lane 12 = no cofactor + enzyme, lane 13 = fully restricted, lane 14 = fully protected. 
 
A higher concentration of M.BsaWI has shown that it is more active with AdoMet, but not with AdoHcy-6-
N3. Full protection is still not seen in either samples, as there is slight restriction even at the highest 
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A higher concentration of M.BsaWI was used in an attempt to reach full protection with 
AdoMet, however, this still could not be achieved, Figure 3.26.  
Lane 1 shows that using 1.75 µM concentration of M.BsaWI does increase the level of 
protection, demonstrating that the turnover of enzyme must be very slow, and therefore a 
high concentration is needed. The DNA is still not fully protected, however, and so the 
conditions will not be suitable for labelling with M.BsaWI. 
 
After M.BsaWI* failed to protect DNA using AdoHcy-6-N3 an alternative cofactor analogue 
was used. AdoHcy-8-Hy-PEG-N3, shown in Figure 3.27A, is a much larger azide-analogue 
produced by Andrew Wilkinson, which has shown higher turnover rates than AdoHcy-6-N3 in 
2-log 
ladder 
2x dilution M.BsaWI* + AdoMet 
NEB2 Buffer 








Figure 3.26: Protection assay showing protection of pUC19 DNA by AdoMet and a 2x 
dilution of M.BsaWI in NEB2 buffer: 
 Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.BsaWI with AdoMet, 
lane 6 = no enzyme + AdoMet, lane 7-10 = 2x dilution M.BsaWI - AdoMet, 
lane 11 = fully restricted, lane 12 = fully protected. 
Increasing the concentration of M.BsaWI led to near full protection of DNA 
with AdoMet as shown by the lack of resitrction in lane 1. Complete 
protection is still not seen, suggesting that enzyme turnover is too slow for 
mapping experiments. 
 
 1              2              3                4           5               6              7            8             9              10              11            12               
113 
 
assays with M.TaqI (unpublished data). It may be also that this cofactor analogue is more 
suited to the mutation made to the cofactor binding pocket of M.BsaWI, and therefore has 
greater affinity to it. A protection assay was attempted using this cofactor analogue, but no 



















Figure 3.27: A) Structure of AdoMet analogue AdoHcy-8-Hy-PEG-N3 B) Protection 
assay showing protection of pUC19 DNA by AdoHcy-8-Hy-PEG-N3 and a 2x dilution 
of M.BsaWI in NEB2 buffer: 
 Lane 1 = 2-log ladder, lanes 2-5 = 2x dilution M.BsaWI with AdoHcy-8-
Hy-PEG-N3, lane 6 = no enzyme + AdoHcy-8-Hy-PEG-N3, lane 7-10 = 2x 
dilution M.BsaWI - AdoHcy-8-Hy-PEG-N3 lane 11 = fully restricted, lane 12 = 
fully protected. 
M.BsaWI is not active with AdoHcy-8-Hy-PEG-N3, as demonstrated by full 
restriction in all test lanes. 
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It was decided that M.BsaWI will not be suitable for use in this thesis for labelling 
experiments. None of the mutated MTases proved to be efficient with the synthetic cofactors 
tested. This could be due to the mutation to the binding pocket not being favourable for 
AdoHcy-6-N3 or AdoHcy-8-Hy-PEG-N3.  
 
It may be that the structure should be investigated further and protein expression optimised to 
ensure that the best mutations have been made to the cofactor pocket, and that the protein is 
correctly folded and active. Other synthetic cofactor analogues could also be tested to see if 
this mutated enzyme has a greater affinity to them, and therefore higher levels of activity. It 
may also be interested to see how well wild type M.BsaWI interacts with the synthetic 
cofactors, as it may be that actually the WT has greater activity and is more suitable for 
labelling than that mutated versions. This should be considered if looking to continue with 







 Protection assay summary 
This chapter saw a number of protection assays test the activity of different enzymes and 
cofactors. There following conclusions were made: 
• M.TaqI protein is active with both AdoMet and AdoHcy-6-N3, and therefore 
suitable for labelling experiments. 
• Residual AdoMet coeluting with M.TaqI protein may inhibit labelling, but can 
be removed via incubation with TCGA-containing oligos if required. 
• The lowest concentration of M.TaqI protein should be used in order to not 
unintentionally add residual AdoMet into the reaction. Low concentrations of 
M.TaqI can still result in full labelling, as demonstrated by mass spec. 
• Mutant enzymes (M.BsaWI and M.SfoI) are not fully active with any of the 
cofactors tested, and are not suitable for further experiments at this point. 
• Enzyme M.HincII is not active with the cofactors tested and is not suitable for 
further experiments at this point. 
• M.BseCI enzyme can be used instead of M.HincII, and is active with AdoMet. 
M.BseCI can therefore be used for methylation and mapping experiments with 
M.TaqI. 
 
 General conclusion 
This chapter shows expression of five enzymes, three of which have not been yet been 
reported. DNA alkylation was successful with M.TaqI, but others were not active and able to 
achieve full labelling. MTase activity could be improved with optimised protein expression 




M.TaqI has been successfully produced and is efficient in alkylating DNA with AdoHcy-6-
N3, as confirmed by mass spectrometry. It has since been documented that using a higher 
concentration of M.TaqI leads to complete labelling of DNA, leaving none of the sample 
hemi-labelled, in work carried out by Andrew Wilkinson (not documented). This suggests 
that labelling efficiency is higher than that stated, and often reaches completion. This 
technology will be used extensively throughout the rest of this thesis for various imaging 
applications. Results from gel electrophoresis suggested that around 0.4 nM M.TaqI per nM 
of sites is a suitable amount to ensure full labelling without unnecessarily adding too much 
excess AdoMet into the reaction. Results from mass spectrometry showed that M.TaqI has a 
turnover of 19 in an hour of labelling, and so an even lower MTase concentration than that 
tested in gel electrophoresis could be used. Care should be taken to use as little M.TaqI as 
possible in each reaction to ensure that excess residual AdoMet is not unnecessarily added 
into the mix, which could result in methylation rather than labelling of the DNA of interest. If 
single-molecule work is to be carried out, further investigation into removal of residual 
AdoMet may be necessary to ensure efficient labelling. This may involve extensive washing 
of the protein during the purification process121.  
 
If wanting to continue the production of a toolbox for dual-colour labelling, further rational 
design and structural work into mutant enzymes should be carried out. This will ensure that 
the mutations made are optimal for the specific synthetic cofactors produced. Random 
mutagenesis could also be explored as a means to test different mutations with a range of 
cofactor analogues. More work into optimisation of expression conditions should also be 











This chapter looks to explore the cytogenetic mutations that can occur and are indicative to 
diseases such as cancer, in particular investigating chromosome aneuploidy. FISH is a 
technique that is frequently used to diagnose large mutations such as the loss or gain of entire 
chromosomes, due to its rapid nature and ability to be used on both interphase and metaphase 
cells35. This means that when harvesting samples they do not necessarily have to be 
synchronised (i.e. applying mitotic blocks to achieve as many cells in metaphase as possible – 
as is the case for karyotyping), which again saves time and speeds up time to result, which is 
crucial for many patients that need treatment as quickly as possible. The use of oligoprobes 
for FISH is investigated in this chapter, in an attempt to further improve turnaround times 
when looking at chromosome enumeration. The MTase-labelling technology tested in 
Chapter 3 is used to label oligoprobes to see if it can be effectively applied to this technique, 
and whether this results in bright probes that are easily detected, with short preparation times. 
 
 Detecting genetic instability in cancer 
As discussed in the introduction, fluorescence in situ hybridisation (FISH) is a cytogenetic 
technique used to detect and localise specific DNA sequences both in metaphase and 
interphase cells. Due to the high specificity, sensitivity and speed in which this technique can 
be carried out, FISH is routinely used both for diagnostics and research for a range of 
disorders from haematological malignancies to solid tumour samples35,129.  
 
As discussed in 1.1.4, genetic instability – which includes both numerical and structural 
chromosomal abnormalities – is a key hallmark of many cancers10,20,130. Aneuploidy, for 
example, is a numerical abnormality that involves the loss of gain of an entire chromosome, 
or in some cases multiple chromosomes. This is likely caused by errors that occur in cell 
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division, described in 1.1.3, which can result in improper spindle assembly and separation of 
sister chromatids during mitosis (or meiosis). Uncontrolled cell division is a key 
characteristic of cancer, due to mutations in genes that encode cell cycle regulator proteins, 
such as tumour suppressor genes. This means that DNA damage or mutations that give rise to 
cancer can often go undetected, allowing the mutated cells to rapidly proliferate. 
 
Acute lymphoblastic leukaemia (ALL) is an aggressive form of cancer that affects white 
blood cells in both adults and children, requiring immediate treatment131. Although ALL is 
rare – with around 650 new diagnoses every year in the UK – it is the most common type of 
childhood cancer, with approximately 85 % of cases affecting those under the age of 15132. 
Survival rate for children with ALL has recently been reported to be around 90 %133, with 
babies and adults significantly lower at 50 %134 and 35 %135 respectively. Prompt diagnosis 
of patients is key in order to administer treatments to patient with ALL as quickly as possible, 
in a hope to improve prognosis. 
 
ALL is a complex disorder that typically emerges when a lymphoblast gains multiple 
mutations in the genes that affect blood cell development; research has suggested that these 
mutations can be inherited – e.g. mutations to the genes p53, CDKN2A/2B or IKZ1 – or 
caused by environmental risk factors such as radiation131,133,135. Individually, one mutation 
puts a person at low risk of developing ALL, but this increases significantly if there are 
multiple mutations present131. There are many structural and numerical mutations that have 
been linked to ALL, such as mutations in C-MYC, a transcription factor involved in 
increased cell division, and translocations of two genes BCR and ABL to form a BCR/ABL 
fusion gene. The BCR/ABL mutation encodes a tyrosine kinase that promotes cell division, 
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which is a mechanism that cancer cells then use to rapidly divide and grow. This is a common 
mutation also found in CML, and is investigated in Chapter 5. As discussed above, 
aneuploidy is also a hallmark in many cancers, including ALL, where multiple chromosomes 
can be missing, or duplicated, in each cell; the use of FISH for chromosome enumeration will 
be explored in this chapter.  
 
 Probe design for enumeration 
FISH probes are designed to be complementary to the DNA sequence within the region of 
interest, and labelled with fluorophores. As discussed previously, these probes are annealed 
to a slide containing fixed patient cells, after heating to a temperature capable of denaturing 
the DNA – or chemical denaturation – of both probe and patient so that it is single stranded, 
before cooling to 37 ⁰C, for hybridisation. Probes can be used on their own or in combination 
in a probe cocktail. A mixture of fluorescent dyes (usually red, green and blue) can be used to 
label the different probes and view different abnormalities within one screening. 
 
There are three main types of probes that are routinely used in FISH – locus-specific, 
centromeric/telomeric and whole chromosome paint, Figure 4.1 – the use of which depends 




Locus-specific probes are designed to by complementary to a region or a gene of interest, and 
can therefore detect gene translocations, deletions and amplification; this is explored in 
Chapter 5. Whole chromosome paints can be used as enumeration probes, but are mostly used 
to determine whether unbalanced or balanced chromosomal rearrangements have occurred, or 
to identify the origin of additional material found within the cell137.  
 
Centromeric and telomeric probes target α-satellite repetitive regions located at the 
centromere, where two sister chromatids meet, or on the telomeres at the end of 
chromosomes138–140. Centromeric probes are generally used as enumeration probes, and are 
highly useful in many genetic disorders including those associated with trisomies, as well as 
cases of cancer. ALL in particular, is a complex disorder that characterises itself in many 
ways, one of which being the loss or gain or various chromosomes; this can be detected using 
Figure 4.1: There are four main probe types. Locus-specific probes 
target particular regions or genes, and are useful for loss/gain of a 
region or translocations. Centromeric and telomeric probes bind to 
repetitive regions at the middle or ends of a chromosome, 
respectively. Whole chromosome paints are useful for origin of 
marker chromosome analysis.  
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centromeric FISH probes. There are complexities in designing centromeric probes for FISH, 
however, due to the repetitive nature of the centromere. 
 
As stated above, centromeres form part of a specialised DNA sequence that join each pair of 
sister chromatids, Figure 4.2.  
 
In most eukaryotic cells, the centromere’s DNA sequence is made up of large arrays of non-
coding repetitive DNA (satellite DNA) and, in humans, the primary centromeric unit is called 
α-satellite (or alphoid DNA)141. This satellite DNA is the main component of all centromeres, 
and a structural constituent of heterochromatin (condensed DNA)142. Each unit is based on a 
171 bp A-T rich monomer, which makes up a higher order repeat (HOR) that is tandemly 
repeated potentially hundreds to thousands of times, spanning megabases in total143.  
 
Monomers from each specific chromosome are reported to be 50 to 70 % identical144,145 so 
there are regions that are highly repetitive across all chromosomes, and FISH probes need to 
be designed for this region carefully to avoid cross-hybridisation143,146,147. For chromosome 
Figure 4.2: Chromosome with centromere 
linking two sister chromatids in the middle. 
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specific units, each repeat within a HOR is approximately 97 to 100 % identical, and so this 
conserved region can be used for probe design. O’Keefe et al., investigate the 2.7 kb alpha-
satellite HOR repeat unit for 17CEN in a paper in 1996,148 which is comprised of 16 
monomers each of 171 bp. They report the use of oligoprobes to study this region, noting that 
the probes can distinguish between two highly homologous sequences within this region, 
differing at only 4 bases to each other. These probes have since been used in many studies to 
investigate methods of detecting both of these highly similar sequences148–150. These 
sequences will be used in this thesis to explore the use of oligoprobes for 17CEN 
enumeration. 
 
 Oligoprobes for FISH 
Oligoprobes are short sequences of DNA (around 50 bp) designed to be complementary to 
the region of interest18. Unlike most commonly used FISH probes, they are not derived from 
BACs, but are designed synthetically16. Due to the short length and low complexity of the 
probe, this leads to faster hybridisation kinetics compared to traditional probes (which can be 
hundreds of kilobases in length), as well as greater specificity to the target19. If these were to 
be implemented clinically, this could result in faster results for patients, making them highly 
favourable over standard probes. These faster hybridisation times also allow potential for 
same-day diagnosis of diseases that typically take multiple rounds to detect. As stated above, 
for presentation of ALL at WMRGL, an initial round testing for BCR/ABL, MLL and 
TEL/AML1 is performed, which takes 16 hours to hybridise. If the initial round shows no 
abnormalities, a second round looking highlighting IGH and E2A is tested, again with an 
overnight hybridisation. With shorter hybridisation times, both rounds could be performed 




Another benefit of these synthetic probes is the ability to design and tailor them with high 
specificity to target uncommon abnormalities and variations20. This flexibility sets them apart 
from other FISH probe companies who are only able to create probes for common 
abnormalities, or those that are easily available within a BAC library. There is an increasing 
amount of sequence information available now, thanks to the advancement of sequencing 
technologies, making it easier to design oligoprobes to unique ROIs45,151–153. 
 
 Labelling of probes 
As discussed briefly in Chapter 1, there are various ways to fluorescently label DNA, many 
of which vary in the amount of specialist training and reagents required. As MTase-directed 
labelling could be performed easily with a kit simply containing a buffer, MTase and cofactor 
analogue, it seems like a suitable method for labelling of oligoprobes in both a diagnostic and 
research lab. It is also incredibly easy to incorporate MTase recognition sites into oligoprobe 
sequence designs, allowing control over the position, and quantity, of fluorophores, giving 
the user a high level of control over the sensitivity of the probe. Currently, BACs are mostly 
labelled using nick translation, a method developed by Rigby and Paul Berg in 1977106. This 
is a fairly time-consuming process, where DNA is treated with deoxyribonuclease I (DNase I) 
which creates nicks in the phosphate backbone of the sequence. This is followed by the 
addition of DNA Polymerase I which, by 5’-3’exonuclease activity, replaces nucleotides at 
nicked sites with fluorescently tagged dNTPs. It also usually requires the addition of ligases 
to fill in any non-specific nicks. In contrast, using MTases is a much simpler protocol, which 





 Fluorophore choice and properties 
As discussed in the introduction of this thesis, fluorescent probes are invaluable tools, as they 
allow the investigation of the structure and function of biomolecules, as well as the sequence 
of DNA within an organism’s genome. In this way, they can be used to detect genetic 
abnormalities that may play a role in the pathogenesis of certain diseases.  
 
When using FISH in the clinic, it is common for multiple probes to be used simultaneously in 
order to detect a range of mutations. Quite often this is to check for abnormalities that 
routinely occur together, or to rule multiple mutations out at once. It is often also the case that 
two probes are used as one can be a positive control for a single gene probe (i.e. using a 
control probe for the centromere of chromosome 17, while using a single gene probe for the 
same chromosome, such as p53). For this reason, it is necessary that multiple fluorophores 
are used that are stable, spectrally distinguishable and bright. For MTase labelling, it is also 
crucial that these fluorophores are compatible with our labelling technology, which is 
discussed further in the results section of this chapter. 
 
In this chapter, different fluorophores are used in an attempt to perform multiple 
hybridisations of various loci at once. This means that fluorophores had to be considered that 
would be efficient with both the chemistry being used, and the microscope set up (i.e. the 
excitation and emission must be suitable for the lasers and filters in the lab). Other factors 
that can be considered are the quantum yield (i.e. the number of photons emitted per photons 
absorbed, which determines the fluorophores’ efficiency) and photostability of the 
fluorophores154–156. Quantum yield is directly proportional to how bright the probe will be, 
and so the higher this is, the higher the potential SNR. Photostability is important as the 
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fluorophores are irreversibly destroyed by photobleaching when exposed to high laser powers 
and long excitation times, which will result in decreased SNR.  
 
The main deciding factor for choosing fluorophores for oligoprobes in this thesis was that 
they were spectrally distinguishable and compatible with the MTase labelling technology. 
There are now many dyes that have been developed across the UV/vis spectrum that are 
commercially available and capable of easy coupling chemistry. Dyes can easily be chosen 
based on their brightness and photostability, and their emission and excitation checked to 









The aim of this chapter is to explore the use of MTase-labelled oligoprobes in FISH. Due to 
the short size of the oligoprobes in comparison to the more commonly used BAC-derived 
probes, it is hypothesised that hybridisation to patient slides should occur in a significantly 
decreased time. As the probes are labelled with MTases rather than other labelling methods, 
this also allows full flexibility in the location of the fluorophore, as well as being able to 
easily add additional fluorophores to the probe design, increasing sensitivity. 
 
After discussions with the scientists at West Midlands Regional Genetics lab (WMRGL), 
who use FISH regularly to diagnose ALL, it emerged that they often perform several 
“rounds” of FISH tests in order to determine the exact mutations that a patient has. This can 
also determine the prognosis and direction for treatment, as some cytogenetic subtypes have 
worse prognosis than others. Mutations that are tested for are initially BCR/ABL, MLL/ 
TEL/AML1, followed by IGH and E2A, these look for various translocations of 
amplifications that could be involved in the development of ALL. Enumeration of various 
chromosomes (1, 7, 17 followed by X, 6 and 10) is then tested, with loss of 1, 7 or 17 being 
associated with poor prognosis for ALL patients. As each hybridisation typically takes 16 
hours, this process can often take multiple days to reach a diagnosis using the current FISH 
protocol. It was hypothesised that by using oligoprobes, it may be possible to speed up the 
time to result for these tests, potentially providing the option to perform several tests in a 
single day. This could be a more efficient way of diagnosing patients, as multiple mutations 
can be detected in a significantly shorter timeframe, reaching the conclusion of ALL much 
quicker. WMRGL suggested that focus was initially placed on designing probes to detect loss 
of chromosome 17, to see if using the MTase labelling technology combined with 
oligoprobes could provide a quicker and more efficient means to obtaining results for patients 
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potentially with ALL in critical need of timely treatment. This chapter will aim to label 
oligoprobes designed specifically for the 17CEN region with M.TaqI and AdoHcy-6-N3 to 
see if hybridisation times can be improved, and that bright probes can be detected. Conditions 
– including wash buffer stringency, probe concentration, hybridisation buffer components 
and probe design – will be analysed and optimised in order to be confident that the 
oligoprobes can hybridise consistently, and correctly identify the region of interest (ROI). If 
successful, probes for the centromere of chromosome 1 and 7 will also be explored. 
  
Research has found that oligoprobes are able to discriminate between cytogenetically 
indistinguishable homologous samples44. Structural variations that differ only at a few bases 
are able to be detected by these oligoprobes when designed to target these areas148. This 
provides huge potential in diagnosing disorders and abnormalities that contain SNPs or other 
small structural changes that current genetic techniques struggle to detect. Spinal Muscular 
Atrophy (SMA), a neuromuscular disorder, is the most common genetic cause of death in 
infancy157. The disease is characterised by mutations and therefore loss of functionality in the 
gene SMN1111. Nearly identical gene SMN2, which only has one critical nucleotide 
difference, can be present in variable numbers in patients and therefore restore some of the 
functionality lost from the SMN1 mutation112. This can result in varying levels of severity of 
the disease. Due to the similarity in sequence, traditional FISH cannot currently be used to 
distinguish between SMN1 and SMN2, which is critical for successful diagnosis and 
treatment. Due to variations in copy number on SMN2 gene, as well as having different 
conformations of SMN1 (1:1 or 2:0 carriers) this also causes problems in diagnosis using 
molecular techniques. Using oligoprobes that can distinguish between highly similar 
sequences may prove to be an invaluable technique, and will be explored further in this 
chapter, by attempting to detect highly homologous centromere sequences.  
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 Results and discussion 
The overall aim of this chapter was to test and optimise the use of MTase-labelled 
oligoprobes in FISH. Using M.TaqI and AdoHcy-6-N3 that had been tested in the previous 
chapter, this labelling technology was used to attach fluorophores to a DNA hairpin targeting 
the centromeric region of chromosome 17 – followed by the centromere of chromosomes 1 
and 7. This chapter hopes to produce an oligoprobe that can successfully bind to the target, 
and be detectable using fluorescence microscopy. Automating the process of assessing signal 
to noise ratio were also investigated in order to determine the best conditions for the probes. 
Using oligoprobes may make it possible to achieve faster hybridisation times than current 
FISH workflows, which could result in faster turnaround times, quicker results for patients 
and prompt treatment for a range of diseases. They can also be designed for any region of the 
genome and engineered to avoid specific repetitive sequences. 
 
 Hairpin oligoprobes for rapid chromosome enumeration 
As discussed in the introduction of this chapter, oligoprobes have been proven to hybridise 
more rapidly to ROIs in FISH. This is due to their short size (typically < 100 bases) resulting 
in faster hybridisation kinetics38,46. The potential for the use of oligoprobes in diagnostic 
laboratories is vast. These short hybridisation times could mean faster patient diagnosis, 
ultimately leading to quicker administration of treatment. After discussion with West 
Midlands Regional Genetics Laboratory (WMRGL), it was decided that as proof of concept a 
probe for the centromere of chromosome 17 (17CEN) would be designed. Loss of 17CEN 
can be indicative of acute lymphocytic leukaemia (ALL), and is currently tested (along with a 
probe for chromosome 1 and 7) using FISH in a 16-hour hybridisation. As ALL is a complex 
disease, it can take many rounds of FISH to come to a conclusive diagnosis. This means that 
with each round taking 16 hours, it can be days before a diagnosis is met, and a patient's 
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condition could rapidly deteriorate while waiting for treatment. With the ability of 
oligoprobes to potentially hybridise to ROIs much faster than traditional probes, this 
technology could be used to provide rapid diagnosis in laboratories. Multiple tests could also 
be performed in a single day, rather than waiting for an overnight hybridisation with each 
round of testing, increasing the chance of a timely delivery of treatment to the patient.  
 
Oligoprobes were designed using short sequences targeting a region within the centromere of 
chromosome 17. The sequence was obtained from work by O’Keefe et al.44 and confirmed by 
performing a BLAT search against the human genome. A BLAT search is a tool that allows 
DNA sequences to be compared about the human genome, highlighting matches of 95 % or 
greater for 25 bases or more. This region was selected as it was identified as being unique to 
chromosome 17 and should not hybridise elsewhere under stringent wash conditions. 
According to the study, this region of DNA can exist in two highly homologous forms. The 
two variants, which differ at 4 base positions, will be referred to as 17CEN1 and 17CEN2. 
Humans are thought to either have 17CEN1, 17CEN2, or a mixture of both within their 
chromosome 17 centromeres, which will be explored later in this thesis. A hairpin design 
included a double-stranded portion of the probe, shown in Figure 4.3A. This double-stranded 
region is necessary for future MTase labelling – which will be tested if the initial design is 
successful after trialling with prelabelled probes – so that the MTase can bind to and label the 
DNA strand77. To test the efficiency of the hairpin probe design to hybridise uniquely to 
chromosome 17, and to see if such as small piece of DNA can be detected, 17CEN1 and 2 
were ordered from IDT DNA with a Texas Red NHS-ester (Abs 596 Em 613) conjugated to 
the 5' end. The two variants were mixed to ensure the area could be detected (in case the 
patient only had one or the other). The prelabelled 17CEN probe was hybridised to a patient 
sample as described in 2.2.7, and visualised using an inverted, epifluorescence microscope 
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equipped with a 100x objective lens (Nikon, 1.49/oil TIRF) and cooled EMCCD camera 
(Photometrics, Evolve® 512 Delta). Excitation at 405 nm and 561 nm was achieved using 
solid state lasers (Coherent, OBIS) to visualise DAPI (nuclear stain) and Texas Red (probe) 
respectively. As can be seen in Figure 4.3B, the probe successfully bound to chromosome 17 
and could be clearly detected under these conditions. This confirms not only that the hairpin 
design can efficiency bind to the human genome and is detectable using FISH, but also that 
the recognition sequence is specific to that loci, and does not hybridise elsewhere under these 
conditions. The result also came with just a 15-minute hybridisation time – significantly 
lower than the 16-hour hybridisation time used currently by clinical laboratory protocols. 
This could have a huge impact on the current turnaround times of FISH results. 
 
While the prelabelled 17CEN probes were successful in highlighting the ROI, they were 
expensive to order; 100 nM of Texas Red-labelled oligo (the lowest concentration that could 
be ordered from IDT for this size oligo) was ~£70, and both 17CEN1 and 2 needed to be 
A 
Figure 4.3: A) Schematic of hairpin probe design with fluorophore at 5' 
end B) A hairpin 17CEN probe visualised by FISH on human 




ordered to account for both homologues of that region. This means that if different ROIs were 
needed – which would be the case for anything other than repetitive centromeric/telomeric 
regions – the cost of labelling oligoprobes in this way would be too high for many diagnostic 
laboratories. If wanting to look at single genes for example, where potentially hundreds of 
oligos are across the ROI, the price would increase substantially. By labelling the hairpins 
using MTase-labelling technology the price can be lowered significantly, as the enzyme and 
cofactor are manufactured inhouse and at a high yield, with only microlitres of each being 
used per labelling reaction. As discovered in Chapter 3, MTase labelling is best when using 
the lowest possible concentration of M.TaqI, and the amounts of cofactor and enzyme needed 
to label the oligoprobes would be incredibly small for a large batch of probes. This 
technology could therefore lower the price of probes significantly. Labelling with MTases 
also allows control over how many fluorophores can be attached to the probe by 
incorporating extra MTase recognition sites within the probe design, as well as offering the 
flexibility of where to place the sites within the probe sequence, or even to have different 
MTase recognition sites within one probe for dual colour. The hairpin structure in the 
sequence of the oligoprobe, shown in Figure 4.4, is critical to the labelling procedure as 
MTases recognise, and bind to, double stranded DNA sequences77.  
 
Figure 4.4: Schematic of oligoprobe targeting 17CEN1. By altering the amount of red 
“TCGA” sites within the sequence, extra fluorophores can be attached to the probe by 
M.TaqI, which should increase sensitivity. 
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By incorporating a hairpin into the design, this allows the recognition sequence to occur as a 
double stranded piece of DNA, leaving the binding site open for hybridisation to the ROI. By 
labelling using MTases, the number of labelling sites can be altered by the addition of extra 
recognition sequences within the design. Addition of extra sites could increase sensitivity, or 
increase the chance of a probe having a label attached, which will be explored later in this 
chapter. This means that if alkylation does not reach 100 % completion, i.e. not all sites 
receive azide functionality, that even a hemi-methylated strand could potentially be detected 
if the fluorophore is bright enough. M.TaqI (recognition sequence TCGA) will be used to 
label the oligoprobes, due to its efficiency with synthetic cofactors – namely AdoHcy-6-N3 – 
as shown in Chapter 3. 
 
The 17CEN hairpin sequences were ordered from IDT without the attached fluorophore, to be 
labelled using the MTase technology at a significantly reduced cost (100 nM unlabelled oligo 
was ~£10 whereas 100 nM Texas Red-labelled oligo was ~£70). Based on these prices, if 
wanting to order multiple colours and multiples ROIs – which would be necessary if wanting 
to use these probes in a diagnostic lab – the prelabelled probes would be far too expensive for 
many laboratories to consider. As M.TaqI and AdoHcy-6-N3 were successfully used for 
alkylation experiments in Chapter 3, they were now used to attempt labelling of the 
oligoprobes. 17CEN1 and 17CEN2 were labelled with DBCO dyes using SPAAC click-
chemistry as discussed in Chapter 3. There are limited DBCO dyes commercially available, 
but TAMRA DBCO (Abs 553/Em 575) was initially tested as its properties were like that of 




The oligoprobe was labelled and hybridised to the sample for 15 minutes as described in 
2.2.4 and 2.2.7. As can be seen in Figure 4.5, the oligoprobes can clearly be detected under 
the conditions used. This means that the oligoprobe design is suitable for MTase-labelling 
experiments, opening up the potential for this technology to be used in wider FISH 
applications for various mutations and diseases. This could have a significant impact on 
turnaround-times for patient results in clinical laboratories, and shows huge potential for 
prompt diagnosis of diseases such as ALL where rapid treatment is required. The flexibility 
and affordability of this technology could be revolutionary to dianogstic labs that require 
quick and efficient testing in often complicated situations, such as in cases of ALL where the 
karyotype is can be complex and requires multiple rounds of testing. 
 
  
Figure 4.5: Human metaphase nuclei on 46XX/XY 
sample showing a successful 15-minute hybridisation of 
MTase-labelled 17CEN1/2 with TAMRA DBCO. 
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 Optimisation of oligoprobe design 
 
 
Figure 4.6: Scheme of FISH process and points for optimisation. Different parameters 
were tested in terms of probe design, probe mixture, hybridisation conditions and wash 
stringencies in order to produce the highest SNR. 
 
To obtain efficient and reproducible results, conditions for MTase-FISH need to be 
optimised. There were many factors to consider at each stage of the protocol, such as the 
oligoprobe design itself, number of fluorophores, concentration of probe, hybridisation 
conditions, and wash stringencies (Figure 4.6), all of which are discussed in this chapter. It's 
important to note that each condition was tested with samples from the same patient – 
prepared under the exact same conditions and at the same time – to keep variables as 
consistent as possible, as some patients may have more of less copies of the repetitive 
centromeric region. This could result in some probes appearing brighter than others if a 
patient had more copies of that region, due to the increased number of sites rather than the 
change in condition. Conditions were assessed qualitatively by manual visualisation and, 
where possible, quantitatively using the image analysis software, Icy159. Quantitative analysis 
was not always possible if the samples had particularly high background, or if samples were 
of poor quality. Protocols were designed for Icy to detect interphase nuclei (Figure 4.7A), as 
well as the spots within them, and obtain the fluorescence intensity of those areas. A 
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from the 405 channel, and tools for spot detection (using the 561 channel) within those ROIs 
detected probes (Figure 4.7C). Background and artefacts visible outside of the ROIs (such as 
the spot seen outside of the nuclei in Figure 4.7C) were ignored by the software. Intensity of 
both the nuclei and the spots (probes) were measured in the 561-channel so that signal to 
noise ratio (SNR) could be calculated.  
 
Figure 4.7: A) FISH image of human interphase nuclei with two signals in each 
B) Icy thresholds to locate interphase nuclei (the ROI) C) Spot detector locates 
probes (shown in blue) within the interphase nuclei, and ignores those outside. 
The values for fluorescence intensity for these regions can be collected and used 





SNR was calculated by dividing the average signal fluorescence by the average background 
intensity of the nuclei. This shows how bright the probe is in comparison to the background 
fluorescence, and so the higher the SNR, the better the probe for confident and accurate 
detection.  
 
First, the probe concentration was examined. After purification, 17CEN (1 and 2 combined) 
measured at ~ 14 ng/µl. A range of concentrations of TAMRA-labelled oligoprobes were 
tested and visualised (0 ng/µl, 1 ng/µl, 2 ng/µl, 4 ng/µl, 6 ng/µl, 8 ng/µl and 10 ng/µl). For 
each of them a standard amount of hybridisation buffer (5 µl) was used, as this is a typical 
volume used at WMRGL and would be easy to incorporate into the current protocol. Probes 
were visible for each of the examples, with no obvious improvement in SNR as the 
concentration increased, as seen in Figure 4.8.  
Figure 4.8: Interphase nuclei showing increasing concentration of 17CEN 
probes labelled with TAMRA DBCO. Probes were visible in all conditions and 
changing the concentration did not appear to have a significant impact on signal 
strength.  
1 ng/µl 2 ng/µl 4 ng/µl 




It is interesting to note that with a low concentration (1 ng/µl) of probe, signals are still 
detectable using FISH, although not very bright. From 2 ng/µl, background fluorescence 
appears to have slightly decreased – but not significantly – this may mean that an increased 
number of probes have hybridised to the target, resulting in higher signal to noise. All 
samples do have some background fluorescence, potentially caused by excess free-probe on 
the slide being trapped under the coverslip, suggesting that the wash conditions should be 
optimised.  
 
Going forward, it appears that adding extra probe does not have a significant effect on SNR 
based on these qualitative results, and so as little as possible should be used in order to save 
cost. Adding too much unnecessary probe may also have an effect on the amount of 
background if not sufficiently washed away from the sample before imaging, or if the 
stringency is not high enough to remove all of the non-specifically bound probe. It may also 
be that the volume of hybridisation buffer could have an effect on the amount of probe that 
can penetrate and bind to the sample. Dextran sulphate – one of the key components in the 
hybridisation buffer – acts as a volume exclusion agent, enhancing hybridisation by creating a 
crowded environment, increasing the effective local probe concentration160. In future, it could 
be useful to test different amounts of hybridisation buffer, and therefore dextran sulphate 
concentrations, to see if this has an effect on hybridisation. 
 
Quantitative analysis allows us to gain further insight into the optimum conditions for probe 
concentration. Between 50 and 100 interphase nuclei images of each sample were taken and 
analysed using Icy. From these images, the mean fluorescence intensity (MFI) of the probe 
were calculated using spot detection with the intensity of the 561 laser for that region. SNR 
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was calculated by dividing the MFI of the spots by the MFI of the whole nucleus in the 561 
channel; a higher SNR means that the signal is brighter than the background and is the best 
choice for FISH conditions. The results in Figure 4.9, appear to confirm the qualitative 
result, that increasing the probe concentration does not have a significant effect on SNR. 
There is no noteworthy change in the median SNR (as shown by the horizontal line across 
each box plot) or mean (shown as an X) across all concentrations. All of the boxes overlap, 
demonstrating the that the data is similar across each condition. The "whiskers" of each box 
plot are also fairly consistent, suggesting again that there is not much variation between the 
conditions, and that most of the data for each plot is close to the mean value.  
 
Figure 4.9: Box plot showing SNR of different concentrations of 17CEN TAMRA-
labelled probe. There was no significant variation between conditions. 
 
It is important to note that, as stated above, to keep costs down, it would be therefore be 
optimal to use the least amount of probe necessary for detection. Testing wash stringencies 
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may be a way to further reduce background noise in the cells and increase sensitivity of the 
probes, as it could prevent non-specific binding; this will be explored later in this chapter. 
 
FISH probes are already expensive to order and, if wanting to use prelabelled-oligoprobes, 
single gene detection - i.e. needing a new probe for each loci – could be impractical due to 
cost. It is not certain how many fluorophores are needed to detect a signal, but the fewer, the 
better, in terms of cost per test. By producing an alternative that is just as bright, or brighter, 
than the probes currently on the market, this could reduce the number of probes needed (i.e. 
the concentration needed) for a visible signal, and therefore reduce cost. By labelling 
oligoprobes with MTases, this allows flexibility in how many labels are attached to the probe. 
Incorporating TCGA sites into the probe designs means any number of M.TaqI sites can be 
added, potentially making the probe brighter. A bright probe, combined with faster 
hybridisation rates, could have a significant impact in terms of quality of – and confidence in 
– results for diagnostic labs. 
 
Five different probe designs were tested, each with either a different number of TCGA sites, 
or different “spacers” between sites. Probes with one, two or three sites placed directly next 
to each other were used, as well as one with two sites separated by 2 bp and one with two 
sites separated by 15 bp (Figure 4.10). 2 bp spacing was chosen to see if this could affect 
MTase labelling efficiency, as the extra bases were thought to be potentially needed for the 
MTase to dock onto the strand. The 15 bp spacing was chosen in an attempt to prevent 
quenching of fluorophores as typical donor-acceptor systems see quenching of dyes at a 




Figure 4.11 shows that increasing the number of labelling sites did not appear to significantly 
improve the SNR. The median and mean SNR do seem to slightly increase with the number 
of sites, but not significantly so. This could be further tested with the addition of more sites 
into the sequence, but this would also increase the cost per probe, which should be a 
consideration during design. The 2 bp spacing between sites also appeared to have no effect 
on labelling efficiency, as the 2 bp sample has very similar SNR median and interquartile 
values as the 2-site sample with no spacing. It could be that in both samples the fluorophores 
are quenched from being too close to one another, which is why they have similar SNR to the 
1-site and 3-site samples. Having 15 bp spacing between sites does seem to have had a 
positive effect on SNR, with the median of this sample being slightly higher than all other 
samples, including the 3-site sample. An increased spacing of 30 bp could be considered to 
see if this has an even bigger impact on the intensity of the fluorophores, although this 
increase in probe size could also increase hybridisation time and cost. A 3-site probe with 15 
bp could also be considered for testing to see if this again increases SNR, but this would be 
Figure 4.10: Five different probe designs were 
ordered with varying amounts of M.TaqI sites or 
spacers to see if this had an impact on SNR. 
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more expensive to order and could be seen as unnecessary if the 1-site probes are detectable. 
This may need to be considered for single gene probes where there are significantly less 
probes bound to the region than with repetitive centromeric regions. 
 
 
Recent work by Schröder et al has explored the effect of closely positioned dyes on 
fluorescence, stating that a stronger signal of fluorescence was obtained with distances of 
around five base pairs162. A distance of around 7 bps indicated permanent separation of dyes, 
but the oligoprobe used in Figure 4.6, with 2 bp linker (and therefore six base pairs between 
dyes) does not necessarily support this. It is important to note, however, that as M.TaqI is 
palindromic, there is often a dye on both strands that will inevitably interact with one another. 
A different enzyme (with a non-palindromic recognition site) could be considered if this 
Figure 4.11: Graph showing SNR of different 17CEN probe designs with varied number 
of labelling sites, or different linker spacing between sites. There appears to be no 
significant difference, although the 15 bp spacer has a slight increase in SNR. 
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appears to be a problem, but the results here do not indicate that this affects the ability to 
detect the probes. 
 
 Optimisation of oligoFISH conditions 
As discussed in the introduction of this chapter, formamide is a commonly used solvent in 
FISH hybridisation buffers. The addition of formamide results in the destabilisation of DNA 
complexes as it competes with hydrogen bond formation between Watson-Crick base pairs. 
Addition of 1 % formamide to a probe mix lowers the melting temperature (Tm) of 
probe:target by 0.72 °C163. Tm is defined by the temperature at which 50 % of double stranded 
DNA (dsDNA) denatures to become single stranded DNA (ssDNA). This is determined by 
the probe:target length, as well as the C:G composition. The oligoanalyzer tool on IDT's 
website was used to determine the Tm of probe:target for 17CEN1 and 2, which were 58.6 °C 
and 59 °C respectively. Careful consideration of formamide concentration in the 
hybridisation buffer was needed due to the low probe:target Tm to prevent accidental 
denaturation during the hybridisation step at 37 °C. Standard hybridisation buffer typically 
contains ~70 % formamide, which may prove too stringent for small oligoprobes compared to 
traditional probes (the longer the probe the higher the melting temperature). If too low a 
stringency is used, however, this may lead to a higher level of non-specific binding resulting 
in cross-hybridisation and high background.  
 
Hybridisation buffers were made up as listed in Table 4.1 to include 30 %, 40 %, 50 %, 60 % 
or 70 % formamide. These buffers were tested along with Cytocell Hybridisation Buffer B 
(~70 % formamide) with 17CEN1/2 TAMRA DBCO following the protocol in Chapter 2. 
Each sample was visualised on the microscope and between 50 and 100 images of interphase 
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nuclei were taken. These images (a representative selection shown in Figure 4.12) were 
analysed using Icy to determine the signal intensity for each visible probe.  
 
Buffer Tm 17CEN probe:target 
30% formamide 48.2 °C 
40% formamide 44.6 °C 
50% formamide 41 °C 
60% formamide 37.4 °C 
70% formamide 33.8 °C 
Cytocell 70% formamide 33.8 °C 
Table 4.1: Table showing melting temperatures (Tm) of 17CEN probe to target DNA. As 
formamide concentration increases, the melting temperature of probe to target 
decreases, which will need to be considered when performing heated steps during the 
FISH protocol. 
 
From manually assessing the samples by eye, the optimum formamide concentration 
appeared to be between 40 and 50 per cent. Any higher than this and the probe began to get 
lost in the background, as contrast in the image needed to be increased to be able to visualise 
the spots. This suggests that at higher concentrations of formamide, there are not as many 
probes bound to the region, resulting in a reduction of signal to noise. This is important to 
consider if planning on moving to other probe designs that are targeting single genes, as each 
oligo would have a unique sequence to bind to (as opposed to a repetitive sequence in 




Figure 4.12: Interphase nuclei showing hybridisation of 17CEN probes with 
varying percentages (30-70 %) of formamide in buffer. Probe signal appeared 
to reduce as formamide increased, due to less probe binding to the ROI. 
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Quantitative data showed the same as qualitative, as can be seen in Figure 4.13; optimum 
formamide percentage appeared to be ~40-50 % as this resulted in the highest SNR. SNR 
medians and means for 40 and 50 % formamide samples are significantly higher than 60 % 
formamide and above, and the range within the interquartile regions are also higher. 30 % 
formamide appears to not be stringent enough, resulting in lower signal to noise as there will 
be non-specifically probes bound that contribute to the background. Going forward, 40 % 
seems to be the best option for this probe design as it has the least variability across all 
images (as indicated by a reasonably small box and whiskers), and has the highest mean and 
median SNR. 
 
Figure 4.13: Graph showing SNR of 17CEN probe with different percentages of 
formamide within the hybridisation buffer. Between 40 and 50 % formamide seemed to 
have a positive effect on SNR. 
 
From looking at the Tms of the probe:target for different formamide conditions in Table 4.1, 
this supports the results in Figure 4.12 and Figure 4.13. The probes were hybridised to the 
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patient sample at 37 °C. Increasing the formamide percentage to a point where probe:target is 
reduced to near the hybridisation temperature means that there is a chance that some of the 
probes simply will not anneal to the target, and remain as a single-stranded probe. This means 
that while some probes are annealed and present, the hybridisation is not 100 % efficient. 
When using 30 % formamide, the condition was not stringent enough, resulting in a higher 
background which Icy detected (meaning a lower SNR).  
 
Another factor influencing stringency of the reaction is the post-hybridisation wash. This 
wash removes any non-specifically bound probes from the slide, as well as any free-dye in 
the solution. The more stringent the wash (i.e. the higher the temperature or lower the salt 
concentration), the less background will be present in the sample due to removal of weakly 
bound probes to non-target regions. High salt in the buffer destabilises charge repulsion 
between the negatively-charged phosphate backbone of the double-stranded DNA, therefore 
making the complex more stable160,164. This means that in using lower salt concentration in 
the high stringency wash, this reduces the weakly bound probes that are bound non-
specifically, reducing background. Heat is also important as when applied to double-stranded 
DNA, it disrupts the hydrogen bonds between base pairs, again destabilising the complex, 
and reducing the amount of non-specifically bound probe160. Typically, at WMRGL, slides 
are washed for 2 minutes at 72 ⁰C in a high-stringency wash buffer (0.4x SSC, 0.3 % 
IPEGAL), followed by 30 seconds at room temperature in a low-stringency wash buffer (2x 
SSC, 0.1% IPEGAL). The combination of low ionic concentration and high temperature of 
the high-stringency buffer destabilises the bond between the probe and any mismatched 




As oligoprobes are designed to bind specifically to their ROI44, this makes them more 
accurate than BAC-derived probes, which bind around the whole region without having 100 
% sequence homology. If an oligoprobe was non-specifically bound to a region without 100 
% sequence homology, then the Tm of the bound double-stranded region would be low due to 
the short size of the oligo, meaning that the wash (or the formamide in the hybridisation 
buffer) would denature the short piece of double-stranded DNA and dissociate the probe. 
This means that oligoprobes may need a less stringent wash than larger BAC-derived probes. 
A 72 ⁰C wash (as carried out in the standard WMRGL protocol) is higher than the Tm of the 






Five wash conditions were considered as shown in Table 4.2. These explored various wash 
times, as well as a heated wash, to find the optimum condition for bright signals with low 
background. 
 
The samples used for this experiment consistently had higher levels of background than 
usual. This was possibly due to poor quality sample from harvesting, or that the sample had 
deteriorated. In particular, the background on the lower stringency washes was high, leaving 
artefacts and high levels of non-specifically bound probes within the nucleus. Using Icy to 
analyse these samples proved difficult due to the high level of background, and so manual, 
qualitative analysis was performed. Images from each condition were observed and visually 
analysed to detect signals. The images, found in Figure 4.14, were selected to be 
representative of the interphase nuclei acquired for each condition.  
Sample High stringency 
(0.4x SSC, 0.3% IPEGAL) 
Low stringency 
(2x SSC, 0.1% IPEGAL) 
1 1 minute RT  1 minute RT 
2 2 minutes 72 ⁰C 30 seconds RT 
3 2 minutes RT 30 seconds RT 
4 5 minutes RT 5 minutes RT 
5 10 minutes RT 10 minutes RT 
Table 4.2: Table showing different wash conditions tested with 17CEN probes, to see if 





Figure 4.14: Interphase nuclei cells showing the effects of increased 
stringency in wash buffer conditions. Each condition shows the image in 
the 405 (DAPI), 561 (TAMRA) and merged 405/561 channel. Increased 





















As can be seen from the different samples, having a 2-minute high-stringency wash or less 
did not efficiently remove much background from the slides, as indicated by the high amount 
of non-specifically bound probe in the nuclei of samples 1-3, Figure 4.14. While it is 
possible to detect signals for these repetitive centromeric probes under these conditions, if 
attempting recognition of single genes, where there is potentially a lot less probes binding to 
the ROI, the background may be too high if the signals are not bright enough. If probe is 
bound non-specifically, it may take more time in the high-stringency wash buffer (where the 
salt concentration is lower to destabilise the double-stranded DNA complex) for the strands 
to denature. With high levels of background, this reduces the confidence a clinician can have 
when making a diagnosis, and so to increase the reliability, a longer, higher-stringency wash 
should be used. Performing a 5-minute (or 10-minute) high- and low-stringency wash, sample 
4 (and 5) in Figure 4.14, appeared to reduce background in this sample significantly, and 
should be considered in future. While this is slightly longer than the wash times used in the 
clinic, the reduction in hybridisation time means the whole process is still considerably 
quicker using oligoprobes, and would still significantly reduce time to result.  
 
As all hybridisations so far were successful at only 15 minutes, various times were tested to 
see if this allowed more probes to bind to the ROI and therefore, a stronger signal. Although 
enough probes have bound to 17CEN to be detectable after 15 minutes in previous 
experiments, it may be that not all of the sites had actually been labelled within the ROI – as 
there are potentially thousands of repeats within the centromere – and so there is potential for 




Five different time-points were used for hybridisation: 2 minutes, 15 minutes, 1 hour, 5 
hours, overnight (16 hours). As can be seen in Figure 4.15, SNR appears to increase 
significantly up to an hour of hybridisation and then remain constant. The mean and median 
marks of the box plots for 1 hour and above are significantly higher than the 2-, and 5-minute 
hybridisations, as well as the upper-quartile range. This suggests that it takes an hour for all 
probes within the set to anneal to their target. Interestingly, the probes are visible after 
hybridisation times as short as 2 minutes, which shows that enough probes do rapidly bind to 
the target in this time to be detected. This suggests that a 15-minute hybridisation (or even a 
2-minute hybridisation) may be sufficient if rapid enumeration is needed – which may be the 
case if a patient needs urgent treatment – and this could prove to be revolutionary for FISH 
diagnostics. For non-repetitive probes, however, a longer (1-hour hybridisation) should be 
considered, as this could improve SNR by ensuring that there is enough time for each 
individual probe to find its unique target and be detectable. 
 
Figure 4.15: Graph showing SNR of 17CEN probes after various hybridisation times. 
SNR increases significantly if probes are hybridised for an hour or longer, possibly 
due to more oligos having time to bind to the ROI. 
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  MTase-labelled oligoprobes as a diagnostic tool for ALL 
Once 17CEN labelling with TAMRA DBCO was optimised, attempts moved to finding other 
fluorophores that could be used for MTase labelling of different oligoprobes; by creating a 
toolbox of optimised conditions for different coloured dyes, this could allow multiple 
oligoFISH probes to be hybridised simultaneously. This would mean that in a single test, 
multiple abnormalities could be detected at once, which would be useful in cases where the 
karyotype shows various mutations (such as in ALL as discussed). Dyes were chosen that 
were compatible with the microscope filter and lasers available, and had to be distinguishable 
from other dyes used, i.e. their excitation/emission spectrums did not significantly  
overlap. 
 
A dye was needed from the far-red end of the spectrum, and so Alexa 647 DBCO (Abs 
648 nm/Em 671 nm) was originally selected. The probe was labelled and hybridised to a 46 
XX/XY sample as described in 2.2.4 and 2.2.7, the conditions being the same as with 
successful detection of 17CEN-TAMRA. When visualising the sample, however, background 
fluorescence was high, making it impossible to reliably detect a distinguishable ROI. This 
could be due to the negative charge of the Alexa 647 DBCO dye, see Figure 4.19, preventing 
full hybridisation to the negatively charged DNA, which results in excess free probe, or non-
Figure 4.16: Alexa 647 DBCO structure. The fluorophore carries a 
negative charge which may prevent hybridisation to negatively-
charged DNA, making it unsuitable for use with oligoprobes. 
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specifically bound probe. An optimised, higher stringency wash step could be tested to see if 
this removes excess dye, but this is not ideal if wanting to use in conjunction with TAMRA-
labelled probes. Fluorophores will only be considered suitable if they can be detected using 
similar conditions to the TAMRA-labelled probes, so that they can be used simultaneously in 
a test. 
 
Atto 647N NHS-ester (Abs 647 nm/Em 661 nm) had previously been successfully used for 
MTase labelling technology with amine cofactor AdoHcy-6-NH2
96, so this dye was then 
considered. Atto 647N is a cationic dye, carrying a positive charge, and its features also show 
that it has excellent fluorescence quantum yield and high photostability, making it a good 
candidate to test. As AdoHcy-6-N3 had been working well for labelling of oligoprobes, this 
was still used, with the addition of a DBCO-amine linker added into the reaction with the 
NHS-ester, as described in 2.2.5. 
 
Using Atto 647N-labelled probes was not as straightforward as using TAMRA and, while 
probes could be detected, it appeared to also show free dye binding to DNA non-specifically, 
which has been a problem reported in previous literature156. Even after a high stringency 
wash (10 mins 0.4x SSC/0.3 % IPEGAL followed by 10 mins 2x SSC/0.1 % IPEGAL), 
background signal in images was high (Figure 4.20A), possibly due to excess free dye in the 
probe mixture itself. A more intense purification (i.e. one with extra wash steps in the 
protocol) was tested in an attempt to remove the excess dye from the probe mix. Originally, 
mini Quick Spin Oligo (Sigma-Aldrich) sephadex columns were used for purification, 
designed for removing unincorporated nucleotides from a labelled oligo sample. These allow 
larger molecules to pass through while retaining those that are smaller (such as unlabelled 
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DNA or free dye). While this is a simple and quick protocol to follow – with only a two-step 
spin procedure – this does not include a wash step, and relies on the sorting of molecules by 
size to purify the sample. In contrast, Qiagen’s QIAquick Nucleotide Removal Kit, contains a 
silica membrane which binds the oligos before a subsequent wash step using an ethanol-
based buffer. This additional wash step removes excess salts and dyes. Using the QIAquick 
columns for purification of oligoprobes before hybridisation resulted in significant 
improvement in visible signal to noise ratio of samples, and probes were more easily –and 
reliably – detectable (Figure 4.20B). Using the QIAquick columns, this shows that Atto 
647N may be a suitable fluorophore to use with TAMRA to form a multicolour probe mix for 
detection of multiple mutations in a single test. 
 
In order to produce a mixed probe containing three colours, a “green” dye (with an emission 
wavelength between 500–565 nm) also needed to be tested. Labelling was performed with 
Rhodamine Green DBCO dye (Abs 501 nm/Em 526 nm) using the standard labelling 
A 
Figure 4.17: Human 46 XX/XY interphase nuclei hybridised with 17CEN and 
Atto 647N and purified using A) Quick Spin Oligo columns B) QIAquick 
columns containing and extra wash step in the protocol. Using the QIAquick 
columns showed improved reduction in background fluorescence, resulting in 





protocol in Chapter 3 (including the use of the sephadex columns for oligo purification). 
Hybridisation was performed using the same optimised conditions as shown in Chapter 2. 
The dye was coupled to the probe and excited with a 488 nm laser. As can be seen in Figure 
4.21, the probe successfully bound to 17CEN and was easily detectable with the standard 
oligoprobe conditions (as used with TAMRA in the previous chapter). This result suggests 
that Rhodamine Green DBCO would be a suitable choice for dye to be used in conjunction 
with TAMRA to provide a mixed multicolour probe. The next step is to test if all three 
fluorophores that have been successfully used for labelling (TAMRA, Rhodamine Green and 
Atto 647N) can be efficiently distinguished in a single test. 
 
 
As mentioned in previously, ALL is a complex disease characterised by a number of 
chromosomal abnormalities, one of which being loss of chromosome 1, 7 or 17. At WMRGL, 
they perform several rounds of FISH for a patient with suspected ALL, with one of the 
rounds being a simultaneous test for loss of chromosome 1, 7 and 17 using probes designed 
Figure 4.18: Human 46 XX/XY A) metaphase and B) interphase nuclei. 
Both images show 17CEN oligoprobes labelled with rhodamine green 
DBCO dye successfully hybridising to the target of interest (17CEN) under 




for the centromeres of these chromosomes. With the oligoprobes hybridising efficiently in 
just 15 minutes, a screen for hypodiploidy of these three chromosomes could be performed in 
a significantly shorter space of time (currently 16 hours in the clinic). This also means that if 
the test came back negative (i.e. the patient does not have that mutation), another round of 
FISH could be quickly carried out within the same day to identify the correct mutation. 
Currently, a negative result would result in another overnight hybridisation being set up and 
could take days to determine the actual mutation that is present. Faster hybridisation times 
could result in rapid cancer diagnosis for a patient, which means that they could be quickly 





The centromere for 7CEN was the next loci to be investigated for MTase-labelling. The 
sequence for 7CEN was taken from a paper looking at rapid chromosome enumeration165, and 
checked on USCG genome browser to ensure that it mapped to the correct region. The BLAT 
function on the website was used for this, which displays sequences (of 25 bases or more)  
within the human genome that match with 95 % or greater similarity; in this way it is possible 
to check whether the sequence being used maps to the correct chromosome, and is unique in 
doing so, i.e. it will not hybridise elsewhere. Probes were ordered from IDT (the sequence 
can be found in Table 2.7), annealed as in Chapter 2, and labelled with TAMRA DBCO. A 
15-minute hybridisation was performed with the 7CEN TAMRA-labelled probes and the 
sample analysed by excitation at 561 nm. As can be seen in Figure 4.22A, 7CEN was 
efficiently detected. Samples hybridised with both 7CEN (TAMRA) and 17CEN (Rhodamine 
Green) were then also tested, with Figure 4.22B showing that the oligoprobes were 
successful in highlighting these regions of interest simultaneously.  
 
Figure 4.19: A) Human metaphase nuclei showing 7CEN (TAMRA) successfully 
hybridising to target. B) Human interphase nuclei showing 7CEN (TAMRA) and 
17 CEN (Rhodamine Green) simultaneously highlighting the ROIs using 




Due to the complexity of the alpha satellite region of chromosome 1 – this chromosome 
shares much of its tandemly repeated DNA with many other chromosomes147,166,167, care had 
to be taken to ensure a unique region was targeted. There is still large gap in sequencing data 
for assembled centromere regions of the human genome due to the limitations of current 
sequencing techniques. This is because the tandem repeats of each chromosome are so 
similar, making these regions difficult to distinguish; this is something that the emergence of 
technologies such as nanopore sequencing are helping to tackle, and scientists are optimistic 
that the gaps will be filled in the near future. 1CEN is incredibly repetitive, and initial 
attempts to find a unique region (taken from current literature168 and labelled, hybridised and 
washed as described in Chapter 2) failed, as demonstrated by the cross hybridisation present 
in Figure 4.23. This shows that, while the probe appears to have hybridised to the centromere 
of chromosome 1, it was not specific enough to that region, and has also hybridised to 
numerous other centromeres that contain the same tandem repeat. This sequence is therefore 
unsuitable for detection of 1CEN. 
 
Figure 4.20: A) Interphase and B) metaphase nuclei showing cross 
hybridisation of 1CEN probe labelled with TAMRA DBCO. The 
sequence chosen for 1CEN oligoprobe was not unique to this loci, and 




After searching the literature, a different region of 1CEN115 was targeted and the sequence 
ordered from IDT. Probes were labelled as follows: 1CEN (Atto647N), 7CEN (TAMRA), 
17CEN (Rhodamine Green) using the protocol in Chapter 2, and tested with a 15-minute 
hybridisation. This sequence appeared to be unique to 1CEN and, as can be seen in Figure 
4.24, the MTase-labelled probes successfully bound to their appropriate targets.  
 
Probes did not appear in every nucleus, however, and it may be that further optimisation of 
the conditions or sequences is needed in order to see a more homogenous result. This may 
prove difficult as the different oligoprobes could require slightly different hybridisation or 


















Figure 4.21: A) Metaphase nuclei showing 1CEN (TAMRA) 
hybridised with 17 CEN (Rhodamine Green). B) Zoomed in 
interphase nuclei showing 1CEN (TAMRA), 7CEN (Atto 
647N) and 17CEN (Rhodamine Green) all hybridised 
simultaneously in 15 minutes. 
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balance will need to be found in order to optimise conditions for each sequence so that can all 
be detected reliably. It would be useful to test the three probes with different wash and 
hybridisation conditions to determine which is the best compromise in order to see each one 
clearly, and with certainty, to avoid false negatives or positives.  
 
This oligoFISH protocol has shown a significant reduction in the time taken to prepare the 
samples and get results (shown in Figure 4.25A), which could potentially have huge 
implications in terms of turnaround times for diagnostics. This is of particular interest for 
diseases such as certain cancers, where quicker administration of treatment could directly 
improve prognosis for a patient. Slide preparation beforehand from patient samples was 
identical to the SOP currently used at WMRGL and so would require no changes to current 
protocol. Denaturation of the DNA was performed manually by incubation at 72 °C for two 
minutes in buffer (2M NaOH/100 % EtOH) before being passed through a dehydration series 
(2 minutes 100 %, 85 % and 75 % MeOH); this mimics the protocol that popular commercial 
FISH probe manufacturer Cytocell uses. As stated previously, current probes are then 
hybridised to the slide for typically 16 hours (or overnight). These MTase-labelled 
oligoprobes have shown a significant decrease in the time taken to hybridise – with results for 
enumeration in as little as 2 minutes – due to their much smaller size than traditional FISH 
probes; this could have a huge impact on turnaround times, prompt treatment and, ultimately, 
a more positive prognosis for the patient. As discussed in the previous chapter, it does seem 
that increasing the time of the wash (5 minutes at 0.4x SSC/0.3 % IPEGAL and then 5 
minutes at 2x SSC/0.1 % IPEGAL) may be useful to remove excess background and gain a 
clearer signal, but this is a minor time loss compared to the saving of hybridisation times (see 






While using oligoprobes does have distinct advantages in hybridisation time and specificity, 
it is important to note that they appear to much more sensitive to both sequence design and 





































Figure 4.22: Graphs showing A) Total time taken for each step in 
minutes of oligoFISH and FISH protocols B) Comparison of typical 
time taken for each step of both oligoFISH and FISH for centromeric 
probes. Hybridisation is significantly quicker in oligoFISH making 





probe when designing them, for instance the length, GC content (which determines the 
melting temperature) and specificity to the ROI. Going forward, as more sequencing 
information becomes available through advancements in technology such as nanopore 
sequencing, it may become easier to design these short oligoprobes bioinformatically and 
target the exact region required. This may provide valuable information to produce probes 
that have more favourable characteristics, making them less sensitive to the wash conditions. 
 
Despite further optimisation being needed, this method still shows huge potential for the use 
of oligoprobes in FISH to detect multiple genetic abnormalities – such as those associated 
with ALL – in a single, rapid test. 
 
 Detection of small base differences 
Another valuable attribute of oligoprobes, is their apparent ability to distinguish between 
highly homologous sequences44,148. This is due to their short size in comparison to the more 
commonly used BAC derived probes. This specificity means that despite FISH typically 
being a cytogenetic technique, oligoprobes could be used to detect differences in sequences 




As discussed in the introduction of this chapter, the ability to achieve single base resolution 
combined with long range sequence information is vital for detection of SNPs in cases such 
as SMA. Current sequencing efforts are capable of detecting mutations down to the single 
base but lose sequence context in the process, resulting in loss of information as to where the 
SNP is on the specific chromosome – i.e. are they a 1:1 or 2:0 carrier of the SMA gene, 
Figure 4.16. Current FISH and other cytogenetic techniques can also not be used, as SMN1 
bears a huge resemblance to SMN2, only differing in five positions, and current probes are 
not sensitive enough to detect this subtle difference in sequence. 
The region targeted by the 17CEN probes in this chapter contained two highly homologous 
sequences, hence two slightly different sequences (17CEN1 and 17CEN2) were used 
simultaneously. These sequences differ only at 4 base positions. To investigate the potential 
for SNP detection with the oligoprobes, experiments were carried out as a proof of concept to 
see if the probes could distinguish the differences between patients that had copies of 
17CEN1, 17CEN2 or a combination of both. The various combinations of 17CEN1/2 that a 
patient can have within their chromosome pairs are shown in, Figure 4.17. 
A B 
Figure 4.23: Schematic showing A) A 1:1 carrier of the 
SMN1 gene, with reduced risk of a child with SMA B) A 
2:0 carrier of SMN1, with an increased risk of a child 
with SMA. 2:0 carriers are impossible to detect using 




Figure 4.24: Schematic showing the variant combinations of 17CEN a 
patient could have across chromosome pairs, with red symbolising 
17CEN1 and green 17CEN2. A) 17CEN1 only B) 17CEN1 and 17CEN2 C) 




A mixture of 17CEN1 labelled with TAMRA and17CEN2 labelled with Rhodamine Green 
were hybridised to patient samples using the standard oligoprobe protocol. Results seemed to 
be inconsistent; while there were some patients whose nuclei did appear to show both probes, 
the quality of the samples was poor and so it was difficult to be confident in the result. Some 
of the results did seem to show a difference between patients who had both 17CEN1 and 
17CEN2 in in equal quantities, such as in Figure 4.18, which appears to show a patient with 
1 copy of 17CEN1 (one red signal) and one centromere containing both 17CEN1 and 2 (a 
mixture of red and green signal, circled). 
 
This result shows promise for the technique in detecting SNPs if conditions and probe design 
are optimise, particularly to remove excess background to get clearer and brighter signal. If 
wanting to use oligoprobes to detect SNPs, it is crucial that the differences between SMN1 
and SMN2 can be distinguished, therefore the signal must be bright enough to detect (as there 
will be significantly less probes bound to the individual ROI as opposed to repetitive 
Figure 4.25: Interphase nuclei hybridised with 17CEN1 TAMRA and 
17CEN2 rhodamine green. Results seems to indicate that the patient 
has one copy of 17CEN1 and one of 17CEN1/17CEN2, as shown by the 
mixed red/green signal, circled. 
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centromeric probes). Probe design and hybridisation conditions will need further optimisation 





 Conclusions and future work 
 
 
In this chapter, oligoprobes have successfully highlighted the centromere of chromosome 1, 7 
and 17. The MTase labelling technology tested in Chapter 2 has been used to label these short 
hairpin sequences using M.TaqI, AdoHcy-6-N3 and three different dyes. The main outcomes 
of this chapter, and the optimised conditions that should be considered going forward, are 
summarised in Figure 4.26. 
 
The main accomplishment of these oligoprobes is that they can rapidly hybridise in as little as 
two minutes. For many cancers and genetic diseases, prompt diagnosis is directly correlated 
to an improved prognosis, and so this quick turnaround of results could have huge 
implications on patient health. It also means that in complex cases where multiple rounds of 
testing need to be performed to reach a conclusive diagnosis, numerous tests can be 
performed in a single day – rather than having to wait for an overnight hybridisation – again 
speeding up the time to results and supporting timely administration of treatment. The results 
of this chapter do show that it is likely to take approximately an hour for the complete set of 
oligos to bind to the target, but in urgent cases, probes can still be detected down to as little as 
two-minute hybridisation. As centromeric probes have potentially thousands of repeats, they 
still appear to be detectable with this short hybridisation time, a longer hybridisation time 
Probe design

















at high and low 
stringency at RT
Figure 4.26: Optimised conditions for 17CEN oligoprobes to achieve the best SNR 
for each parameter tested either quantitatively, qualitatively or both. 
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should be considered when testing non-repetitive probes to ensure that there is enough probes 
bound to the ROI to be detectable. 
 
Formamide percentage also showed to have an effect on SNR, with 40 to 50 % formamide 
being the optimum amount to use. The addition of formamide destabilises double stranded 
DNA by lowering the melting temperature. This result highlights the importance and 
sensitivity of hybridisation and SNR, and suggests that these conditions should be optimised 
for each new oligo ROI to ensure that the formamide concentration does not affect the probe 
binding during the hybridisation step. 
  
This chapter also discovered that washing slides for at least five minutes at both low and high 
stringency (at room temperature) significantly reduced background, washing away any probe 
that had bound non-specifically to the nuclei. This significantly increased the brightness of 
the probes and should be considered in future to achieve the highest SNR. Despite this 
washing step being slightly longer than the traditional method used by WMRGL, the 
significant decrease in time for hybridisation means that a result is still produced in a fraction 
of the time. 
 
The concentration of probe used did not seem to make a difference to the SNR. As little 
probe as possible should be used going forward to reduce cost and background from non-
specifically bound probe. The number of labelling sites incorporated into the design also 
appeared to make a limited difference to SNR, however this could be because not enough 
sites were added to make an impact. Adding additional sites to the probe design would 
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significantly increase the cost of the probes, however, and also increase hybridisation times, 
so is not considered necessary at this point. 
 
The oligoprobes were reasonably successful in highlighting variant sequences for probes that 
differed at only 4 base positions, but this will need to be optimised in order to confirm this. 
Perhaps it would be wise to test a sequence that not as repetitive as centromeric loci, but 
contains more copies than a single-copy loci, as the next step. Probe design could also be 
optimised in an attempt to boost the signal of each probe, increasing the sensitivity. 
 
In the future, it may be useful to see if these small oligoprobes have other applications in 
different tissues types, e.g. paraffins. As they are much smaller than traditionally used probes, 
it may be that they are more permeable into tissue sample and may bind more efficiently. The 
potential for oligoprobes to detect highly homologous sequences could also be used to study 
inheritance and evolution over time, by comparing homologs from parents across generations 
















MTase-labelled oligoprobes have been used in Chapter 4 for chromosome enumeration 
associated with acute lymphoblastic leukaemia (ALL), targeting repetitive centromeric 
regions of chromosomes 1, 7 and 17. This chapter uses this optimised technology to detect 
single genes that are linked to specific cancers, including chronic myeloid leukaemia (CML).  
 
 Genetic abnormalities and cancer 
As discussed in the previous chapter, aneuploidy (the presence of an abnormal number of 
chromosomes within a cell) can be indicative of various cancers including ALL131. There are 
a number of other clinically significant mutations, many of which can be diagnosed and 
monitored using FISH. 
 
Cells are constantly exposed to a variety of stresses from the environment that lead to DNA 
damage, which results in mutations that induce genomic instability and can lead to the 




p53 is a tumour suppressor protein that is inactivated in around half of all human cancers, 
making it the most common genetic mutations in human cancer170. This protein is often 
referred to as the “guardian of the genome” as it is involved in cell cycle arrest, sending 
damaged DNA to be repaired before replication. If the DNA cannot be repaired, p53 induces 
apoptosis of the cell, eliminating the risk of mutation, and therefore cancer, from the cell line. 
p53 mutations are therefore a key target for FISH probes as mutation within this gene can 
lead to uncontrollable growth of cancerous cells, and is implicated in many different 
cancers9,171. 
 
Figure 5.1: The DNA repair process involves several proteins. When the repair 
process fails, damage accumulates in the cell and it is either directed to apoptosis, or 
senescence (where the cell no longer divides but remains within the cell). 





Chronic myeloid leukaemia (CML), a cancer of the blood and bone marrow, was the first 
cancer to be associated with a clear genetic abnormality172. The translocation of chromosome 
9 and 22 is present in 95 % of cases of CML. As a result, part of the BCR gene (chromosome 
22) fuses with the ABL gene (chromosome 9), producing the BCR/ABL gene-fusion known 
as the Philadelphia chromosome, Figure 5.2. This makes it an important region to study for 
both efficient diagnostics and new approaches for cancer therapy, and it is usually the first 
mutation tested when a patient has suspected CML. 
 
As discussed in the introduction of this thesis, there are many different probe types depending 
on the mutation that is being investigated. Chapter 4 explored the use of repetitive 
centromeric probes, which are used for whole chromosome enumeration, a mutation that 
occurs in many cancers such as ALL, as well as in genetic disorders such as Down’s 
syndrome. If wanting to look for amplification or loss of a specific gene – such as loss of p53 
– which again is common in many different cancers, gene-specific probes covering the whole 
Figure 5.2: Schematic showing the BCR/ABL gene-fusion 
that creates the Philadelphia chromosome, commonly 
associated with CML. 
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ROI can be used. Another common probe that is used is for translocations, which are 
important biomarkers for different cancers. As stated above, a translocation commonly occurs 
in cases of CML where part of chromosome 9 fuses with part of chromosome 22. This 
mutation is investigated using a break-apart probe for the genes BCR and ABL, on 
chromosomes 22 and 9 respectively. Break-apart probes are designed to flank either side of 
the point where the genes will split during the translocation, Figure 5.3. In this way, either 
side of the ROI can be detected and monitored, and the translocation detected. If using a 
break-apart probe for a single gene, probes can be designed with different colours either side 
of the break point so that the colours will split if a translocation is present, or if part of the 
gene is missing. 
 
Figure 5.3: Break-apart probes are designed to flank the ROI so that 






As stated above, the BCR/ABL gene fusions occurs in ~ 95 % of all cases of CML, but it is 
also significantly prevalent in cases of ALL173, and in rare occasions in acute myeloid 
leukaemia (AML)174. In both AML and ALL, this translocation is associated with an 
extremely poor prognosis, often not responding well to chemotherapy alone, and therefore 
requiring an urgent bone marrow transplant. FISH is essential in highlighting these 
translocations rapidly, and with oligoprobes making this process even quicker, this could be 
revolutionary for treatment of cancer patients.  
 
 Branched probes for signal amplification 
If oligoprobes are to be used for SNP detection, only a small portion of DNA will be binding 
to the ROI, unlike potentially thousands that bind for centromeric regions. This means that 
the probes will need to have exceptionally high SNR, and the probe design will need to 
amplify the fluorophore signal so that it is bright enough to detect with certainty. Many 
different methods for probe amplification have been explored in the literature in order to 
achieve high SNR in these challenging situations, often involving the multiplexing of 
numerous DNA (or RNA) oligos.  
 
Multiplexing imaging strands is a popular method, as it allows a single binding site with 
multiple fluorophores attached. One such method, coined clampFISH (click-activated 
FISH)175, has a primary probe that binds to the sequence of interest (Figure 5.4A), before 
secondary and tertiary probes bind to the first. This pattern of multiplexing continues, with 
the signal of the probe effectively doubling with each round of amplification, Figure 5.4B175. 
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This method claims to achieve both high specificity and up to 400x signal amplification, 
which could potentially be used to determine SNPs.  
 
 
Other methods include the targeted programmed growth of detectable concatemers in situ 
using enzymatic rolling circle amplification (RCA)176 or hybridisation chain reaction 
(HCR)177,178. Both of these techniques result in the generation of multiple copies of DNA 
strands that can amplify a signal when bound to the ROI. 
 
This assembly of dendritic "branched" DNA structures to create large DNA scaffolds that 
fluorescent probes can bind to has proven successful in amplifying signal for many lab 
groups179,180. Beliveau et al. have published several papers exploring this in a technique they 
have coined Oligopaint45,181,182. Oligopaint amplifies libraries of single-stranded fluorophore-
conjugated oligos that can be used to visualise regions ranging from tens of kilobases to 
megabases45, as well as small mutations and SNPs. Each oligo is designed to be 
complementary to a short stretch of the target genome, as well as a region that binds to a 
secondary oligo that further enhances fluorescent signals, Figure 5.5. 
 
Figure 5.4: clampFISH uses a primary probe that binds to a ROI, which then 





This technique was further developed by Beliveau et al. into SABER (signal amplification by 
exchange reaction) multiplexed imaging, Figure 5.6183. This involves using the same oligo-
based FISH probes with long, single-stranded DNA concatemers that acts as a scaffold to 
bind short complementary fluorescent imaging strands. The authors show that SABER can 
amplify RNA and DNA FISH signals 5- to 450-fold in fixed cells and tissues.  
Figure 5.5: Oligopaint amplifies libraries of single-stranded fluorescently-labelled oligos 
that bind to a ROI in a unique way to amplify probe signal. This technique has been 
used to visualise regions from tens of kilobases to megabases, as well as SNPs. Taken 
from Beliveau et al. (2012). 
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This technique claims to provide an inexpensive way to amplify the signal of both RNA and 
DNA FISH probes in fixed cells and tissues, and could again be used to amplify signals to 
visualise SNPs. 
 
Despite these studies showing the promise of multiplexed FISH probes, the strategies are still 
fairly complicated to implement. Designing oligoprobes remains troublesome for some areas 
of the human genome, and a knowledge of bioinformatics is necessary to ensure that unique 
regions are chosen. Optimisation of the individual techniques for each ROI would also be 
imperative, as well as testing different sample types and regions of the genome. Probe 
amplification will be explored in this thesis, but alternative methods for SNP detection will 
also be investigated. 
 
  
Figure 5.6: SABER amplifies FISH imaging even further using a multiplex probe 
approach, where multiple fluorescently-labelled oligos bind to a single oligo. Taken 




As the genes p53 and BCR/ABL are commonly involved in mutations resulting in cancer 
development, these will be areas of focus for oligoprobe production. If the same 15-minute 
hybridisation is achievable as in Chapter 4 with the centromeric probes, this could provide a 
very powerful tool for rapid diagnosis of these diseases, and therefore timely treatment for 
patients.  
 
A new probe design will be tested to investigate if multiplexing may be useful for detecting 
small mutations such as SNPs. As proof of concept this will be tested using 17CEN, as the 








 Results and discussion 
The overall aim of this chapter was to use the optimised MTase-labelling technology from 
previous chapters to develop probes for single genes.  
 
 Single gene detection using oligoprobes 
Production of MTase-labelled FISH probes for the repetitive centromeres of chromosome 1, 
7 and 17 – where only a single target was used for each – was reasonably successful. Probes 
were visible after just 15 minutes of hybridisation, although optimisation is needed to 
improve the consistency of results. The next goal was to try and test the capability of 
oligoprobes to detect non-repetitive, single genes. As discussed in the introduction of this 
chapter, gene detection is common in FISH to detect loss or amplification of a specific gene, 
as well as chromosomal translocations, all of which can be involved in various pathogenic 
pathways. Like centromeric probes, these gene probes also take 16 hours to hybridise, and so 
a rapid test – potentially provided by using oligoprobes – could have implications in 
turnaround times for patients. This is useful, as stated previously, for patients with cancers 
that need prompt treatment or for pre- or postnatal cases that need urgent diagnosis. Again, 
with a shorter hybridisation time, multiple tests could be performed consecutively in a single 
day rather than waiting for an overnight hybridisation if a result comes back negative.  
 
As BAC probes do not need 100 % fidelity to bind, i.e. they do not need to match the target 
of interest exactly, one long piece of DNA can be used to target the ROI. However, as 
oligoprobes are short and highly specific, these probes need to be designed to tile across the 
entire gene region. In order to product oligoprobes for a gene, for example, multiple 
sequences will have to designed to tile across the entire ROI. This is a challenge compared to 
designing oligoprobes for centromeres – which contained a single sequence repeated 
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hundreds to thousands of times – as numerous sequences will need to be used in order to 
achieve a bright signal, Figure 5.7. Several probes will have to be designed to each cover a 
small and specific portion of the ROI, and they all must have similar characteristics to one 
another to ensure consistent hybridisation. They must all also be unique to the ROI to ensure 
that they do not hybridise elsewhere in the genome. 
 
 
As proof of concept, the p53 gene was investigated, as this is commonly mutated in cases of 
cancer170, as discussed in the introduction of this chapter. p53 is also present on chromosome 
17, and so this could allow the use of the 17CEN probes as a control, to check that it is 
highlighting the correct chromosome.  
 
Oligoarray151 – a free software that generates gene-specific oligonucleotides based on certain 
input parameters – was used to mine the human genome for short unique sequences from the 
p53 region. 20 sequences were chosen (8.1) that had a GC content of over 50 % and were 
reasonably evenly spread across the 19,149 base pairs of the gene, in order to span the whole 
region. These were checked using BLAST to determine sequence identity, and to ensure that 
Figure 5.7: Simplified schematic showing labelled 
oligoprobes tiled across a ROI. Multiple probes are 




they would not hybridise elsewhere on the genome. Sequences were ordered from IDT in the 
same hairpin formation as the centromeric probes, labelled with TAMRA DBCO, and 
prepared for FISH as in 2.2.4. 
 
Unfortunately, despite attempting both a short (15-minute) and overnight hybridisation, the 
probes were not detectable, Figure 5.8. An overnight hybridisation was performed in case it 
took longer for these oligos to anneal as it is not repetitive DNA. As the hairpin design, 
MTase-labelling chemistry and the TAMRA DBCO dye have all been confirmed to be 
compatible with this protocol, this gives an idea to the areas that may need optimising. It 
could be that the probe sequences that were chosen were not ideal for this region; if those 
particular sequences are variable among individuals then it may be that the oligoprobes are 
too specific to use. Extra analysis would be required to ensure that the targets are not regions 
that have SNPs or other variants from person to person. As we know that oligoprobes are 
extremely sensitive to both hybridisation and wash conditions, it could be that these could be 
optimised for this design, however, as there is no signal detected at all, this suggests that it is 
more likely to be a problem with the sequence itself. It could also be that the probe density is 
not enough, i.e. more than 20 probes are needed in order to see a signal. This could be 
rectified by potentially changing the probe design to incorporate an amplified labelling stand, 





Discussions were had with WMRGL and Cytocell (Oxford Gene Technology (OGT)) on the 
potential of MTase-labelled oligoprobes in other FISH projects. Cytocell was interested in 
exploring this technology due to the fact that these oligos can be designed bioinformatically, 
and there is control over fluorophore position and number, which could enhance the probes’ 
sensitivity. There is also potential for these probes to be used for rapid diagnosis in flow 
cytometry-based applications, coined by some as flowFISH184,185. It is also favourable that 
these oligoprobes are inexpensive to produce and, even with low concentration of probe, they 
were successful in rapidly detecting ROIs (for centromeres at least). Cytocell expressed 
interest in using oligoprobes to detect BCR/ABL translocations and offered to assist in the 
design of probes for the BCR regions as proof of concept. 
 
Figure 5.8: Metaphase and interphase human nuclei after 
p53 overnight hybridisation. No probes were detected 
suggesting that they need to be redesigned. 
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As discussed in the introduction of this chapter, chronic myeloid leukaemia (CML), a cancer 
of the blood and bone marrow, was the first cancer to be associated with a clear genetic 
abnormality172. The translocation of chromosome 9 and 22 is present in 95 % of cases of 
CML. As a result, part of the BCR gene (chromosome 22) fuses with the ABL gene 
(chromosome 9), producing the BCR/ABL gene-fusion known as the Philadelphia 
Chromosome, Figure 5.2. This makes it an important region to study for both efficient 
diagnostics and new approaches for cancer therapy. 
 
Currently, FISH is the gold standard for testing for this translocation, making it an interesting 
target for the oligoprobes and, in the clinic, probes typically hybridise in 16 hours. The BCR 
gene on chromosome 22 was selected as the initial ROI as proof-of-concept for this 
technology. As the probes would no longer be detecting repetitive DNA, each oligoprobe 
would need to be designed to target a unique region of the gene.  
 
OGT kindly aided probe design for oligoprobes for the BCR gene. 89 potential ROIs were 
sent from OGT, selecting target regions approximately 350 bp apart, which targeted the BCR 
gene specifically and fit the parameters needed for the oligoprobe conditions. From the 89 
sequences, 83 met the specification of being < 60 bases in length (once M.TaqI labelling sites 
had been added), ~55 % GC content, and Tm of ~70 °C. These specifications were required in 
order to keep cost of the oligos low, as well as ensuring that they had similar properties and 
would hybridise under the same conditions. This is four times more oligoprobes than were 
ordered when attempting to target p53 and should be detectable; the sequences were picked 
using the software OGT’s use for their research and diagnostic work, and so were confident 
that they would be specific to the ROI if the hybridisation conditions can be optimised. 
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Probes were ordered in a 96 well plate from IDT and labelled with TAMRA DBCO using 
M.TaqI and AdoHcy-6-N3 as described in Chapter 2, Figure 5.9. As results from Chapter 3 
suggested that it takes an hour for all probes to anneal to the ROI, hybridisations were set up 
for the BCR probe for 15 minutes, one hour, and overnight. Initially, 40 % formamide was 
used in the hybridisation buffer for these samples, as this was seen to be the optimum 
stringency for the oligoprobes in Chapter 3.  
  
Figure 5.9: Schematic of the BCR oligoprobe workflow. Oligos were ordered in a 96-
well plate, pooled and labelled with the MTase M.TaqI, before being mixed with 
hybridisation buffer and hybridised to the patient sample. 
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The images in Figure 5.10 show that when using 40 % formamide, there is a high level of 
cross-hybridisation. A faint signal can be seen on chromosomes which look to be 
chromosome 22, however with such high background it is difficult to say with certainty. Two 
faint signals can be seen in every sample at all time-points. By increasing the stringency in 
these conditions, it may be possible to inhibit probes binding non-specifically and reduce the 
level of cross-hybridisation. It is important to note that these oligos have been designed to 
have a higher Tm than those used in the 17CEN experiments, and so a higher formamide 







Figure 5.10: Images showing A) Interphase nucleus with BCR probes showing high levels of 
background B) Metaphase nucleus containing BCR probe with slight cross-hybridisation. An 




Samples were set up using 50 %, 60 %, and 70 % formamide hybridisation buffers, and left to 
hybridise for one hour. At 50 % formamide, high levels of cross-hybridisation were still 
observed. However, when increasing the formamide concentration to 60 % and above, clear 
signals can be seen for the ROI with a significant reduction in background (Figure 5.11). 
This again highlights how sensitive these oligoprobes are to the hybridisation conditions; 
increasing the formamide concentration reduces the amount of non-specifically bound probes 
to other areas of the human genome, which in turn amplifies the SNR. A careful balance 
needs to be found where the formamide concentration, and therefore the melting temperature 
of the DNA, is enough to allow all of the oligoprobes to bind to their target, while reducing 
the amount that seem to associate to sequences elsewhere. It could also be that as there is 
only a limited amount of fluorophores that could be bound to each region – because the DNA 
is not repetitive like centromeric sequences – the probes were not bright enough to produce a 
good SNR compared to the background. Optimised probe designs could be explored to 
amplify the signal and improve SNR by incorporating more fluorophores that bind to each 
ROI. 
  
Figure 5.11: Interphase and metaphase cells showing clear signal for BCR probes using 70 % 
formamide hybridisation buffer and a one-hour hybridisation. 
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 Exploring the potential of branched oligoprobes 
 
The current probe design may need to be engineered in a way to efficiently detect SNPs by 
improving the brightness of the probe. The idea of a new probe design able to extend and 
add-on extra fluorescent blocks would mean that a signal could be detected for just one ROI. 
Oligos were synthesised using a different design built on the success of the hairpins; the idea 
being that a primary "docking strand" would hybridise to the ROI, and a secondary "imaging 
strand" to the docking strand as shown in Figure 5.12A. This would allow for a batch of 
imaging strands to be labelled, ready to be used for any new ROIs – saving valuable time – as 
well as the potential for various ROIs to be labelled with different MTases all in one reaction. 
As proof of concept, the design was based on the previously successful 17CEN sequence, and 
the probe was labelled and hybridised using an adapted protocol in Chapter 3. Results, 
Figure 5.12B, showed that this design could successfully hybridise to the target, showing 
potential for this as a way to amplify the target area for visualisation of SNPs.  
 
Further work should be done to test this design – and others – to calculate the best SNR for 




ROI binding site 
Figure 5.12: A) New probe design involving a primary ‘docking strand’ that binds to the 
ROI, and a secondary fluorescently-labelled ‘imaging strand’ that binds to the primary 
strand for detection using fluorescence microscopy B) Interphase and metaphase nuclei 




the centromeric repetitive probes – and may prove useful for future rapidly-hybridising single 
gene probes – the signal may still not be bright enough to detect SNPs. The probes did not 
appear to be significantly brighter than when using the original oligoprobes, and background 
in some samples was still present, which could cause problems such as recording false 
negative/positives when moving to SNP detection. Improved SNR from optimised 
hybridisation and washing conditions will need to be investigated before moving onto SNP 
detection for this approach. In the meantime, other options for long range sequence context 





 Conclusions and future work 
Following on from the successful production of BCR oligoprobes, the next logical step would 
be to produce oligoprobes for the ABL gene to be able to test for the BCR/ABL translocation. 
Ideally these would be tested on patients with a normal karyotype initially, to test for probe 
efficiency, followed by testing on patients with the confirmed translocation. If these probes 
were successful in highlighting the translocation, they could be suitable in the clinic for 
diagnosing CML – and in a quicker timeframe. Care will need to be taken to ensure that the 
hybridisation and wash conditions are similar for both the BCR and ABL probe so that they 
can both be tested simultaneously. 
 
Alternative probe designs could be explored, including a dendritic probe design, where 
fluorescently-labelled oligos are multiplexed to provide a bright signal. Once an optimised 
probe design has been achieved, further investigation into using oligoprobes to detect small 
variants and SNPs could be performed. In order for this to be successful, i.e. for the signal to 













The introduction of this thesis described some of the genetic tests that can be used to 
determine carriers of certain diseases, or as a diagnostic, and now, this chapter attempts to 
overcome some of the limitations of these techniques.  
 
 DNA mapping 
DNA mapping is an alternative method that can be used to detect potential SNPs in cases 
such as SMA93,186. While sequencing allows detection down the single-base resolution, the 
sample preparation fragments the genome into smaller fractions beforehand, and sequence 
context is lost. This means that, while you can detect the SNPs, it is not always easy to see 
where this lies within the whole genome, and if there are gaps and repeat regions then this 
information is inaccessible. This is where DNA mapping could prove invaluable, as it allows 
both long range sequence information to be detected, and could potentially also allow single 
molecules to be uncovered. In this way, DNA mapping could bridge the gap between 
cytogenetic and molecular DNA technologies, enabling SNP detection while visualising a 
larger region of the genome.  
 
 In 2010, Neely et al. proposed a novel idea for mapping using DNA MTases109. This 
involved direct observation of single molecules of DNA stretched via molecular combing 
(discussed in 6.1.3) and using MTase enzymes to fluorescently label the DNA sequence 
specifically. This novel technology allows analysis of the DNA sequence without 
compromising the sequence’s integrity, providing an ordered optical map. The resulting 




 DNA extension 
In order to be able to localise fluorescent tags along a DNA strand, extension and 
linearisation of the molecule is essential as, in solution, DNA is in a random coil 
conformation. This can be approached in various ways, either across a solid surface or 
linearised in solution. In 1998, as discussed in 1.2.5, Fibre FISH39 – a form of FISH that 
involves the stretching of chromosomes – was one of the earliest techniques to use the DNA 
extension approach. One of the main limitations of this technique is the ability to uniformly 
stretch the DNA and therefore accurately measure DNA length. 
 
 Molecular combing 
One means to provide extension of DNA is to stretch the molecule and deposit it along a 
solid surface. This could be by fixing DNA to a surface via positively charged amines e.g. 
using polylysine100 or (3-aminopropyl)tiethoxysilane (APTES)99 and applying extension 
force. Although, as mentioned earlier when referring to Meng et al. and Cai et al. 
respectively, this has been shown to result in non-uniform stretching (around 85 % partial 
extension) rendering accurate distance measurements a challenge. A more reproducible 
technique is DNA molecular combing. Molecular combing was first developed in 1994 by 
Bensimon et al.187 and later reviewed by Bensimon and Herrick in 2009130. This method 
involves the preparation of a hydrophobic surface, which the DNA sample is then deposited 
onto. Through hydrophobic interactions of the exposed bases at the end of the DNA with the 
surface, ends of the DNA bind to the surface, and the rest of the molecule is stretched out of 
the solution in a linear fashion, Figure 6.2.  Tethering of the DNA ends has been found to be 
most successful at around a pH of 6 as, at a lower pH, the DNA molecules will adsorb 
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strongly – and non-specifically – to the surface, and at higher pH they will adsorb too 
weakly188. Once the droplet has been placed, the air-water contact line (meniscus) provides 
stretching forces from surface tension to unravel the DNA in the droplet's direction of travel.  
 
Silane chemistry is often used to prepare the hydrophobic surface for combing189, although 
more recently many groups have gained more success using polymer spin coating with 
examples such as poly(methylmethacrylate) (PMMA)188. In 2014, Vranken et al.78 used super 
resolution microscopy and MTase-directed click chemistry, to provide an optical map for 
bacteriophage genomes. Using molecular combing onto hydrophobic slides made using alkyl-
silane, the group obtained around 70 % labelling at target sites, with approximately one site 
every 500 bp. This approach offers potential for this technique in DNA mapping, as it bridges 
the gap between typical sequencing outputs and traditional long-range mapping experiments. 
Deen et al.97 have very recently, in 2015, had great success in using the polymer Zeonex for 
coating the slides for deposition. When compared to coating with other polymers, this group 
found that Zeonex was significantly more efficient in DNA capture and uniform surface 
coverage, and achieved very promising results from only picograms of material, as shown in 
Figure 6.297. This study has demonstrated the potential for molecular combing, without the 
Hydrophobic 
surface 
Coiled DNA in 
solution 
Solution 
Linearised DNA Tethered end 
Figure 6.1: Molecular combing to produce linearised DNA. At ~ pH 6,  exposed bases 
of DNA in solution will bind strongly and specifically to a hydrophobic surface. As 
the meniscus is moved, the DNA is stretched uniformly onto the surface. 
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need for amplification of samples, and may prove highly beneficial if concentrations of DNA 
available are very low (i.e. picograms per microlitre). 
 
 Nanofluidic devices 
Using nanofluidic devices is a popular method of extended DNA molecules without 
immobilisation, allowing linearisation in the solution phase190. Stretching of DNA is driven 
by the confinement in small channels with dimensions less than DNA persistence length (~50 
nm)191, which can lead to extension of the DNA to lengths of around 60-70 % of its 
theoretical (solution phase) length. This method is of great interest as it is a high throughput 
method, allowing hundreds of DNA molecules to be passed through the channels and mapped 
in parallel, and therefore rapidly. This is a necessity, if optical mapping is to keep up to speed 
with other genetic techniques such as NGS. Restriction mapping has been shown to be 
successful whilst using nanofluidic devices by Riehn et al.190, which allows the DNA to pass 
through the channels while maintaining the order of the sequences. A drawback of this 
technique however, is that the DNA is always in motion, which negatively affects the 
resolution that can be acquired. An interesting direction for nanofluidics may be to combine 
this high throughput technique with a fluorescent labelling technique such as with MTases or 
nicking enzymes108. Alternatively, another group have also shown that mapping via 
Figure 6.2: A representation of DNA combing and the receding air-water interface 
created as the droplet is moved in the direction of travel (left). Microscope images of 
deposition of DNA on three different polymer surface, of which Zeonex had the most 
efficient deposition (right). Taken from Deen et al. (2015). 
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nanofluidics is also possible from denaturing DNA using heat and formamide192, and 
visualising the sequence-specific melting using YOYO-1. 
 
 MTases and DNA mapping 
Since the emergence of optical mapping via restriction enzymes, nicking enzymes, and more 
recently MTases, have been explored26,93,94,96. MTases show great potential as a way to label 
DNA with both a high level of specificity and at a high density. This provides potential for 
MTases in a number of diagnostic applications which will be discussed later in this thesis. 
Labelling DNA sequence-specifically using MTases and stretching single DNA molecules 
onto a surface via combing, can provide an ordered optical map. This novel technology 
allows analysis of the DNA sequence without compromising the sequence’s integrity and can 
provide a scaffold to aid genome assembly in conjunction with sequencing.  
 
By combining both high- and low-density labelling by producing enzymes that recognise 
different length recognition sequences, it will be possible to produce a dual colour map, 
which will be highly useful in diagnosing genetic disorders. Enzymes with recognition 
sequences between 4-8 bps will be produced and screened with cofactors to produce an 
MTase-labelling toolbox. 
 
Advances in DNA hybridisation techniques (e.g. FISH) and sequencing technologies (e.g. 
next generation sequencing (NGS)) have surpassed the use of restriction mapping in rapid 
DNA identification. Though they are more commonly used, both hybridisation and 
sequencing techniques have their own set of problems. NGS is currently at the forefront of 
sequencing technologies – although long-read sequencing is rapidly developing – however it 
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still faces issues with copy number variations (CNV), ensemble averaging, and reconstruction 
of the genome after amplification of sequences. As this technique focuses on small base 
differences, it loses any larger structural information. On the-other-hand, cytogenetic 
techniques such as FISH, focus on much larger regions of interest (ROI). FISH is currently 
the gold standard in detecting large rearrangements, amplifications, or deletions of genetic 
material but it is not possible to detect changes at the single-base level. Optical mapping 
attempts to overcome some of these challenges.  
 
 MTases and SNP detection 
Some MTases display highly specific recognition of their target motifs. Therefore, it has been 
hypothesised that they could be used in detection of single nucleotide polymorphisms 
(SNPs). SNPs are variations of single nucleotides that occur at a specific position in a DNA 
sequence. This genetic variation can be the underlying cause for susceptibility to certain 
diseases e.g. cystic fibrosis, and also impact the severity of those illnesses23.  
 
Spinal muscular atrophy (SMA) is a recessive neurodegenerative disease characterised by the 
loss of the SMN1 gene119. A nearly identical gene, SMN2, has only one critical nucleotide 
difference. SMN2 can be present in variable numbers in patients and therefore restores some 
of the functionality lost from the SMN1 mutation, resulting in varying levels of severity of 
the disease112. It is possible to be a carrier of SMA if you only have one copy of SMN1, or if 




Currently it is not possible to determine with 100 % certainty whether someone is a silent 
carrier. Molecular techniques, such as multiplex ligation-dependent probe amplification 
(MLPA) – a variation of multiplex PCR that amplifies multiple targets using with a 
single primer pair – can detect two copies of SMN1, but cannot determine if they are in the 
2:0 formation or 1:1. Cytogenetic techniques, such as FISH, can also not be used for this 
arrangement, as they do not have the specificity to work at the single-base level.  
 
M.Hpy188I is an MTase which targets TCNGA113. This sequence is disrupted by a single 
base change difference in the sequence of SMN1, but not in SMN2. If a patient’s DNA could 
be labelled with M.Hpy188I and mapped, it could be possible to determine whether a 
patient’s SMN1 genes are in the 1:1 or 2:0 formation based on the pattern produced from the 
SMN1 SMN2 
Wild type 
2 copies of 
SMN1 
Carrier 




2 copies SMN1 
Figure 6.3: Schematic showing copy number and position of SMN1 
and SMN2 in different patients. It can be difficult to determine 
carriers of SMA due to silent carriers with two copies of SMN1 on one 
chromosome (2:0 carriers). This makes it problematic to distinguish 
this from the wild type using molecular techniques. 
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fluorophores. In this way it could be possible to detect silent carriers of SMA by locating the 






As discussed in previous chapter, M.Hpy188I, is an MTase that targets TCNGA. This 
sequence is disrupted in the sequence of SMN1, but not in SMN2. If a patient’s DNA could 
be labelled with M.Hpy188I and mapped, it could be possible to determine whether a 
patient’s SMN1 genes are in the 1:1 or 2:0 formation based on the pattern produced from the 
fluorophores. In this way it could be possible to detect silent carriers of SMA. As proof of 
concept, this chapter will explore the use of M.BseCI for DNA methylation, to observe 
whether this will block M.TaqI labelling at overlapping sites. 
 
 Results and discussion 
An alternative method to SNP detection that was also considered is DNA mapping. As 
described in 1.5.3, this technique could be used in conjunction with sequencing to provide 
valuable information on sequence context, while also detecting small rearrangements or 
differences to the reference genome; a severe limitation of current techniques. Physical maps 
display both long- and short-range sequence information. This could prove invaluable in 
cases of SMA to detect the location of SMN1 genes on potential parents to determine 
whether they have a 1:1 or 2:0 genotype, and could potentially distinguish between highly 
homologous SMN1 and SMN2. In this way, carrier detection will be improved significantly, 
and appropriate measures can be put in place if a couple is planning to have a child, and can 
be used to calculate risk of SMA development. SMN1 and SMN2 differ at one critical 
nucleotide position on exon 7. This difference in sequence disrupts the recognition sequence 
of MTase M.Hpy188I, resulting in a loss of fluorophore if attempting to map the region. This 
means that DNA mapping using this MTase could potentially identify the presence of the 




Mapping involves labelling the DNA – in the case of this thesis, with MTases – and then 
stretching single DNA molecules along a hydrophobic surface. The sample is visualised 
using fluorescence microscopy and the pattern of fluorophores analysed to determine the 
DNA’s underlying sequence.  
 
 Blocking alkylation with methlyation 
DNA combing was carried out following the protocol described by Deen et al97. Optimum 
combing, which has been investigated in great detail by other researchers26,78,93,96, resulted in 
uniformly-stretched individual DNA molecules of around 1.52 times the crystallographic 
length. As a proof-of-concept, lambda DNA was methylated with M.BseCI DNA, followed 
by labelling with Atto 647N using M.TaqI and AdoHcy-6-N3 as described in Chapter 2. As 
the M.BseCI recognition site (ATCGAT) overlaps with M.TaqI's (TCGA), we would expect 
some of the TCGA sites to be blocked, and therefore a loss of fluorophore. On lambda, 15 out 
of 121 M.TaqI sites should be blocked by M.BseCI methylation. If it is possible to detect 
single loss of a fluorophore from a reference sequence, such as with M.BseCI methylation 
and M.TaqI labelling, this provides hope that this method may be suitable for discrimination 
of SMN1 from SMN2.  
 
A protection assay was carried out on M.BseCI-methylated, M.BseCI- and M.TaqI-
methylated and unmethylated lambda to confirm whether the 15 ‘blocked’ TaqI sites could be 
detected at this level. This would be determined by a subtle change in pattern of the gel due 
to different DNA fragments being produced by restriction enzymes. Gel electrophoresis does 
not have the necessary resolution to determine exact DNA differences down to single base 
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resolution, but it may indicate whether M.BseCI methylation will block M.TaqI labelling for 
future mapping experiments.  
 
Lambda was methylated with either M.BseCI or both M.BseCI and M.TaqI, and restriction 
was attempted with R.ClaI (which has the same recognition sequence as M.BseCI 
(AT^CGAT)) and R.TaqI (T^CGA). Results will determine whether M.BseCI methylation 
will block R.TaqI restriction, and whether this can be detected in the gel.  
 
As can be seen in lane 2 of Figure 6.4, M.BseCI efficiently methylates lambda DNA, 
preventing it from restriction by its corresponding restriction enzyme R.ClaI. As the 
recognition site of M.BseCI overlaps with M.TaqI, methylation with M.BseCI should block 
15 out of the 121 M.TaqI sites present on lambda. Lanes 3 and 9 allow comparison of 
M.BseCI methylated and unmethylated DNA cut with R.TaqI. These results show the very 




The blocked pattern in lane 3 demonstrates the potential of using mapping to uncover further 
information on the slightly altered sequences, at a higher resolution. While the gel gives an 
indication that there is a difference in the sequences, it does not provide detail down the 
single base – and would therefore not be able to detect SNPs – and does also not provide long 
range information such as sequence context. This does show that mapping could be a feasible 





























Figure 6.4: Protection assay of M.BseCI methylated lambda. 
Lane 1 = 1 kb extend ladder, lane 2 = M.BseCI methylated lambda + R.ClaI 
restriction, lane 3 =M.BseCI methylated lambda + R.TaqI restriction, lanes 4 and 5 = 
M.BseCI + M.TaqI methylated lambda + and – R.TaqI restriction, lanes 6 and 7 = 
M.TaqI methylated lambda + and – R.TaqI restriction, lane 8 = unmethylated 
lambda + R.TaqI restriction, lane 9 = unmethylated lambda + R.ClaI restriction, lane 
10 = unmethylated lambda. 
 
M.BseCI has blocked restriction of some M.TaqI sites, as highlighted by the change in 
restriction pattern between lane 3 and 9. 
 
 1                   2                   3                 4                  5                  6                 7                   8                  9                 10              11           
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15 fluorophore positions). As the protection assay showed efficient blocking of M.TaqI 
alkylation by methylation with M.BseCI, the sample was used for DNA mapping.  
 
 DNA mapping with MTases 
Both unmethylated and M.BseCI-methylated lambda were labelled with Atto647N using 
M.TaqI. The sample were deposited on a Zeonex surface as described in 2.3.5 – which 
involved dragging the fluorescently-labelled DNA droplet across a hydrophobic coverslip – 
and visualised via fluorescence microscopy. The challenge was to discover whether it is 
possible to determine if the sample was unmethylated or methylated, therefore efficiently 
detecting the loss of 15 out of the 121 M.TaqI labels. The schematic in Figure 6.5 displays a 
visual representation of how M.BseCI methylation can block M.TaqI labelling at those 
overlapping sites. This difference in pattern of fluorescence (i.e. the loss of fluorophore at 
Figure 6.5: Schematic illustrating how M.BseCI methylation of lambda DNA 
can block M.TaqI fluorescent labelling at those sites due to an overlap of 
recognition sequence. This could serve as a point of concept for detecting SNPs 
in the human genome. 
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those sites) should be detected using the DNA mapping approach, showing potential for 
distinguishing highly homologous sequences. 
 
A grid of images was taken for each sample and analysed using a MATLAB script written by 
Nathaniel Wand and Darren Smith. The script extracts each linear barcode from the stacked 
image before cleaning them (e.g. removing any barcodes that are obviously the incorrect 
size/length or intensity). ‘Junk’ barcodes are removed at this point, which includes those that 
have occurred due to poor combing technique – resulting in overlapping barcode artefacts – 
and contaminated DNA during the labelling preparation. Poor combing often resulted from 
using either too high a concentration of DNA, and so the sample was too dense, or too little 
DNA, leaving the sample too sparse. Care also had to be taken to ensure that the equipment 
was flat when running so that the DNA travelled in a straight line, and that the speed was 
consistent to stop the pipette tip from ‘jolting’ out of place when depositing the DNA. For 
simple alignment, the barcodes are then each aligned to the known reference sequence (i.e. 
unmethylated lambda or M.BseCI-methylated (blocked) lambda). First, M.BseCI-blocked 
lambda was analysed and compared to both a blocked and unblocked reference genome to see 
if the blocked sites could be detected by the subtle change in intensity.  
 
Barcodes were extracted from the sample and an alignment weight calculated for each 
compared to the reference, Figure 6.6A/E. Barcodes with an alignment weight of over 0.7 
were considered to be a “good” fit, based on in silico data produced by Nathaniel Wand (and 
documented in his thesis), and from these a consensus barcode was formed, Figure 6.6B/F. 
As can be seen from Figure 6.6C/G, for both samples the middle of the genome produced the 
most contributing barcodes, this is probably due to this being the most well mapped area 
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during deposition, as the ends of the images tended to be either too sparse, or too dense. 
Figure 6.6D/H show the mean intensity of well-aligned barcodes after background 
subtraction using a rolling ball average; the mean alignment displays any discrepancies 
between the experimental consensus barcode and the reference. The experimental barcodes fit 
both references fairly well – which is to be expected as they differ at only 15 sites – but it 
seems that at around 15 kbp in particular, the intensity profile is more suited to the blocked 
reference. When compared to the unblocked reference, the first of the two peaks of the 15 














Figure 6.6: M.BseCI “blocked” lambda DNA was labelled with Atto 647N at M.TaqI sites after 
M.BseCI methylation. Barcodes were extracted and aligned to a blocked (A) and unblocked (E) 
lambda reference. Those that had an alignment weight of 0.7 or higher were combined to form a 
reference barcode (B/F). The mean intensity of well-aligned barcodes (0.7 or higher) was compared to 
the reference barcode produced to see how many barcodes fit to each region (C/G) and how well they 





To confirm whether this was a position where lambda was blocked, the M.BseCI-methylated 
sample was compared to the two references (unmethylated and blocked) on a single plot, 
Figure 6.7. The dotted grey line displays the positions of the blocked sites on the genome, 
which explains the drop in intensity at these points, most noticeably at 15 kbp as mentioned 
above. 
 
The sample was then compared to a mixed database of genomes to see if the correct sequence 
could be identified. For this, a slightly different script was used that, instead of comparing 
each individual barcode to the “known” reference, ran in a loop comparing every barcode to 
each other. While this took longer to perform, this meant that a more accurate match could be 
made, as it would not be attempting to fit them all to a “known” genome. 
Figure 6.7: "Blocked" lambda sample was labelled with Atto 647N at M.TaqI sites after 
M.BseCI methylation. The mean of experimental barcodes after extraction and 
alignment was compared to the reference barcodes for blocked and unblocked lambda. 
The experimental sample barcodes were a better fit to the blocked reference barcode, 




As can be seen in Figure 6.8A, some barcodes mapped to many other references, which is 
due to the larger genomes sharing a high level of sequence identity with lambda. As the 
threshold increases, however, it does point more to the correct reference of M.BseCI-
methylated lambda, with barcodes only mapping to lambda and blocked-lambda past a 
threshold of 8. While this has successfully identified the correct genome from a potential pool 
of others, the fact that it is not 100 per cent certain – mapping to both unblocked and blocked 
– may cause problems if wanting to be used for diagnostics or screening for clinical samples; 
further optimisation will be needed if this is going to be used as a reliable test for SMA 
carrier detection based on this result. 
  
M.BseCI-blocked sample 
Figure 6.8: Barcodes from the M.BseCI-blocked 
sample were compared against references from a range 
of other genomes. The intensity pattern mapped to 
many of the other genomes as many of them are much 
larger and contain similar sequences to lambda. 
Barcodes of threshold 0.8 and higher only mapped to 
lambda, with the most barcodes correctly mapping to 
M.BseCI-blocked lambda. This shows that while this 
technique can align to the correct genome, it may cause 




The experiment was repeated with unmethylated DNA, to see how well this matched to both 
the blocked and unblocked references. The data was analysed in the same way as the previous 
sample, with Figure 6.9 displaying the results. Again, the middle of the genome was better 
represented within the sample, shown in Figure 6.9C/G, and the barcodes mapped fairly well 
to both references. One notable difference is again in the 15 kbp region in Figure 6.9D/H; D 
shows that some of the barcodes do follow the same pattern as the blocked reference, 
possibly due to the DNA not being completely labelled, resulting in coincidental loss of 
fluorophores at this point. H does map this region much more closely to the unmethylated 
reference, following the correct pattern of a slightly higher first peak at ~15 kbp compared to 
the second, where a blocked site would be present. Improvements will need to be made to the 
mapping process (both deposition and analysis) if wanting to make more confident 












Figure 6.9: Unmethylated lambda sample labelled with Atto 647N using M.TaqI. Barcodes were 
extracted and aligned to a blocked (A) and unblocked (E) lambda reference. Those that had an 
alignment weight of 0.7 or higher were combined to form a reference barcode (B/F). The mean 
intensity of well-aligned barcodes (0.7 or higher) was compared to the reference barcode 
produced to see how many barcodes fit to each region (C/G) and how well they fit each genome 
(D/H). The unblocked lambda sample does not appear to fit the unmethylated reference 
significantly better than the blocked reference, improvements will need to be made for more 




 Figure 6.10 shows unlabelled barcodes that fit to the blocked reference with a threshold of 
over 7. The fact that there are barcodes that do seem to incorrectly fit to this reference 
highlights the problems that may be encountered if trying to use this as a technique for SNP 
detection. It may be that the labelling and deposition protocols need to be optimised to ensure 
that fluorophores are present at all unblocked TaqI sites before mapping, as inefficient 
labelling/deposition would lead to a lower intensity, and therefore give false results.  
Figure 6.10: Unmethylated lambda was labelled with Atto 647N at M.TaqI sites. 
The mean of experimental barcodes after extraction and alignment was compared 
to the reference barcodes for blocked and unblocked lambda. The experimental 
sample barcodes did not seem to fit more closely to the unblocked reference, 
possibly due to ineffective labelling of the DNA during sample preparation 




Again, when attempting to map the samples without a “known” genome, it was possible to 
correctly identify the sample; in this case as unblocked lambda, Figure 6.11. The majority of 
the barcodes did map to the correct genome, which does show potential for this technique. 
However, until the protocol has been optimised to provide certainty – i.e. only identifying the 
correct genome at a high threshold – it would not be suitable for SNP detection for carrier 
testing in the clinic.  
Figure 6.11: Barcodes from the unblocked 
sample were compared against references from 
a range of other genomes. The intensity pattern 
mapped to many of the other genomes as many 
of them are much larger and contain similar 
sequences to lambda. Barcodes of threshold 0.8 
and higher only mapped to lambda, with the 
most barcodes correctly mapping to 
unmethlyated lambda. This shows that while 
this technique can align to the correct genome, 





 Conclusions and future work 
 
As an alternative route to SNP detection to oligoprobes, the Hpy188i MTase could be 
produced in an attempt to detect the SNP in SMN1. The work in this chapter suggests that the 
current mapping protocol is not currently sensitive enough to identify these SNPs with 
enough certainty for the clinic, but it shows promise for further work in the future. Labelling 
and deposition protocols should be optimised in an attempt to improve the reliability of this 
technique. 
 
If the protein expression of mutated MTases can be optimised to ensure higher yield and 
activity with synthetic cofactors, further mapping experiments could be carried out. It would 
be interesting to explore dual colour mapping by combining labelling with different MTases 
that target both high- and low-density DNA sequences, to map regions of the human genome. 
This could support DNA sequencing by providing a visual scaffold to help determine the 
order of specific DNA motifs – a common problem with current sequence techniques.  
 
DNA mapping provides the opportunity to overcome the limitations of sequencing highly 
repetitive regions of the human genome, or those that contain gaps, but the conditions for 









7  General discussion and future work 
 
 General discussion 
This thesis has explored the use of MTase-directed labelling of DNA for various applications, 
including diagnostics. MTases offer a range of advantages over other labelling techniques 
due to their high specificity and precision, which is ideal for microscopy-based technologies 
– such as FISH – that require a reliable, efficient, and cost-effective method of labelling DNA 
to uncover the underlying mutations attributing to many diseases. 
 
The following points have been achieved in this thesis: 
1. Active M.TaqI protein has been successfully expressed, and an optimised protocol for 
this process has been developed. M.TaqI has been used in a number of labelling 
reactions and is active with both AdoMet and AdoHcy-6-N3. 
2. Engineered MTases were expressed, with one (M.BsaWI) showing partial activity 
with AdoMet. This could be useful in future mapping experiments and should be 
pursued if wanting to continue this work. 
3. Oligoprobes were successfully produced for 17CEN using a hairpin design. These 
probes were then labelled with M.TaqI and SPAAC chemistry and were able to detect 
the ROI using FISH, in as little as a two minute hybridisation.  
4. Following the success of 17CEN, probes were also produced for 1CEN and 7CEN 
and labelled with different dyes. All three colours could be detected simultaneously 
using FISH, which could significantly improve time to result for patients with ALL. 
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5. Oligoprobes were successfully produced for detection of the BCR gene. This shows 
potential for the use of these probes for single gene detection, as well as for 
translocations such as BCR/ABL. 
6. Oligoprobes designed for the highly homologous 17CEN1 and 17CEN2 were 
somewhat successful in highlighting these slightly different sequences, but design and 
conditions will need to be optimised in order to be reliable. This shows potential for 
oligoprobes to be used for SNP detection.  
7. Using M.BsaWI to methylate lambda DNA before labelling with M.TaqI showed that 
when mapping this sample, it is possible to detect the small difference in fluorophore 
pattern caused by the blocked methylation sites. This again shows promise for SNP 
detection but will need to be optimised if used in clinical applications.  
 
 Optimisation of MTases in labelling reactions 
Chapter three explored the optimal protocol for producing high yields of active M.TaqI 
protein, as well as different methods to attempt to remove residual AdoMet from the M.TaqI 
protein complex. Complete removal of AdoMet was not successful, but mass spectrometry 
results of alkylated DNA showed that using an appropriate concentration of M.TaqI for the 
number of labelling sites resulted in the majority of sites being alkylated (as opposed to 
methylated from residual AdoMet). This suggests that AdoMet may not cause as much of a 
problem to labelling as originally suggested, and that optimum concentration of M.TaqI is 
more important in order to have enough to label the DNA but without using it in excess. 
Results suggested that around 0.4 nM M.TaqI per nM of sites is a suitable amount to ensure 
full labelling without unnecessarily adding excess AdoMet into the reaction. Results from 
mass spectrometry showed that M.TaqI has a turnover of 19 in an hour of alkylation, and so 
an even lower MTase concentration than that tested in gel electrophoresis could potentially 
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be used. In order to fully remove AdoMet from the complex, extensive washing of the 
M.TaqI protein during purification could be tested. 
 
Chapter three also saw the investigation of different MTase mutations – that were introduced 
to the DNA sequence based on previous literature – and their expression, and the effect that 
these engineered sites had on alkylation with synthetic cofactor analogues. Engineering 
MTases for DNA mapping applications was mostly unsuccessful. More research into the 
structural changes to the cofactor pocket should be carried out for each protein and specific 
cofactor analogues if wanting to pursue this as an approach for dual colour mapping. 
M.BsaWI showed the most promise, offering near-full protection in the presence of AdoMet 
– but none with AdoHcy-6-N3 – but further work would need to be performed to enable this 
protein to be active with other cofactors for labelling; testing wild type M.BsaWI may be 
interesting for future work to see if there is an improvement of its activity with the cofactors. 
and this approach should not be dismissed as a powerful tool for mapping. Optimisation of 
the conditions for expression of these proteins should also be performed to achieve a high 
enough yield of active protein. Wild type M.BseCI was successfully used to methylate 
lambda DNA, and was used DNA mapping applications in Chapter 5. 
 
Optimising oligoprobe design and conditions for FISH 
 Chapter four showed the exciting potential of MTase-labelled DNA as oligoprobes in FISH, 
and demonstrated that these small hairpins could anneal to patient samples significantly 
quicker than the traditional FISH protocol. Probes designed for the centromere of 
chromosome 17 (17CEN) hybridised in as little as two minutes, which could have a huge 
impact on the turnaround times for patient results. Chapter five showed that probes for 1CEN 
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and 7CEN could also be annealed rapidly – alongside 17CEN – to test for enumeration of all 
three probes simultaneously. These probes were labelled with the dyes TAMRA, Rhodamine 
Green and Atto 647N in order to be distinguished from one another. This rapid hybridisation 
could potentially improve prognosis for patients with complex forms of cancer such as ALL, 
which rely on prompt diagnosis.  
 
Conditions should be further optimised to ensure that all oligoprobes are as efficient, and 
bright, as current BAC probes. Different parameters were explored in Chapter three in order 
to achieve the best SNR; these included probe concentration, number of M.TaqI sites in probe 
design, formamide percentage in hybridisation buffer, hybridisation time and wash 
stringency.  
 
Formamide percentage was one of the conditions that had the most effect on SNR, with 40 to 
50 % formamide being the optimum amount. The addition of formamide destabilises double 
stranded DNA by lowering the melting temperature. After calculating the melting 
temperature of the 17CEN sequence, it showed that a concentration of 60 % and over lowered 
the melting temperature to 37 ⁰C or less, which meant that a hybridisation temperature of 37 
⁰C was too high for all of the oligos to bind, and resulted in decreased SNR. Formamide 
percentages of less than 40 had the opposite problem; there was an increased amount of non-
specifically bound probe contributing to noise and decreasing the SNR. This result 
highlighted the importance and sensitivity of hybridisation and SNR and suggested that these 
conditions should be optimised for each new oligo ROI. 
 
Hybridisation time also showed to have an affect on SNR and, although probes could be 
detected after only two minutes, SNR increased with hybridisation time up to one hour. This 
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suggests that it takes approximately one hour for all oligos to anneal but, in case of 
centromeric probes where there are many probes binding and contributing to the signal, 
results could be detected after as little as two minutes.  
 
The number of M.TaqI sites within the probe sequence did not appear to have a significant 
impact on the SNR, but this may have been different if even more sites were added. Adding 
extra sites would increase the total oligo length however, which could have an effect on 
hybridisation times, and would significantly impact cost, therefore it seemed unnecessary at 
present as the probes could be detected with only one M.TaqI site.  
 
The final condition to have a significant impact on the brightness of the probes’ signal is the 
wash conditions. Washing slides at 72 ⁰C as per standard FISH protocols was not appropriate 
for the oligos, as this denatured and removed many of the probes that had bound to their 
target. Washing the slides for at least five minutes at both low and high stringency (at room 
temperature) significantly reduced background, washing away any probe that had bound non-
specifically to the nuclei, resulting in bright signals. 
 
In chapter five, probes were also successfully designed for the gene BCR, which shows 
potential for this technology to be used for other mutations such as amplifications, deletions 
or translocations. Results showed that higher formamide percentages were needed for the 
BCR oligoprobes (70 % formamide as opposed to 40 % for the centromeric probes), as they 
have purposely been designed to have higher Tms. This demonstrates that careful design of 
oligos is crucial to ensure efficient hybridisation, and prevent the oligos from becoming 




Detection of SNPs 
 Chapter five also explored the potential of oligoprobes to detect much smaller mutations, due 
to their apparent ability to distinguish between highly homologous sequences. As both 
17CEN1 and 17CEN2 – two sequences that only differ at 5 base positions – can be present in 
the centromere of chromosome 17, these probes were labelled with different fluorophores to 
see if this difference could be detected. The results were inconsistent as there was a high 
amount of background in the samples, however it did appear that some nuclei contained 
different combinations of 17CEN1 and 17CEN2, offering promise for this technique.  
 
To improve SNR, probe amplification should be explored to achieve a much brighter probe, 
as if oligoprobes were to be used to detect a SNP within a single gene, a single fluorophore 
would be difficult to detect. A new probe design was tested which included a primary probe 
binding to the ROI, and a labelled secondary probe binding to that. This probe was successful 
in detecting the ROI and shows potential for this branched oligo approach to potentially add 
numerous “labelled” sites onto a ROI, amplifying the signal further. MTase-labelling lends 
itself nicely to this technique, as a pool of labelled probes could be ready for use for different 
ROIs, providing a quick and cheap option for probe design.  
 
DNA mapping was also tested to see if this approach could determine SNPs, notably for 
detection of carriers of the SMN1/SMN2 genes which are implicated in SMA. Methylation 
with M.BseCI blocks 15 M.TaqI sites on lambda DNA due to an overlap in the two enzymes’ 
recognition sites. By methylating the DNA with M.BseCI before labelling with M.TaqI, 
results showed that, after deposition and mapping of the DNA, “blocked” lambda could be 
distinguished from “unblocked” the majority of the time, despite the sequences only differing 
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at 15 sites. The pattern of fluorescence (barcode) was extracted and assigned to genomes by 
code written in MATLAB to determine the sequence of the DNA. The majority of barcodes 
were matched correctly, but there were some barcodes in both samples that were assigned to 
the incorrect genome. This discrepancy could be attributed to inefficient deposition or sample 
preparation, resulting in potential shearing of DNA, or overlapping strands, which would 
need to be optimised in order to achieve more reliable results, especially if being used for 




 Future work 
The MTase M.TaqI has been successfully used for many applications in this thesis – and 
offers many advantages over other labelling techniques – which opens up the scope for other 
MTases to be used. The development of MTases with different recognition sites would be 
useful to produce a “toolbox” of different enzymes that are active with the cofactor 
analogues. This could prove useful for a variety of projects, in particular where dual colour 
labelling would be advantageous such as when wanting to map large and complex regions. If 
using mutated MTases, research should be made into the exact structural changes to the 
cofactor pocket to ensure that they are suitable, and their gene construct and expression 
should be optimised to ensure an active protein is produced.  
 
MTases are ideal for DNA mapping work, as they provide a method of labelling DNA 
without damaging the bases. If deposition and analysis can be optimised, this provides huge 
potential for mapping to be used in conjunction with sequencing to detect specific ROI, such 
as when monitoring SMA carrier detection. If this can be achieved, the enzyme M.Hpy188i 
should be investigated, as its recognition is disrupted in the protein SMN1, potentially 
allowing the detection of SMN1 and SMN2, while retaining sequence context; which is 
currently not possible using other techniques.  
 
MTase-labelled oligoprobes have shown huge potential for being used in clinical applications 
to rapidly diagnose a range of diseases. Due to their short size, and therefore increased 
specificity, oligos need to be designed extremely carefully to ensure the correct ROI is 
targeted, there are no SNPs in that region, and that it does not cross-hybridise. Oligoprobes 
for FISH is an area of growing interest, and there is increasingly becoming more software to 
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help with probe design, including Oligoarray and iFISH153. As sequencing is providing an 
increasing amount of information on the human genome, this will open up the potential for 
these highly specific oligoprobes to target even more regions, and be applied to many more 
diseases and biomarkers. 
 
Further work should be carried out using MTase-labelled oligoprobe including investigating 
the use of the hairpin design in translocations (e.g. BCR/ABL), and trialling new 
amplified/branched probe designs to improve SNR.  It may also prove useful to test how well 
oligoprobes can highlight regions of the human genome that contain repetitive DNA, but with 
less repeats than large centromeric copies, to serve as a proof-of-concept before attempting 
the more difficult feat of SNP detection. An interesting target could be looking at the CAG 
trinucleotide repeat associated with Huntington disease (HD)193. In healthy patients, the CAG 
region is repeated between 10 and 35 times, but in patients with HD, the same sequence can 
be repeated more than 120 times. By targeting this region, this could prove the versality of 
MTase-directed oligoprobes to detect smaller repeats than those associated with centromeres, 
acting as an interim step between centromeric regions and SNPs.  
 
If oligoprobes can be successfully optimised for SNP detection, these probes have potential 
not only to detect SNPs associated with genetic diseases, but to differentiate homolog 
chromosomes within family groups150,194. This could play a huge part in future genetic studies 
to monitor inheritance, fertility, and evolution, offering further insight into both humans and 





8 Supplementary information 
 
 p53 oligoprobe sequences 
The following DNA sequences (for the gene p53) were ordered from IDT DNA before being 
fluorescently-labelled using M.TaqI d the protocol in 2.2.4. Each sequence was ordered 
following the standard hairpin sequence: 
CCCTCGATCGATCGATCGACCCTTTTGGGTCGATCGATCGATCGAGGGTTTT  
1. AACTTTGCTGCCACCTGTGT  
2. GTAGGACATACCAGCTTAGATTT  
3. TTCAGGTCATATACTCAGCCCTG  
4. TGCCTTCCTAGGTTGGAAAG  
5. AGTTGCTTCAACTACAGGCCT  
6. TACGATGGTGTTACTTCCTGATA  
7. TGTGTAACAGTTCCTGCATGGG  
8. ACTGATTGCTCTTAGGTCTGGC  
9. TTATCCATCCCATCACACCCT  
10. TGTGAGTGGATCCATTGGAAG  
11. AAAGAAGTGCATGGCTGGTGA  
12. ACATTTATTGAGCCCAAGCAGG  
13. TAAAGGAGCTGTTTGGTAGGG  
14. ATTTGTATCCTGGCCCACTGATG  
15. TTGATAACAGGGCGTCCACA  
16. AAACAGAGGAACAGACTGGGC  
17. CTATTGACTAAGGATGTTCAGCA  
18. TTTGTGCCGTACTTACGTCATC  
19. TTCCTCTTACTTGGCAGAGG  
20. TGGATTGGGTAAGCTCCTGACT  
 
 BCR oligoprobe sequences 
The following DNA sequences were ordered from IDT DNA before being fluorescently-
labelled using M.TaqI and the protocol in 2.2.3 and 2.2.4. Each sequence was ordered 
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